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Abstract
Septic shock is a common condition carrying a high mortality. The clinical 
features are a high cardiac output circulation with hypotension and vascular 
hyporeactivity and evidence of organ failure. I developed an organ culture in 
vitro model and a fluid-resuscitated in vivo model of sepsis to investigate 
potential underlying mechanisms for the vascular hyporeactivity, namely 
inducible nitric oxide synthase (iNOS) overproduction and ATP-sensitive K+ 
( K a t p )  channel activation. I also studied the phenomenon of vascular 
supersensitivity to vasopressin/terlipressin in sepsis. I could demonstrate a 
temporal variation in vascular hyporeactivity to lipopolysaccharide (LPS) in rat 
mesenteric artery (RMA) in vitro over a 46 h period. This was reversed by a 
variety of iNOS inhibitors (aminoguanidine, L-NAME, 1400W and GW273629) 
and the guanylyl cyclase inhibitor, ODQ. Likewise, inhibition of the K a t p  
channel via its pore-forming subunit, rather than its sulphonylurea receptor 
(SUR), also reversed LPS-induced hyporeactivity in vitro, though vasopressin 
had no effect In vivo, iNOS inhibition and terlipressin all raised blood pressure 
in the septic animals over and above the pressor effect achieved in non-septic 
animals; K a t p  channel inhibition raised blood pressure in shams more than septic 
animals. However, these agents failed to improve macro- or microcirculatory 
blood flow, nor did they attenuate the metabolic acidosis. In patients with 
norepinephrine-resistant septic shock, I reported the first use of terlipressin in 
reversing hypotension and reducing norepinephrine requirements. Although 
terlipressin represents a significant advance in our ability to treat septic shock, 
care should be taken when using it.
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Introduction
1.1 Sepsis
Sepsis, the exaggerated systemic host response to infection (Bone et a l ,  1992), is the 
leading cause of death in the critically ill. In the United States, sepsis affects 750,000 
people per year, of whom 210,000 die (Murphy et al., 2000 and Angus et al., 2001). 
Data for England and Wales suggest that 51 per 100,000 population per year admitted 
to intensive care units meet criteria for severe sepsis (i.e. sepsis with related organ 
dysfunction) in the first 24 hours of admission. Of these patients, 35% died before 
intensive care unit discharge and a further 12% died during their hospital stay (Padkin et 
al., 2003).
Numerous trials conducted using agents that inhibit the inflammatory cascade have 
generally failed to show any survival benefit. Examples include corticosteroids (Bone et 
al., 1987), endotoxin antibodies (Ziegler et al., 1991), tumour necrosis factor (TNF) 
antagonists (Abraham et a l ,  1995 and Fisher et al., 1996), interleukin-1 receptor 
antagonists (Fisher et a t ,  1994), cyclo-oxygenase (COX) pathway antagonists (Bernard 
et al., 1997) and inducible nitric oxide synthase (iNOS) inhibitors (Lopez et al., 2004 
and Watson et al., 2004). However, recently published studies have demonstrated 
decreased mortality and morbidity as a result of interventions applied to patients with 
sepsis. Recombinant human activated protein C, a naturally-occurring anticoagulant, is 
the first anti-inflammatory agent shown to have statistically significant effectiveness in 
the treatment of sepsis with a 19.4% reduction in the risk of death, and an absolute risk 
reduction of 6.1% (Bernard et al., 2001). van den Berghe and colleagues (van den 
Berghe et al., 2001) demonstrated that intensive insulin therapy in which the blood
26
Introduction
glucose level was maintained at 4.4 -  6 .1 mM resulted in lower morbidity and mortality 
among high-risk surgical patients compared to conventional therapy (10-11.1 mM). 
Such therapy also reduced the frequency of episodes of sepsis by 46% and the mortality 
from bacteraemia (12.5% vs 29.5%). Insulin therapy reduced the rate of death from 
multiple organ failure among patients with sepsis, regardless of whether they had a 
history of diabetes. Rivers reported that an early and aggressive therapeutic strategy that 
optimized cardiac preload, afterload and contractility in patients with severe sepsis and 
septic shock in a Detroit emergency room improved their likelihood of survival (Rivers 
et al., 2001). Likewise, early administration of “low-dose” corticosteroids to septic 
patients with persistent shock requiring ventilation also resulted in improved mortality 
(Annane et a l,  2002).
I chose to examine the mechanisms underlying vasodilatory septic shock. Sepsis usually 
leads to a high cardiac output, low systemic vascular resistance circulation with a 
depressed blood pressure (Parillo, 1993). In such patients, therapy with an ai adrenergic 
agonist is often required to reverse the hypotension. However, hypotension may be 
resistant to high doses of these vasopressor agents, a state known as “vascular 
hyporeactivity”. Despite extensive research, the pathophysiology underlying septic 
shock in humans remains poorly understood. I set out to develop experimental models 
of sepsis to examine the effects of modulating the following mechanisms in 
vasodilatory septic shock -  the nitric oxide (NO) pathway, potassium channels, and 
vasopressin. I also briefly investigated the inducible cyclo-oxygenase (COX-2) 
pathway. Other vasodilatory mechanisms may also be involved in sepsis, for instance,
27
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increased production of calcitonin gene-related peptide (CGRP) (Fatehi-Hassanabad et 
al, 1996). However, time constraints prevented study of these pathways.
A major reason for the current failure to have fully characterised mechanisms 
underlying vascular hyporeactivity and hypotension is that animal models are not 
necessarily representative of the clinical condition of septic shock (reviewed in Fink and 
Heard, 1990 and Deitch, 1998). Thus, one of my aims was to develop more 
reproducible in vitro and in vivo animal models.
1.2 Endotoxin
Gram-negative bacterial infections are responsible for approximately 50% of cases of 
septic shock (reviewed by Thiemermann, 1997). Administration of endotoxin 
(lipopolysaccharide; IPS), a cell wall component ubiquitous to Gram-negative bacteria, 
to animals and human volunteers has been used extensively to mimic Gram-negative 
sepsis (Thiemermann, 1997 and Deitch, 1998). Cells of the innate immune system 
recognise microorganisms and initiate responses through pattem-recognition receptors 
called toll-like receptors (TLRs) (Modlin et a l ,  1999; Vasselon, et al, 2002 and 
Underhill et a l ,  2002). Insight into the role of TLRs in combating infection has been 
provided by studies using C3H/HeJ mice (Modlin et a l ,  1999) which are resistant to 
endotoxin because of a mutation in the toll-like receptor gene (TLR4). Despite their 
resistance to LPS, these mice have increased mortality in authentic sepsis (Hagberg et 
al,  1985 and Hotchkiss et a l ,  1999). TLR4 mutations have also been identified in 
humans and may make people more susceptible to infection (Arbour et a l,  2000). Thus
28
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total blockade of LPS may be detrimental. Indeed, trials using monoclonal endotoxin 
antibodies to treat patients with sepsis have been unsuccessful (Warren et al., 1993).
1.3 Pro-inflammatory cytokines
Several cytokines are considered to be involved in the pathophysiology of sepsis e.g. 
interleukin 1-p (ILl-p), interleukin-6 , tumour necrosis factor a (TNF-a), interferon-y and 
adenosine (reviewed in Landry and Oliver, 2001). Although cytokines are considered to 
be culprits, they may have beneficial effects in sepsis. Studies in animal models of 
peritonitis demonstrated that blocking TNF-a worsens survival (Eskandari et al., 1992 
and Echtenacher et a l ,  2001). In clinical trials, a TNF receptor fusion protein, which 
binds and neutralises TNF-a, increased mortality (Fisher et a l ,  1996), despite findings 
of protection against death in animal models of bacterial sepsis (Mohler et al., 1993). 
Combination immunotherapy against TNF-a and interleukin-1 receptors was also fatal 
in a neutropenic model of sepsis (Opal et al., 1996). The role of TNF-a in combating 
infection has recently been underscored by the finding that sepsis and other infectious 
complications developed in patients with rheumatoid arthritis treated with TNF 
antagonists (Keane et al., 2001). However, a meta-analysis of 10 sepsis studies with 
over 6500 patients showed an absolute reduction in mortality of 3.5% using anti-TNF 
drugs (Marshall, 2003). In addition, carriers of the TNFB2 allele are at increased risk of 
lethal septic shock (reviewed by Lin, 2004). Thus there may be subgroups of the 
population who will benefit from therapy directed against TNF. Other biologically 
active agents may also prove beneficial when used in specific strategies, but this is 
dependent on our understanding of sepsis improving.
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1.4 Nitric Oxide
In many animal models, endotoxin-induced vascular hyporeactivity is associated with 
enhanced formation of nitric oxide (NO) within the blood vessel (Julou-Schaeffer et al, 
1990). This molecule is synthesised from the semi-essential amino acid L-arginine by a 
family of nitric oxide synthase (NOS) isoenzymes (Moncada & Higgs 1995). There are 
three isoforms of NOS enzymes: nNOS - a neuronal isoform, eNOS - an endothelial 
isoform and iNOS a transcriptionally inducible isoform. nNOS and eNOS are present in 
endothelial cells, certain neurones, platelets, endocardium and skeletal muscle as 
constitutively active enzymes. These two isoforms are calcium-calmodulin dependent 
and generate small amounts of NO (nanomolar range) that acts as a physiological 
mediator. In response to bacterial endotoxins, exotoxins, or pro-inflammatory 
cytokines, iNOS is transcriptionally up-regulated in a wide variety of cells, producing 
substantially amounts (micromolar range) of NO in a calcium-independent manner 
(Vallance and Charles, 1998). Expression of iNOS has been shown to occur in 
endothelial, vascular smooth muscle and myocardial cells, macrophages and circulating 
leucocytes. The adventitia appears to represent the main site of NO production in the 
vasculature (reviewed by Muller et a l,  2000). Furthermore, pro-inflammatory cytokines 
(interleukin-lp and interferon-y) may also increase NO production by upregulating the 
expression of GTP cyclohydrolase 1 (GTPCH-1). Induction of GTPCH-1 leads to the 
generation of tetrahydrobiopterin, an essential cofactor for all NOS isoforms (Bhagat & 
Vallance, 1999). However, eNOS expression has also been shown to be upregulated in 
certain septic models (Bhagat et al., 1999). Indeed, enhanced NO production may result
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from activation of eNOS in the early stages of the septic insult (<1 hour (h)) followed 
by expression of iNOS commencing after 2 - 3 h (Thiemermann, 1994 & 1997).
Once formed, NO can activate soluble guanylyl cyclase which results in vascular 
smooth muscle relaxation via the formation of guanosine 3’-5’ cyclic-monophosphate 
(cGMP) (see Fig 1.1). Consistent with this, inhibition of NOS or soluble guanylyl 
cyclase has been shown to reverse vascular hyporeactivity and hypotension in vivo and 
in vitro (Julou-Schaeffer et al., 1990; Hall et al., 1996; Scott et al., 1996; Kilboum, 
1999; Levy et al., 2004 and Martin et al., 2004). This mechanism is likely to be 
responsible for the immediate effects of NO. The NO derived from iNOS- may interact 
with physiological substrates such as thiols to yield biologically active or inactive S- 
nitrosothiols during endotoxemia. It is possible that these relatively stable, vasoactive 
compounds may act as a storage system for NO, perhaps within the medial layer of 
vascular smooth muscle, and thus mediate longer lasting effects of NO. Dinitrosyl non­
heme iron complexes (DNIC), which occur in different cell types or tissues during 
activation of the iNOS pathway, may also be involved in this putative mechanism 
(reviewed in Muller et al., 2000). After incubation with LPS, four times as much DNIC 
was present in the media compared to the adventitia (Kleschyov et al., 1997). These 
may represent NO stores with which low molecular weight thiols interact to produce 
vasorelaxation (Mulsch et al., 1991). In LPS treated tissues, the vasorelaxant effect of 
the low molecular weight thiol, N-acetylcysteine, correlated with preformed NO stores 
as it was inhibited by the non-selective NOS inhibitor, L-NAME (Muller et al., 1996). 
Interestingly the relaxation observed with N-acetylcysteine was not associated with a
31
Introduction
rise in cGMP or affected by inhibition with cGMP-dependent protein kinase. It was, 
however, attenuated by the non-selective potassium channel inhibitor 
tetrabutylammonium (3mM), and by elevated concentrations of KC1 as the contractile 
agent (Muller et al., 1998). Thus the N-acetylcysteine-induced vasorelaxation, although 
related to preformed NO stores, was mediated by potassium channel activation rather 
than through cGMP. The precise mechanism involved remains unknown, but could 
involve oxidation of thiol residues.
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Figure 1.1 The pathway of nitric oxide (NO) formation and action within a vascular 
smooth muscle cell. NO either diffuses into the cell from the endothelium or adventitia, or 
is synthesised from L-arginine via NO synthase (NOS). The NO then activates soluble 
guanylyl cyclase (sGC) to catalyse the formation of cGMP from GTP, which then 
activates protein kinase G. Inhibitors of various aspects are shown in green. (AMG- 
aminoguanidine; ODQ-1 H-[ 1,2,4]-oxadiazole[4,3-alpha]quinoxalin-1 -one; L-NAME-
N(G)-nitro-l-arginine methyl ester; L-NMMA- NG-monomethyl-L-arginine).
1.5 Human Studies
Septic humans produce much lower quantities of NO than rodents. iNOS induction has 
been particularly difficult to demonstrate in many human cell types (reviewed by 
Vallance & Charles, 1998). However, there is plentiful evidence for enhanced NO 
production in septic shock patients. For example, NO levels of up to 150 micromolar
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were detected in blood from ebola virus victims, with NO being much higher in fatal 
cases and with increasing disease severity (Sanchez et al., 2004). Moreover, positive 
iNOS immunoreactivity has been detected in a handful of human studies. It has been 
demonstrated in the internal mammary artery after incubation with a mixture of 
cytokines and high doses of LPS for 24-48 hours in vitro (Chester et al., 1998) and in 
omental arteries taken from eight septic patients undergoing bowel resection (Stoclet et 
al., 1999). In addition, iNOS activity was detected in muscle, fat and artery but not in 
skin of putrescent areas in 13 patients with septic shock from cellulitis (Annane, 2000). 
They could also not detect iNOS activity in surrounding inflamed areas. Interestingly, 
polymorphisms within the iNOS promoter regions were found in Ghanaian children 
with severe malaria (Cramer et al., 2004).
The observation that NG-monomethyl-L-arginine (L-NMMA) restored blood pressure in 
septic shock patients (Bakker et al., 2004) prompted a large-scale phase III study with 
this agent. However, the study was halted prematurely after an interim analysis revealed 
an increase in deaths in the L-NMMA treated group (Lopez et al., 2004). As mentioned 
above, NO is required for a large range of normal physiological functions. It plays an 
important role in the regulation of organ blood flow distribution and autoregulation, and 
it inhibits the adhesion of platelets and neutrophils to the endothelium. In addition, the 
induction of NOS by cytokines or endotoxin in macrophages greatly contributes to the 
bactericidal effects of these cells (reviewed by Thiermermann 1994 and Hauser et al., 
2004). Thus, NO has been described as both a ‘friend and foe’ in septic shock 
(Springall, 1995). Given its widespread actions, it is not surprising that non-specific
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inhibition of its synthesis in sepsis has been associated with a variety of deleterious 
effects and an increase in mortality.
1.6 Vascular Smooth Muscle
The vascular smooth muscle is located between the endothelium, on the luminal side, 
and the fibroblast-like cells of the adventitia. Vascular smooth muscle cells (VSMCs) 
are excitable cells that are the mechanical effectors of blood vessel diameter. A wide 
variety of agents exert their effect upon blood vessels via vascular smooth muscle. 
These include (i) factors released from the endothelium such as NO, prostacyclin 
(PGI2), endothelin (e.g. Rubanyi & Polokoff, 1994) and endothelium-derived 
hyperpolarising factor (EDHF) (Gryglewski et al., 1986; Palmer et al., 1987 and 
Edwards et al., 1998); (ii) neurotransmitters released from the adventitia, such as 
substance P, norepinephrine, and NO (Hirst & Edwards, 1989 and Guterman, 1999); 
and (iii) factors circulating within the bloodstream such as angiotensin II and 
thromboxane (Hirst & Edwards, 1989). The pH and temperature may also regulate 
vascular smooth muscle function (Hill et al., 2001). Smooth muscle cells can 
themselves generate vasoactive factors after an inflammatory insult, including PGI2 , 
endothelin and NO (Moncada, 1982 and Moncada et al., 1991).
1.6.1 Vascular smooth muscle contraction
All muscle cells use calcium (Ca2+) as a signal for contraction. VSMCs are regulated by 
a variety of neurotransmitters and hormones. These interact with a network of signal 
transduction pathways that ultimately affect contractility either by affecting Ca2+ levels
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in the cell, or the response of the contractile elements to calcium. Ca2+ levels are 
increased by extracellular entry via voltage-gated Ca2+ channels, receptor- operated and 
capacitative (store-operated) Ca2+ channels (transient receptor potential proteins), as 
well as by release from intracellular stores (Nelson and Quayle, 1995). At high 
cytosolic concentrations, Ca2+ forms a complex with calmodulin that activates a kinase, 
which phosphorylates the regulatory light chain of myosin. Phosphorylated myosin 
activates myosin ATPase by actin and the cycling of myosin cross-bridges along actin 
filaments, which contracts the muscles. Vasodilatation occurs when a kinase interacts 
with myosin light chain phosphatase (MLCP), which dephosphorylates myosin and 
prevents muscle contraction (Surks et al., 1999). In smooth muscle, RhoA and Rho- 
kinase (ROCK) play an important role in Ca2+ sensitization, an event that controls 
vascular vessel tone. Ca2+ sensitization of vascular smooth muscle contraction involves 
Rho- and Rho-kinase-dependent suppression of myosin phosphatase activity (Hirata et 
al., 1992). NO dilates hamster resistance arterioles by activating MLCP in a cyclic 
cGMP-dependent manner, thereby reducing the apparent Ca2+ sensitivity of the 
contractile apparatus. MLCP inactivation via the RhoA/Rho kinase pathway 
antagonizes this Ca -desensitizing effect that, in turn, can be restored using RhoA/Rho 
kinase inhibitors (Bolz et al., 2003). Thus cGMP-dependent inhibition of Rho Kinase 
may represent a mechanism of vasodilation in sepsis.
1.6.2 Vascular smooth muscle membrane potential
The membrane potential of vascular smooth muscle is a major determinant of vascular 
tone. All arteries exist in a partially contracted, pressurised state (vascular tone) and can
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either hyperpolarise (make the membrane potential more negative) and dilate, or 
depolarise (make the membrane potential more positive) and thus induce contraction 
(Nelson and Quayle, 1995). There is a steep relationship between vascular tone and 
membrane potential; a few millivolts’ (mV) depolarisation or hyperpolarisation can lead 
to significant alterations in blood vessel diameter (Nelson et al., 1990). The resting 
membrane potential of vascular smooth muscle ranges from -50mV to -70mV, although 
it may vary with blood pressure, becoming depolarised as pressure increases (Nelson & 
Quayle, 1995). This, in turn, opens L-type voltage-gated calcium channels, thereby 
increasing cytosolic Ca2+ concentration and inducing vasoconstriction. Conversely,
2_j_
hyperpolarisation closes these channels, thus decreasing the cytosolic Ca 
concentration and promoting vasodilation (Landry & Oliver, 2001). The membrane 
potential of vascular smooth muscle is controlled by a number of ion transporters and 
channels, such as K+ and chloride (CT) channels. The theoretical K+ equilibrium 
potential (EK) (-82 mV in a physiological gradient of 140mM [K+]0 and 5mM [K+]i) is 
close to the resting membrane potential, indicating that permeability through K+ 
channels is a major factor in determining the resting membrane potential in smooth 
muscle.
1.7 K+ channels and vascular smooth muscle function
Potassium (K+) channels form the largest superfamily of ion channels, with at least 60 - 
ion conducting subunits described (Coetzee et al., 1999). In blood vessels K+ channels 
regulate the resting membrane potential of vascular smooth muscle cells (VSMC) and 
so control vascular tone and blood pressure (Standen & Quayle, 1998). These channels
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when opened promote relaxation and, when closed, promote vasoconstriction. This is 
achieved predominantly via modulation of calcium (Ca2+) entry through voltage- 
sensitive Ca2+ channels and IP3 modulation (Nelson & Quayle, 1995).
1.7.1 Vascular K+ channels
Four main types of K+ channels have been described in vascular smooth muscle. These 
belong either to the voltage-gated K+ channel family comprising of voltage-gated (Kv) 
and Ca2+ -activated K+ channels (Kca) or the inwardly rectifying K+ channel family 
comprising ATP-sensitive K+ ( K a t p )  and strong inward rectifier K+ ( K ir )  channels 
(Nelson & Quayle, 1995). More recently, K+ channels belonging to a family of channels 
with two ion conducting pores (twin pore) have been identified in vascular smooth 
muscle (Gurney et al., 2003), although the physiological role of these channels is far 
from clear.
(i) Kv channels
Voltage-dependent K+ channels (Kv) have been identified in a variety of arteries 
including coronary, cerebral, mesenteric and pulmonary (Nelson & Quayle, 1995 and 
Clapp & Tinker, 1999). The structure consists of a 6 -transmembrane domain (SI-6 ) 
protein with a pore domain (H5) between S5 and S6 . Functional channels are formed 
through the association of 4 separate subunits with or without accessory proteins. The 
channel may be inhibited by 4-aminopyridine (4-AP) with a Ki in the range of 0.2 - 1 
mM (Nelson & Quayle, 1995). In addition, these channels are inhibited by high
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concentrations of tetraethylammonium (TEA+) and barium (Ba2+) ions, although these 
agents also inhibit a variety of other K+channels (Brayden, 1996). Ky channels open in 
response to membrane depolarisation. They appear to play a significant role in 
maintaining the membrane potential of smooth muscle, since inhibition by 4-AP in 
isolated arterial myocytes causes membrane depolarisation (Yuan, 1995), and in intact 
preparations causes vasoconstriction (Knot and Nelson, 1995). There are multiple types 
of Kv subunits in smooth muscle that gives rise to delayed rectifier K+ channels and 
rapidly activating and inactivating (transient) K+ channels. These channels have 
auxiliary beta subunits that regulate both the activation/inactivation properties of these 
channels as well as their pharmacology (reviewed in Korovkina et al., 2002). In 
addition, vasoconstrictors such as histamine may utilise inhibition of Kv channels as a 
mechanism of contraction in some vascular beds (Ishikawa et al., 1993). These channels 
probably also contribute to hypoxic pulmonary constriction (Yuan et al., 2003).
(ii) Kca channels
Ca2+'activated K+channels exist in virtually all excitable cells (Nelson & Quayle, 1995). 
Three main types have been described in endothelial and smooth muscle cells; small 
(SKca), intermediate (IKca) and large (BKca) conductance K+ channels with 
conductances ranging from 10-15 pS, 20-60 pS and 200-300 pS, respectively (Brayden,
1996). The BKca channel is the most widely studied K+ channel. The channel is made 
up of the alpha subunit that spans the membrane, forms the pore and contains the 
voltage sensor, while the beta subunit modulates Ca2+ sensitivity. BKca channels are 
inhibited by TEA+, though at a much lower concentration than other K+ channels, the Kj
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being -200 pM (Langton et al., 1991). It is widely accepted that use of TEA+ at 
concentrations of 1 mM or less is considered specific for this channel. Other highly 
selective blockers include the scorpion toxins iberiotoxin (IbTx) (Giangiacomo et al., 
1992) and charybdotoxin (ChTx) (Jones et al., 1990) which inhibit BKca channels with 
a Kj of less than 10 nM.
BKca channels are voltage-sensitive channels activated in response to increasing [Ca2+]j 
their function is probably geared towards prevent excessive contraction. Indeed, they 
may be important in regulating arterial myogenic response. In certain small arteries, an 
increase in intravascular pressure may cause vasoconstriction (myogenic tone), thereby 
activating the channels, probably to limit excessive depolarisation. IbTx has been 
demonstrated to depolarise contracted coronary arteries (Brayden & Nelson, 1992 and 
Nelson & Quayle, 1995). It is not clear whether these channels contribute to the resting 
membrane potential as inhibitors have had no effect on resting tension (Nelson & 
Quayle, 1995). However, genetic studies have identified the pi subunit as a 
physiological regulator of vascular tone; mice lacking this gene develop systemic 
hypertension and their arteries show vascular hyper-reactivity to agonists (Brenner et 
al., 2000 and Pluger et al., 2000). BKca channels are the target for vasodilators such as 
NO (Bolotina et al., 1994 and Mistry & Garland, 1998) and adenosine (Cabell et al., 
1994). In addition, inhibition of BKca channels may represent a mechanism employed 
by vasoconstrictors as this will hinder the channel’s ability to antagonise further 
depolarisation. Both angiotensin II and the thromboxane mimetic U-44619 inhibits 
BKca channels in coronary arterial smooth muscle (Toro et al., 1990 and Somik and
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Toro, 1992). Endothelial SKca channels have also been shown to have a profound tonic, 
hyperpolarizing influence on resistance arteries in mice. This suggests that the level of 
this channel’s expression in endothelial cells is a fundamental determinant of vascular 
tone and blood pressure (Taylor et al., 2003).
(iii) Kir channels
Inward rectifier ( K ir )  channels pass inward current more readily than outward current. 
Unlike most other K+ channels, they are significantly activated by hyperpolarisation 
negative to Er. They are found mainly in small resistance arteries, but due to their 
peculiar current-voltage relationship can be activated by small increases in K+ ion 
concentration which, in turn, causes vasodilatation (Quayle, et al., 1996). K+ ions may 
be released either from nerve terminals adjacent to smooth muscle cells (McCarron and 
Halpem, 1990) or from the endothelium (Edwards et al., 1998). Kir channels may be 
inhibited by low concentrations of Ba 2+ (half block at -60mV being 2 pM), the 
inhibition of which is voltage-dependent (Nelson and Quayle, 1995). RT-PCR analysis 
in rat mesenteric artery suggests that the channel is likely to be made up of Kir2.1 
subunits (Bradley et al., 1999). Kir channels are strongly expressed in endothelial cells 
where they probably regulate resting membrane potential (Nilius & Droogmans, 2001).
(iv) K a t p  channel
ATP-sensitive K+ channels belong to a class of K+ channels activated by low cytosolic 
ATP or elevated nucleotide diphosphate (NDP) levels, and inhibited by sulphonylurea
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agents such as glibenclamide. Katp channels can also be activated by potassium channel 
opening drugs (KCOs), such as levcromakalim and pinacidil. In vascular smooth 
muscle, KCOs cause membrane hyperpolarisation, increase K+ efflux and produce 
smooth muscle relaxation, the effects of which can be inhibited by glibenclamide 
(Nelson & Quayle, 1995).
The K a t p  channel is an octomeric complex consisting of four pore-forming subunits 
(Kir6 .x) and four sulphonylurea receptor (SUR) subunits (Bryan & Aguilar-Bryan, 
1999). The pore is thought to confer ATP inhibition and determine conductance, while 
the SUR is considered the primary target for sulphonylureas, KCOs and NDP. Different 
combinations of these subunits give rise to K At p  channels with different conductances 
and channel pharmacology. It is generally accepted that the pancreatic (3 cell K a t p  
channel is composed of Kir6.2 and SUR1, and the cardiac type of Kir6.2 and SUR2A. 
SUR2B together with either Kir6 .1 or Kir6.2 are thought to be the K At p  channels within 
smooth muscle. The former corresponds to the nucleotide-diphosphate regulated K+ 
( K n d p )  channel described in most vascular smooth muscles, while the latter is the more 
classical type of K a t p  channel. In all tissues the SUR subunit can be inhibited by agents 
such as glibenclamide, tolbutamide and PNU-99963 (Khan et al., 1997; Bryan & 
Aguilar-Bryan, 1999 and Cui et al., 2003). The latter is a pinacidil-derived inhibitor 
which potently blocks relaxation to the K At p  channel opener, pinacidil with an IC5o of 
18 nM in rat aorta (Khan et al., 1997). Interestingly, the IC5o for inhibition of the SUR 
by glibenclamide is —10-200 nM (Fujita & Kurachi, 2000) whereas at a 1000-fold 
higher concentration, glibenclamide appears to interact with the pore directly (Gribble
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et al., 1998 and Bryan & Aguilar-Bryan, 1999). The pore-forming subunit can be 
inhibited by barium chloride (BaC^) or PNU-37883A, though the latter only appears to 
inhibit smooth muscle K a t p  channels (Nelson & Quayle, 1995; Wellman et al., 1999; 
Surah-Narwal et al., 1999 and Cui et al., 2003). Both the pore and the SUR contain 
Ser/Thr phosphorylation sites for regulation by protein kinases. In smooth muscle, 
vasodilators that increase cAMP and activate protein kinase A (PKA) open the channel, 
whereas vasoconstrictors that activate protein kinase C (PKC) close it (Quayle et al., 
1997).
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Figure 1.2 Mechanism of activation of the K ATp channel within vascular smooth 
muscle cells leading to vasodilatation. The channel may be activated 
pharmacologically or by hypoxia, |ATP, lactic / metabolic acidosis & |N O  -  all of 
which may occur during sepsis.
1.7.2 Sepsis and K+ channels
K+ channels, in particular the KAtp and BKca channels, can be activated by a variety o f 
endogenous vasodilators such as NO (Bolotina et al., 1994), prostacyclin (PGI2 ; 
M urphy & Brayden 1995 & Clapp et al., 1998) and calcitonin gene-related peptide 
(CGRP) (Nelson & Quayle, 1995). Since plasm a levels o f  these are all elevated in septic 
shock (Bernard et al., 1997 and Gomez-Jimenez et al., 1995) it seems highly likely that 
excessive activation o f K+ channels will occur.
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Numerous in vitro and in vivo laboratory studies support an important role for the Katp 
channel in sepsis-induced vascular hyporeactivity and hypotension. In canine, porcine 
and rat in vivo models of LPS-induced shock, the Katp channel inhibitor glibenclamide 
restored blood pressure without having any effect in control animals (Landry & Oliver, 
1992; Vanelli et a l, 1995; Wu et al., 1995; Vanelli et al., 1997; Gardiner et al., 1999; 
Sorrentino et al., 1999 and Preiser et al., 2003). Glibenclamide also increased the 
magnitude of vasopressor responses to phenylephrine in LPS-treated rats (Sorrentino et 
al., 1999) suggesting that Katp channels mediate both hypotension and vascular 
hyporeactivity in vivo.
Partial reversal of LPS-induced hyperpolarisation with glibenclamide was observed in 
rat aortic smooth muscle (Chen et a l, 2000) and in rat mesenteric resistance arteries 
(Wu et al., 2004). Yet in all ex -vivo organ bath studies to date, glibenclamide had either 
no effect on vascular hyporeactivity (Wu et al., 1995; Taguchi et al., 1996 and Preiser 
et al., 2003), or even further reduced contractions (Sorrentino et al., 1999). This 
apparent paradox may relate to differences in the mechanisms of LPS-induced vascular 
dysfunction in vivo versus in vitro, or to the 1 0 - 1 0 0 -fold higher concentrations of 
glibenclamide used in the in vivo studies (Wu et al., 1995). An intriguing possibility to 
consider is that LPS alters the pharmacology of the K At p  channel such that agents 
inhibiting the channel via the sulphonylurea receptor (SUR) become less effective 
(Wilson & Clapp, 2002). Metabolic stress in cardiac muscle has previously been 
reported to render SUR inhibitors ineffectual (Findlay, 1993). In this respect, it is worth 
noting that the pressor effect of glibenclamide in vivo is transient (Landry & Oliver,
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1992; Vanelli et al., 1995; Vanelli et a l ,  1997; Gardiner et al., 1999 and Sorrentino et 
al., 1999) despite its long half-life in plasma (Wu et al., 1995). Moreover, the use of 
glibenclamide as a tool with which to probe K a t p  channel function is complicated by its 
known inhibitory action on thromboxane receptors (Delaey & Van de Voorde, 1995). 
Such a mechanism would be predicted to increase hyporeactivity. Thus it is pertinent to 
investigate the mechanism of vascular hyporeactivity using more potent and selective 
K a t p  channel inhibitors, as well as agents with a different mode of action (Cui et al., 
2003).
Work from this laboratory has shown that hyporeactivity is fully reversed using the 
non-selective K+ channel inhibitor, TEA+ at 10 mM (Hall et al., 1996) and there is 
evidence demonstrating involvement of B K c a  channels, in addition to K a t p  channels. 
NO produced by vascular expression of iNOS activates BKca channels; such a 
mechanism contributes to impaired vasoconstrictor responses during sepsis (Taguchi et 
al., 1996). Similarly, Chen and co-workers, using charybdotoxin, concluded that that 
activation of BKca channels and overproduction of NO in the vascular smooth muscle 
also contribute to vascular hyporeactivity to vasoconstrictor agents in endotoxaemia 
(Chen et al., 1999). Furthermore, patch clamp studies in vascular smooth muscle cells 
have shown that LPS ( 1 0 - 1 0 0  pg ml'1) can activate BKca channels by a mechanism 
independent of iNOS (Yakubovich et al., 2001).
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1.8 Vasopressin (Arginine Vasopressin)
Vasopressin, also known as antidiuretic hormone, is an endogenous hormone produced 
in the hypothalamus and released from the posterior pituitary gland in response to 
increased plasma osmolality, hypovolaemia and hypotension. It is a nonapeptide with a 
disulfide bridge that differs from oxytocin by one amino acid. Despite this difference, 
oxytocin has clearly defined roles in partuition, lactation and sexual behaviour 
(reviewed in Holmes et al., 2003A).
1.8.1 Vasopressin Receptors
The actions of vasopressin are mediated by stimulation of tissue-specific G-protein 
coupled receptors (GPCRs), which belong to a superfamily of receptors with seven 
transmembrane spanning domains. Vasopressin receptors are classified into Vi (VjR), 
V2 (V2R), V3 (V3R) and oxytocin (OTR) subtypes. Some actions of vasopressin may 
also be mediated via P2 purinergic receptors (P2R) (reviewed in Holmes et al., 2003A).
ViRs are found in high density on vascular smooth muscle but are also located in the 
renal medulla, myometrium, bladder, adipocytes, hepatocytes, platelets, spleen, cardiac 
myocytes, brain, and testis (Philips et al., 1990). The ViR, once stimulated activates 
Gq/11 and the (3 isoform of phopholipase C to produce the intracellular messengers 
inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers release of calcium 
from intracellular stores, thus initiating contraction of vascular smooth muscle, while a 
sustained rise in Ca2+ by influx of extracellular Ca2+ results from activation of both 
voltage-gated and receptor operated Ca2+ channels (Katori et al., 2001). The mechanism
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is likely to involve both DAG and also PKC, the latter being activated by DAG and 
recruited to the membrane (Neves et al., 2002). There is considerable interspecies 
variation in the VjR. For example, although rat and human vasopressin are identical, the 
human ViR is only 80% homologous with the rat ViR. This should be borne in mind 
when interpreting animal studies aimed at interpreting receptor subtypes based on the 
use of specific receptor inhibitors.
V2RS are distributed on the renal collecting tubules and endothelial cells and are 
coupled to the s subunit of the G protein complex (Barberis et al., 1998). These are 
responsible for vasopressin’s antidiuretic effect via activation of adenylyl cyclase and 
increased cAMP levels in the kidney. Vasopressin produces vasodilatation in some 
vascular beds with V2RS possibly involved in some instances. Infusion of a selective V2 
agonist in anephric dogs elevated cAMP and this was coincident with a fall in 
peripheral vascular tone (Liard et al., 1992). Secondly, in healthy human volunteers, 
high doses of vasopressin will reduce forearm vascular resistance and this appears to be 
both V2R and NO dependent (Tagawa et a l ,  1993). The V3R is a G-protein-coupled 
pituitary receptor that causes secretion of adrenocorticotrophic hormone (ACTH) and it 
is over-expressed in ACTH-secreting tumours. More than one G-protein appears to 
participate in signal transduction pathways linked to V3RS (Holmes et a l ,  2003A).
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Figure 1.3 Vasopressin: mechanism of action. Activation of vasopressin 1 receptors 
(VIR) in vascular smooth muscle cells triggers and an increase in C a 2+j from the 
endoplasmic reticulum and outside the cell causing contraction via activation of 
myosin light chain kinase (MLCK). Vasopressin 2 receptors (V2R) may cause 
vasodilatation via activation of cAMP
1.8.2 Endogenous vasopressin response in sepsis and other shock states
The vasopressor effect of pituitary extract was first observed in 1895 (Oliver & 
Schaefer). It was isolated and synthesised in the 1950s and shown to have antidiuretic 
and vasopressor effects (Turner et al., 1951 and Du Vigneaud, 1954).
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Plasma vasopressin levels are < 4 pg ml"1 in hydrated humans who have fasted 
overnight. The osmoreceptor-vasopressin renal mechanism is highly sensitive, with a 
maximal increase in urine osmolality requiring vasopressin levels of > 20 pg ml"1. Both 
haemorrhagic and septic shock states are associated with a biphasic response in 
vasopressin levels. In early shock high levels of vasopressin are produced (> 500 pg ml"
1 in dogs and > 300 pg ml'1 in baboons), producing profound vasoconstriction to assist 
end-organ perfusion (Wilson et al., 1981). Prolonged shock is associated with a fall in 
vasopressin levels to 3.1 ± 1.0 pg ml'1 in humans, as opposed to cardiogenic shock 
patients in whom levels remained elevated at 22.7 ± 2.2 pg ml"1 (Landry & Oliver,
1997). Several mechanisms underlying this relative deficiency have been considered. 
These include depletion of neurohypophyseal stores of vasopressin (Morales et al., 
1999) due to excessive baroreceptor firing or autonomic insufficiency, with the lack of 
baroreceptor mediated bradycardia after vasopressin infusion considered as supporting 
evidence (Landry et al., 1997). Also, low concentrations of norepinephrine excite 
central vasopressin neurones whereas elevated norepinephrine levels (that occurs in 
septic shock either endogenously or exogenously) have a central inhibitory effect upon 
the release of vasopressin (Day et al., 1985). In addition, increased NO production by 
vascular endothelium in the posterior pituitary during sepsis may inhibit the production 
of vasopressin (reviewed in Holmes et al., 2001).
1.8.3 Use of vasopressin in septic shock
Vasopressin has been used for over 50 years to treat diabetes insipidus, but only in 
recent years has it emerged as a potential treatment for catecholamine-resistant septic
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shock (reviewed in Holmes et al., 2001). Paradoxically, very small doses of 
vasopressin, using infusion rates of 0.01 to 0.04 IU min'1, which have no pressor effect 
in normal subjects, induce an exaggerated response in septic patients, usually allowing 
considerable reduction (or even cessation) of the high-dose norepinephrine infusion 
(Landry et al., 1997B). Cardiac output is generally maintained, pulmonary vascular 
resistance decreased, and urine output increased (reviewed in Holmes et al., 2001 & 
2003B and Landry et al., 1997A & B). Subsequent studies have generally studied small 
patient numbers, ranging from 10-48 (Landry et al., 1997A; Malay et al., 1999; Holmes 
et al., 2001; Tsuneyoshi et al., 2001; Patel et al., 2002 and Dunser et al., 2003A). 
Adverse events are generally seen in those patients receiving higher doses of 
vasopressin (i.e. >0.04 units min'1). These include arrhythmias, digital and mesenteric 
ischaemia. At levels as low as 10 pg ml' 1 it may constrict the mesenteric circulation 
(Altura et al., 1975). This is mediated by VjRs and has been demonstrated in vitro and 
in vivo in several animal models (Erwald et al., 1976 and Schrauwen et al., 1982). This 
effect has been used therapeutically in the treatment of variceal bleeding (Ohnisi et al., 
1987). It has also been demonstrated to cause platelet aggregation (Bichet et al., 1988 
and Haslam & Rosson, 1972). The V2 receptor agonist, desmopressin, that causes 
release of factor VIIIc and von Willebrand factor, has been used extensively to treat 
bleeding due to dysfunctional platelets (Mannucci et al., 1981). However, low doses of 
vasopressin are less likely to stimulate this effect. Furthermore, vasopressin infusion in 
septic patients has been associated with thrombocytopaenia (Dunser et al., 2004A). At 
lower doses it does not appear to constrict the pulmonary circulation and its selective
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constriction of renal efferent over afferent (via ViR) could prevent renal dysfunction in 
sepsis.
As studies so far performed have been on small numbers of patients, it is uncertain 
whether vasopressin has a beneficial effect on mortality or organ failure in sepsis and 
thus its role in the management of septic shock remains undetermined. At present there 
is a large multicentre, randomised control study comparing vasopressin and 
norepinephrine in septic shock ongoing in Canada and Australia (VASST; Cooper et al., 
2003).
1.8.4 Mechanisms of action of vasopressin in sepsis
The mechanisms for the enhanced sensitivity to vasopressin in sepsis remain largely 
unknown. Autonomic insufficiency in septic shock unmasking vasopressin’s pressor 
effect has been suggested. Pressor sensitivity to physiological concentrations of 
vasopressin was profoundly enhanced following baroreceptor denervation in dogs 
(Cowley et al., 1974). Moreover, patients with orthostatic hypotension exhibit a 1000- 
fold sensitivity to physiological concentrations of vasopressin (Schwartz & Reid, 1983).
Vasopressin may restore vascular tone by at least four different mechanisms, namely: 
activation of ViRs; inhibition of K At p  channels; modulation of nitric oxide; and 
potentiation of adrenergic and other vasoconstrictor agents. Activation of K At p  channels 
may represent a critical mechanism in the hypotension and vasodilatation of septic 
shock. Vasopressin inhibits KATp channels and this may possibly account for its ability
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to restore vascular tone in septic shock patients (Wakatsuki et al., 1992). Vasopressin 
also modulates the actions of NO. It may restore vascular tone by blunting the increase 
in cGMP induced by NO, and by reducing the synthesis of iNOS stimulated by LPS 
(Umino et al., 1999). This inhibition is likely to occur via the VjR since administration 
of the VI receptor antagonist but not the oxytocin receptor antagonist reversed these 
effects (Kusano et al., 1997). However, a vasopressin infusion in septic patients had no 
effect upon serum concentrations of nitrite/nitrate (Dunser et al., 2004B). Vasopressin 
also potentiates the vasoconstrictor effects of several agents including angiotensin II 
(Iverson & Arendshorst, 1998) and norepinephrine (Noguera et al., 1997).
Interestingly, unlike catecholamines used to treat septic shock, vasopressin can dilate 
many vascular beds, for instance pulmonary (Walker et al., 1989), renal (Rudichenko & 
Bejerwaltes, 1995 and Tamaki et al., 1996), cerebral (Okamura et al., 1997) and 
coronary (Okamura et al., 1999). The mechanism of vasodilatation is uncertain. It is 
likely to be mediated by NO and the effect appears at low concentrations. The V2R 
present on the vascular endothelium is likely to be involved. V2 receptor agonists cause 
facial flushing in humans (Bichet et al., 1988) and peripheral vasodilatation in dogs 
(Liard et al., 1992). In addition, activation of endothelial oxytocin receptors (OTRs) 
which, in turn, trigger activation of endothelial isoforms of NOS, will also mediate 
vasopressin-induced dilatation (Thibonnier et al., 1999). Whether vasopressin causes 
vasoconstriction or vasodilatation depends on the vascular bed studied (Garcia-Villalon 
et al., 1996). This may depend upon the receptor density, the model studied (Holmes et 
al., 2001), or the concentration of vasopressin used (Liard, 1987).
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1.9 Role of the Cyclo-oxygenase (COX) pathway in sepsis
During sepsis vasoactive arachidonic acid metabolites of the cyclo-oxygenase (COX) 
pathway are released. These include prostacyclin, thromboxane A2 (TXA2) and 
prostaglandin E2 (Cirino et al., 1996 and Bishop-Bailey et al., 1997). COX exists in two 
isoforms, COX-1 and COX-2. COX-1 is constitutively expressed, whereas COX-2 is 
only expressed at low levels in resting cells. Marked upregulation of COX-2 occurs in 
macrophages and endothelial cells during sepsis. COX-2 expression is induced by LPS, 
a number of inflammatory mediators including the cytokines TNF and IL-1, mitogens 
and growth factors. In particular, thromboxane A2 (TXA2) and prostacyclin levels are 
raised in septic shock (Bernard et al., 1991 and Holtzman, 1991). TXA2 is a potent 
vasoconstrictor and a platelet stimulator (Hamberg et al., 1975). TXA2 downregulates 
iNOS expression in vascular smooth muscle cells stimulated with proinflammatory 
cytokines and it also inhibited NO production in an in vivo inflammatory model 
(Yamada et al., 2003). This suggests that TXA2 has a protective role against the 
development of vascular hyporesponsiveness via its inhibitory action on iNOS and the 
NO pathway in sepsis. Prostaglandin (PGE2) is one of the most potent and inducible of 
the prostanoids produced during inflammation. It is a mediator of sepsis-induced 
immunosuppression, an inhibitor of proinflammatory cytokine expression from 
monocytes, and an inducer of IL-10 production (Reddy et al., 2001; Strassmann et al., 
1994 and van der Pouw et al., 1995). PGE2 also mediates deleterious effects of sepsis 
such as vasodilatation and increased vascular permeability (Portanova et a\., 1996). 
Several studies have shown beneficial effects of non-selective COX inhibitors in 
endotoxin models (Beamer et al., 1987; Wanecek et al., 1997 McKenna, 1990; Gunnett
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et al., 1998 and Strong et al., 2000). However, Reddy and coworkers (2001) evaluated 
the effect of pre-treatment with NS-398, a highly selective COX-2 inhibitor on survival 
and inflammatory mediator production in two mouse models of sepsis and found only 
very modest effects on outcome. Patient studies using the non-selective inhibitors 
ibuprofen and lomoxicam have shown neither benefit nor any haemodynamic effects 
(Bernard et al., 1997; Arons et al., 1999 and Memis et al., 2004).
1.9 Summary and Aims
Septic shock still carries a considerable mortality and morbidity. In recent years there 
has been progress in the management of this condition (reviewed by Hotchkiss and 
Karl, 2003); however numerous trials of agents that inhibit the inflammatory cascade 
have proved unsuccessful. The reasons for this are complex and include an over reliance 
upon animal models not representative of the clinical condition. The aim of this thesis 
was to investigate mechanisms underlying vascular hyporeactivity and hypotension in 
septic shock. I have chosen specifically to examine 3 key components -  nitric oxide 
overproduction, activation of K + channels (especially K a t p  channels) and vasopressin. 
In order to accomplish this I first sought to develop reproducible in vitro and in vivo rat 
models of sepsis, with translational work to patients in the clinical setting.
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Chapter 2
Characterisation of in vitro organ culture models of 
endotoxin-induced vascular hyporeactivity
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2.1 Introduction
Sepsis is characterised by an exaggerated host systemic inflammatory response 
characteristically leading to a high cardiac output, low systemic vascular resistance 
circulation with a low blood pressure (Parillo, 1993). In septic patients, an ai adrenergic 
agonist (usually norepinephrine) is often required to reverse hypotension. However, the 
hypotension may be resistant to high doses of these vasopressor agents, a state known 
as vascular hyporeactivity. A crucial aim o f my thesis was to establish a reproducible 
model of endotoxin-induced vascular hyporeactivity in rat blood vessels and to study 
the cellular mechanisms responsible for this.
Administration o f endotoxin (lipopolysaccharide; LPS), a cell wall component 
ubiquitous to Gram-negative bacteria has been used extensively to mimic Gram- 
negative sepsis (see Thiemermann, 1997, Deitch, 1998 and Bateman et a l , 2003) in 
both animals and human volunteers. Substantial evidence from different species 
suggests that NO is the main mediator o f vascular hyporeactivity in sepsis (reviewed in 
Vincent et al., 2000; Landry and Oliver, 2001 and Hauser et al., 2004,). Endotoxin is 
also known to induce the expression o f other enzymes COX-2 (Bishop-Bailey et al., 
1997A), overproduction o f arachidonic acid metabolites (reviewed in Mitchell et al.,
1995), and thromboxane A2 (Yamada et al., 2003) suggesting that additional 
mechanisms are likely to contribute to endotoxin-induced changes in vascular 
reactivity.
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To date, the majority o f in vitro investigations into the mechanisms underlying vascular 
hyporeactivity have used aortic tissues from rodents (Julou-Schaeffer et al., 1990; Scott 
et al., 1996 and Hall et al., 1996). However, the aorta is a large conduit vessel that only 
makes a small contribution to systemic vascular resistance. In contrast, inducing 
hyporeactivity in smaller rodent blood vessels has proved very difficult. For example, 
hyporeactivity could be demonstrated in small mesenteric and femoral vessels ex-vivo, 
but only if the bathing medium contained L-arginine, the precursor for NO synthesis 
(Schneider et al., 1992, Schneider et al., 1994 and Mitolo-Chieppa et al., 1996). In 
addition, the response to LPS has been shown to differ among vascular beds with 
hypocontractility to methoxamine (an ai adrenergic agonist) seen in aorta and 
mesentery but not renal beds (Farmer et al., 2003) and LPS-dependent vasodilatation 
seen more in coronary and renal arteries than mesenteric and hepatic (Piepot et al., 
2002).
I sought to develop a reproducible in vitro model of hyporeactivity in a smaller artery 
than aorta. I chose to study rat mesenteric artery as the mesenteric circulation is an 
important contributor to vascular tone, receiving 30-40 % of the total cardiac output. I 
sought to develop an organ culture method that I could use to investigate the effect of 
LPS on vascular reactivity to the a i agonist, phenylephrine (PE) and to assess the role 
of the NO pathway in vascular hyporeactivity. I used a variety o f methods, including 
pharmacological inhibitors of iNOS, nitrite assay to assess directly the production of 
NO, as well as immunohistochemistry to look at protein expression of iNOS. I also
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assessed the contribution of inducible COX-2 to vascular hyporeactivity using the 
relatively selective inhibitor, NS-398.
In order to investigate human vessels in vitro, I chose the marginal artery. Only a 
handful o f studies have been able to demonstrate vascular hyporeactivity or induction o f 
nitric oxide synthase in human vessels. These have either used a combination o f  pro- 
inflammatory cytokines and LPS (Throin-Trescacses et al., 1995 and Chester et al., 
1998) or a continuous infusion of lipoteichoic acid derived from staphylococcus aureus 
(Tsuneyoshi et al., 1996) to mimic Gram-positive infection. The marginal artery is a 
third order branch o f the superior colonic artery, which is also part o f  the mesenteric 
circulation and thus compliments my rat in vitro model. I applied the same organ 
culture model principles as with the rat model but added the pro-inflammatory cytokine 
IL -lp  in combination with LPS in an attempt to produce vascular hyporeactivity. When 
IL-1(3 is infused into human cancer patients it has been shown to cause hypotension 
(Dinarello, 1996). As with the rat model, my aim was to characterise the responses o f 
the vessel to LPS and IL -lp  and investigate the contribution o f the NO pathway.
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2.2 Methods 
2.2.1 In vitro model of LPS-induced vascular hyporeactivity to phenylephrine
2.2.2 Dissection of rat mesenteric artery
Male Sprague-Dawley rats (250-300 g body weight) were killed via cervical dislocation 
in accordance with schedule 1 o f the Animals (Scientific Procedures) Act 1986. This 
procedure conforms to the Guide fo r  the Care and Use o f  Laboratory Animals, 
published by the US National Institutes of Health (NIH Publication No. 85-23, revised
1996). The rats were bred in house at University College London. The mesenteric artery 
was dissected out and placed in sterile Hanks Balanced Salts Solution (HBSS). The 
artery was cleaned o f connective tissue and cut into four rings. Rings from 2 animals 
were used per experiment, i.e. 8  in total.
2.2.3 Incubation with LPS
Rings were incubated in sterile Dulbecco's Modified Eagle's Medium (DMEM) for 6 , 20 
or 46 h in an atmosphere o f 95% air / 5% CO2 in a sterile 12-well dish. In these 
experiments (except where stated) the culture medium was supplemented with fetal 
bovine serum (FBS, 10% v/v) and with penicillin-streptomycin solution (100 units ml' 1 
and 100 pg ml"1, respectively). LPS {Salmonella typhosa) was added to the appropriate 
segments at various doses (10 pg ml' 1 -  100 pg ml'1). In a few experiments, vessels 
were incubated within the organ bath with or without 1 pg ml' 1 LPS for 6  h in 
physiological saline solution (PSS) with the following composition (in mM): 112 NaCl,
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5 KC1, 25 NaHCOs, 1 MgCl2, 0.5 KH2P 0 4, 0.5 NaH2P 0 4, 10 glucose, 1.8 CaCl2 and 
0.03 phenol red) gassed with 95% O2/ 5% C 0 2 at 37°C.
2.2.4 Tension experiments
Following incubation in culture medium, tissues were transferred to 25 ml organ bath 
chambers containing PSS, except for experiments using fresh controls, in which rings 
were used immediately after dissection. The rings were suspended between two 
tungsten wires in a jacketed organ bath (Fig. 2.1). One of the wires was fixed to an 
external platform; the other was connected to an isometric force displacement 
transducer (FT-03, Grass Instruments, USA) for measurement o f tension. The 
transducers were coupled to a chart recorder. In all, 8  parallel organ baths were used in 
the tension experiments. Following mounting, the rings allowed to equilibrate at a 
tension o f 1.25 g for 1 h, during which time tissues were washed at 15 min intervals. 
The rings were permitted to relax to a resting tension o f 0.8 -  1 g. Where appropriate, 
LPS was added to the organ baths for the duration o f the experiment. To assess 
contractility, rings were twice contracted with the ai adrenoreceptor agonist 
phenylephrine (PE, 1 pM), separated by a 20 min period during which time tissues were 
washed several times in order to restore tension back to 1 g.
61
Characterisation o f  in vitro orsan culture models o f  LPS-induced vascular hyporeactivitv
STRAIN GAUGE
ORGAN BATH
HEATING
FILAMENT
Figure 2.1 The organ bath apparatus.
Endothelial function was assessed by monitoring relaxation to the endothelium- 
dependent agonist, acetylcholine (Ach, 5 pM) in rings precontracted with 1 (liM PE. 
Endothelium was considered viable if there was greater than 50% relaxation to Ach 
(Fig. 2.2). Such responses were maintained even after 46 h incubation in culture 
medium. The magnitude of the relaxation induced by acetylcholine in control tissues 
did not alter with time in culture medium, being (80.6 ± 0.2%, n= 13 at 6 h and 79.0 ± 
9.7, n= 8, at 20 h). In certain experiments the endothelium was removed by gently 
passing a small tungsten wire through the lumen of the ring or by rubbing the lumen 
with some filter paper soaked in PSS, prior to mounting it in the organ bath. The 
successful removal of the endothelium was confirmed by the lack of response to the 
ACh.
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Figure 2.2 Effect o f acetylcholine (Ach; 5 pM) on an endothelium-intact rat 
mesenteric artery ring incubated for 20 h in culture medium. The tissue was pre­
contracted with phenylephrine (PE; 1 pM).
2.2.5 Experimental protocols
At least 5 mesenteric rings, taken from a minimum of three animals, were used for each 
experimental group. Cumulative concentration-response curves were constructed to PE 
(10'9 to 10'5 M) with the agonist added at 5 min intervals. The contractile response of 
the rings to the agonist reached a plateau within 5 min. Except where indicated, all 
concentration-response curves were constructed using endothelium-intact rings.
I wished to develop a reproducible model of LPS-induced vascular hyporeactivity in rat 
mesenteric artery. No prior studies had been carried out on this vessel. I initially added 
LPS to PSS within the organ bath for a 6 h period of incubation, but was unable to
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demonstrate hyporeactivity using this method. Thus I developed an organ culture model 
using culture medium containing fetal bovine serum at 3 different incubation periods -  
6  h, 20 h and 46 h. I wished to characterise the vascular response to LPS in rat 
mesenteric artery and specifically examine the induction o f nitric oxide in this response. 
I thus performed the following experiments.
(i) Concentration-response to LPS
I was interested to see whether pathophysiologically relevant concentrations o f LPS 
measured in humans were sufficient to produce vascular hyporeactivity. I thus used 
concentrations of LPS ranging from 10 pg m l ' 1 to 100 pg ml'1. Individual 
concentrations were added to the culture medium and the tissues incubated overnight 
for 2 0  h.
(ii) Varying duration o f LPS incubation
Tissues were incubated in the presence or absence of LPS (1 pg ml'1) for 6 , 20 and 46 h 
prior to mounting in the organ bath.
(iii) Effect o f fetal bovine serum (FBS)
Rings were incubated with and without LPS (1 pg m l1) for 6 , 20 and 46 h in the 
presence or absence o f 10% FBS in the culture medium.
64
Characterisation o f  in vitro orsan culture models ofLPS-induced vascular hyporeactivitv
(iv) Role o f endothelium
Following incubation with and without LPS (1 pg ml'1) for 20 h some rings were 
denuded o f endothelium. However, for all subsequent experiments I used endothelial- 
intact rings so as to study the effects of LPS upon the whole blood vessel.
(v) Role of the NO / cGMP pathway in mediating vascular hyporeactivity
(a) Inhibition o f  nitric oxide synthase (NOS)
Rings were incubated with and without LPS (1 pg m l1) for 6 , 20 and 46 h. The 
following NOS inhibitors were added to the organ bath 25 min prior to construction o f a 
concentration-response curve to PE: “-nitro-L-arginine methyl ester (L-NAME; 300 
pM), aminoguanidine (400 pM), 1400W (10 pM) and GW273629 (10 pM). The NOS 
inhibitors were added to LPS treated and non-LPS treated control tissues that had been 
incubated in culture medium. In a separate series of experiments, aminoguanidine (400 
pM) was added to fresh control tissues immediately following harvest from the rat, 
prior to constructing a concentration-response curve to PE. In a further series of 
experiments, 1400W (10 pM) was added to the culture medium at the same time as the 
LPS for incubation periods o f 20 and 46 h prior to a concentration-response curve to 
PE.
(b) Inhibition o f  soluble guanylyl cyclase
As above, rings were incubated with and without LPS (1 pg m l'1) for 20 and 46 h and 
the selective soluble guanylyl cyclase inhibitor, lH-(l,2,4)oxadiazole(4,3-a)quinoxalin-
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1-one ODQ (3 pM) was added to the organ bath 25 min prior to the addition o f 
cumulative doses o f PE.
(vi) Effect o f LPS on responses to the thromboxane A2 mimetic U46619
I compared the vasoconstrictive properties o f the thromboxane A2 mimetic (9,11- 
dideoxy-9a, 11 a-methanoepoxy prostaglandin F2«), U46619 to PE in this model. Rings, 
either endothelium-denuded or intact, were incubated for 20 h with and without LPS (1 
pg ml'1) prior to constructing concentration-response curves to U46619 (10 '9 to 10‘6 M).
(vii) Concentration-response curves to the NO donor S-nitroso-N-acetyl-D, L- 
penicillamine (SNAP)
Concentration-response curves to SNAP (10’10-10'5M) were constructed following 
precontraction with either 1 pM PE or 0.1 pM U46619 in fresh endothelium-intact 
tissues. The iNOS inhibitor 1400W (10 pM), and ODQ (1 pM) - were added 25 min 
prior to the addition o f SNAP. Concentrations of SNAP were added in cumulative 
fashion every 5 min once contraction to PE had plateaued. The tissues had always 
maximally relaxed to the concentration of SNAP added within 5 min.
(viii) Inhibition of cyclo-oxygenase-2 (COX-2) activity
I investigated the effect o f the relatively selective cyclo-oxygenase-2 inhibitor, NS-398 
[N-(2-(Cyclohexyloxy)-4-nitrophenyl)- methanesulfonamide] (10 pM) in the in vitro 
model. Rings were incubated with and without LPS (1 pg m l1) for 20 h and NS-398 
was added to the organ bath 25 min prior to addition of PE.
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2.2.6 Nitrite determination
Due to the rapid metabolism and breakdown of NO, it is difficult to measure its 
production directly. However, a stable end product of NO metabolism, nitrite (NO2 ), is 
often used as a marker o f NO production (Thiemermann, 1997) and it is traditionally 
measured using the Griess reaction. The Griess reaction is based upon a NO2"- 
dependent diazotisation reaction, which produces a coloured azo compound that can be 
measured colorimetrically. This reaction can be used to determine NO2’ levels in cell 
culture supernatants. NO 2" reacts with acidified sulphanilamide and N -1 - 
napthylenediamine dihydrochloride to produce a coloured azo compound in a 
concentration-dependent manner. NO2’ formation can be thus used as a surrogate 
marker of NO production (Schmidt and Kelm, 1996).
Mesenteric rings were incubated for 20 h in culture medium containing serum, in the 
absence or presence of LPS 1 pg ml"1 ± 1400W (10 pM) or ODQ (3 pM). Following 
this, 150 pi o f the culture medium was pipetted into a 96-well microtitre plate. An equal 
volume o f Griess reagent (1% (w/v) sulphanilamide, 0.01% (w/v) N -l-
napthylethylenediamine dihydrochloride in 5% (v/v) phosphoric acid) was added to 
each well, mixed and left to stand for 15 min. A standard curve (Fig. 2.3) was prepared 
each time the assay was performed by serially diluting known concentrations of sodium 
nitrite (0.1 -  30 pM) and mixing with equal volumes o f Griess reagent. N 0 2" 
concentration was determined calorimetrically by subtracting the absorbance at 540 nm 
from that obtained at 620 nm (620 nm was a reference wavelength only).
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Figure 2.3 Nitrite standard curve were prepared by serially diluting 
sodium nitrite solution (Sigma, UK) to the desired concentration (n=2).
(i) Protein determination using the Lowry method
To normalise NO2 " concentration for tissue mass, the protein content of samples was 
measured following measurements of NO2 '. Each mesenteric arterial ring was dissolved 
overnight in 100 pi o f 2.5 M NaOH in a sonnicator. The following day samples were 
diluted in 400 pi H2 O. This was because 0.5 M NaOH was the maximum concentration 
of alkali acceptable to use in the Biorad DC protein assay (Biorad, U.S.A.), a standard 
assay based on the Lowry method (Lowry et al., 1951). Protein standards were prepared 
from bovine serum albumin, which was dissolved in 0.5M NaOH and diluted at a 
variety o f concentrations between 0.2 and 1.4 mg ml' 1 (Fig. 2.4). 5 pi o f standards and 
samples, 25 pi o f an alkaline copper tartrate solution and 200 pi o f a dilute Folin 
reagent were added to each well o f a 96 well plate. The solution was mixed for 5 
seconds. After 15 min absorbance was read at 750 nm.
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Figure 2.4 An Example of a standard curve using the Biorad DC protein assay.
2.2.7 Immunohistochemical staining of iNOS
Rings of LPS-treated mesenteric arteries and their appropriate controls taken from both 
in vitro (LPS, Salmonella Typhosa 1 pg ml’1) or in vivo (LPS, 40 mg kg ' 1 Klebsiella 
Pneumoniae; see chapter 3) models of vascular hyporeactivity were rinsed in phosphate 
buffered saline (PBS), immersed in OCT fixative (Histologicals Ltd, UK) and left on 
dry ice until frozen. The OCT block was then placed on a cryostat (-20°C) to cut 
sections. Cryostat sections (7 pM) were brought to room temperature and left to dry for 
30 min. The sections were then fixed in acetone (-20°C) for 20 min, allowed to dry and 
rehydrated in running tap water. Endogenous peroxidase was inhibited with 0.3% H2 O2 
in methanol for 30 min followed by 3 washes in PBS. Non-specific binding o f the 
secondary antibody was blocked by incubating the sections in 3% normal goat serum in 
PBS. Sections were drained and incubated overnight at 4 °C with the primary antibody -
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monoclonal rabbit anti-mouse iNOS (Upstate Biotechnology NY, U.S.A.) at 1:200 
dilution. Negative controls were sections incubated overnight without the primary 
antibody. Sections were washed in PBS three times (5 min) and incubated for 45 min 
with the biotin conjugated anti-rabbit antibody (1:1000 dilution; Sigma, U.K.) and 
washed again in PBS 3 times (5 min). Sections were then incubated using the avidin -  
biotin system for 45 min and washed a further 3 times in PBS (5 min). The antigen was 
visualised by immersion o f the sections in a diaminobenzidine solution. Sections were 
lightly counterstained with Mayer’s haematoxylin and dehydrated through a series of 
alcohols, cleaned in xylene and permanently mounted in DPX (Merck, U.K.).
2.2.8 In vitro model of vascular hyporeactivity in human marginal artery
2.2.9 Dissection of human marginal artery
This artery is formed by the anastomosis of the distal portions o f the superior and 
inferior mesenteric arteries and runs in the wall o f the colon. Human colonic marginal 
artery was collected from patients undergoing large bowel resection for a neoplasm or 
inflammatory bowel disease. The tissues were provided, with the patients’ consent, by 
the colorectal surgeon Professor Boulos at University College London Hospitals. The 
artery was dissected clear of the resected bowel, placed in HBSS and cleaned of 
connective tissue. This procedure took at least one hour as there was a substantial 
amount of fatty tissue surrounding the vessels. There were often delays in being notified 
that the operation was complete and thus the specimen may have been left in a bowl for
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over 1 hour prior to collection. Once cleaned, the artery was cut into rings, up to 6  
depending on the length o f tissue obtained.
2.2.10 Incubation with LPS ± interleukin-1 beta (IL-lp)
Tissues were then incubated with LPS (<Salmonella typhosa) ± IL -ip  to induce vascular 
hyporeactivity. Previous studies have used 100 units ml' 1 alone to induce hyporeactivity 
(Thorin Trescases et al., 1995) or COX-2 (Bishop-Bailey et al., 1997 b). A combination 
o f 5 units ml' 1 o f IL -ip  with LPS 10 pg ml' 1 had been used to induce iNOS in human 
tissue (Chester et al., 1998) and, as cytokines are expensive, I used this concentration 
together with LPS up to 100 pg ml'1. Rings were incubated in sterile DMEM for 20 or
o
46 h at 37 C in an atmosphere o f 95% air / 5% CO2 . In all experiments the culture 
medium was supplemented with 10% FBS.
2.2.11 Tension experiments
Following incubation in culture medium, rings of marginal artery were that had been 
incubated in culture medium either alone (control), or with IL-lp (10 units m l'1) and / or 
LPS (10 pg ml'1) were transferred to the organ bath chamber as described previously for 
the rat mesenteric artery. The tissues were subjected to a tension o f 2 g and permitted to 
relax to a resting tension of 1.5 g and concentration-response curves were constructed to 
PE (10'9 to 104 M). No previous studies using this vessel had been performed to suggest 
a resting tension. The human vessels have a much tougher layer of adventitia and I 
found that whatever tension I used they would relax to 1-1.5 g and thus I used 1.5 g.
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2.2.12 Experimental protocols
(i) Dose and duration o f incubation of LPS and IL-1 p
LPS, at doses o f 1, 10 or 100 pg ml'1, IL-lp (10 units ml’1) or a combination (10 pg ml' 
1 LPS + 10 units ml"1 IL -ip) were added to the culture medium and tissues incubated for 
a total o f 20 h (3 patients) or 46 h ( 6  patients). LPS was not added to the organ bath 
during the experiments.
(ii) Nitric oxide synthase inhibition
As with the rat model, I wished to characterise the vascular responses within this vessel. 
Since the non-selective NOS inhibitor, L-NMMA reversed hypotension in septic 
patients (Grover et a l,  1999), I investigated the effect o f iNOS inhibition in this model. 
The non-specific NOS inhibitor, L-NAME (300 pM) or the highly specific iNOS 
inhibitor, 1400W (10 pM) was added to the organ bath o f tissues treated with LPS + IL- 
lp  25 min prior to a cumulative concentration-response curves to PE.
2.3 Statistical analysis
All data are represented as mean ± standard error of the mean (s.e.m.) o f n observations. 
Statistical analysis was performed using SigmaStat (Jandel Corporation, Chicago, 
U.S.A.). To compare differences between two groups, a paired or unpaired Student’s t- 
test was used. For multiple groups where several measurements were made in the same 
tissue / whole animal over time, where appropriate, two way ANOVA with repeated 
measures was used and, corrected for multiple comparisons against the control group 
(Bonferroni) or all groups (Student-Newman Keuls). The concentration o f agonist
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causing a 50% contraction or relaxation of the maximal response is expressed as the 
pECso value and was calculated using the sigmoidal curve fitting routine in Origin 6.0 
software (Microcal, Northampton, MA, U.S.A.). Individual pECso values were obtained 
from each experiment and the mean values between experimental groups compared 
using one way ANOVA (with Bonferroni or Student-Newman Keuls correction as 
appropriate). In all cases, a P  value < 0.05 was considered statistically significant.
2.4 Reagents and solutions
Hanks Balanced Salt Solution containing calcium and magnesium (Invitrogen Ltd, 
Paisley, U.K.) was supplemented with 5 mM HEPES, 2 mM NaHCCh, 50 units ml"1 
penicillin and 50 pg ml' 1 streptomycin. Dulbecco’s Modified Eagle’s Medium was 
supplemented with penicillin-streptomycin solution ( 1 0 0  units ml"1 and 1 0 0  pg ml"1, 
respectively) and 2 mM L-glutamine (Invitrogen Ltd) and where appropriate fetal 
bovine serum. L-NAME, aminoguanidine, LPS {Salmonella typhosa), acetylcholine, 
sodium nitrite and phenylephrine were all obtained from Sigma Chemical Company 
(Poole, Dorset, U.K.). Fetal bovine serum was obtained from Invitrogen Ltd, U46619 
from Affiniti-Research, (Exeter, U.K.) and 1400W, ODQ, NS-398 and SNAP from 
Alexis Corporation (Nottingham, U.K.). GW 273629 was kindly donated by 
GlaxoSmithKline (Stevenage, U.K.).
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2.5 Results
2.5.1 Characterisation of an in vitro rat model of sepsis
2.5.1.1 Effect of LPS on contractile responses to PE in mesenteric artery
A typical cumulative concentration-response curve to phenylephrine (PE) in an 
endothelium-intact rat mesenteric artery (RMA) incubated in culture medium 
supplemented with 1 0 % fetal bovine serum in the absence (control) and presence o f 1 
pg ml"1 LPS for 6  h and 20 h is shown in Figure 2.5. Unless otherwise stated all results 
refer to endothelial intact RMA. LPS induced marked hyporeactivity to PE, causing a 
substantial depression in the maximal response and a shift to the right of the 
concentration-response curve compared to control tissues. In contrast, no hyporeactivity 
to PE was observed if tissues were incubated with 1 pg ml"1 LPS in PSS for 6  h in the 
organ bath chamber (data not shown).
Reported levels for biologically active endotoxin in sepsis vary widely, reflecting 
differences in LPS standards, assays, diseases and models utilized. In humans, maximal 
reported concentrations o f LPS range from as low as 0.05 -  4 ng ml' 1 (van Deventer et 
al., 1988 and Parillo et al., 1991) to as high as 10 ng ml"1 of lipopolysaccharides in 
systemic meningococcal disease (Brandtzaeg et al., 1989). It has been shown that 
concentrations as low as 1 ng ml"1 o f LPS suppressed contractions to norepinephrine in 
rat aorta when incubated for 16 h (Mckenna, 1990). Thus I examined the effect of 
varying the LPS concentration in RMA incubated for 20 h in culture medium
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supplemented with serum. At all concentrations LPS (1-100 pg ml'1) induced significant 
hyporeactivity to PE (P < 0.001, two-way ANOVA; Fig. 2.6A) with the maximal 
response (EMax) in the presence of 1 pg ml"1 LPS being suppressed from 1 . 6 6  ± 0.27 g to 
0.7 ± 0.14 g («=5-6). In addition, LPS caused a rightward shift o f the pECso compared 
to controls (n=5-6; P  < 0.001, one-way ANOVA, Table 2.1 A). The degree of 
hyporeactivity induced by LPS was similar over this concentration range. A further set 
of experiments using the same organ culture model investigated what threshold 
concentration o f LPS was required to induce significant vascular hyporeactivity. LPS 
induced significant hyporeactivity at concentrations as low as 0.001 pg ml"1 (P < 0.001, 
two-way ANOVA; Fig. 2.6B). In addition, there was a rightward shift o f the pECso 
from control to LPS 0.01 ng ml' 1 (P < 0.05 one-way ANOVA; Table 2. IB).
Table 2.1 Effect of LPS upon contractile responses to phenylephrine 
A. Comparison of pECso and EMax values for control and LPS treated tissues
Data are expressed as mean ± s.e.m. of > 5 observations
Rat mesenteric 
artery
pECso E]Vfax (g) n
Control 6.54 ± 0 .1 9 1.55 ± 0 .1 9 5
LPS 1 pg ml"1 5.81 ±0 .05* 0.69 ±0 .11 6
LPS 10 pg ml"1 5.64 ± 0.07* 0.60 ± 0 .1 2 6
LPS 100 pg ml"1 5.61 ±0 .05* 0.79 ± 0 .1 4 5
* P<0 . 0 0 1  compared to control
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B. Comparison of pECso and EMax values for control and LPS treated tissues
Rat mesenteric 
artery
pECso EMax (§) n
Control 7.17± 0.18 0 . 8 6  ± 0.08 6
LPS 0.1 ng ml"1 6.79 ±0.11 0.15 ±0.06 7
LPS 0.01 ng ml' 1 6.33 ±0.13* 0 . 2 1  ±0.08 6
LPS lOpgml"1 7.07 ± 0.29 0.85 ± 0.2 6
*P<0.05 compared to control
It was not possible to calculate accurate pECsoS for LPS lpg  ml"1 and 1 ng ml' 1 as the 
concentration response curves were flat.
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Figure 2.5 Representative traces of contractile responses to phenylephrine for control and LPS 
(1 pg m l1) treated rat mesenteric arteries for either A) 6 h or B) 20 h. All tissues were 
endothelium intact and incubated in culture medium containing serum. Phenylephrine was 
added at half log units at 5 min intervals as shown by the arrows.
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Figure 2.6 Effect of varying concentrations of LPS on contractile responses to PE. 
Tissues were incubated (with serum) for 20 h with A) LPS 1-100 pg ml'1 and B) 
LPS 10 pg ml'1 to lpg ml'1. LPS induces hyporeactivity at all concentrations aside 
from 10 pg ml'1 (PO.OOl, ANOVA). Data are expressed as mean ± s.e.m. of 5-6 
observations from 8 animals.
78
Characterisation o f in vitro organ culture models ofLPS-induced vascular hyporeactivity
2.5.1.2 Effect of duration of incubation and presence of serum upon response to 
LPS
In vivo models have shown a difference in the amount of NO generated and 
haemodynamic response over time in animals given LPS (Lui et al., 1997 and Rees et 
al., 1998). In addition, LPS-induced expression of mRNA for iNOS has been shown to 
vary in rat aorta in vitro (Mitchell et al., 1997). There had been no such work on rat 
mesenteric artery and thus I investigated 3 different durations of incubation. In the 
development of the in vitro model, I wished to examine the effect of adding serum to 
the culture medium. Serum contains LPS binding protein and soluble CD 14 which have 
key roles in recognition of LPS via toll receptors (Knapp et al., 2005). I thus wished to 
investigate whether culture medium with added serum produced more profound 
vascular hyporeactivity in this model.
Control tissues were incubated in the presence and absence of fetal bovine serum (FBS; 
10% v/v) for 6 , 20 or 46 h. Over this time course, peak responses to PE were 
comparable over the whole concentration range to those observed in fresh controls (P > 
0.05, two-way ANOVA; Fig. 2.7A and C). However, contractions elicited from tissues 
incubated for 46 h in culture medium with or without serum were much less sustained 
than those observed at either 6  or 20 h. For example, at 1 pM PE, peak contractions 
over a 5 min period declined by 2% at 6  h, 9% at 20 h and 42 % at 46 h. Moreover, 
when tissues were incubated in the presence of LPS, there appeared to be a differential 
effect on the contractile responses to PE. In serum-free conditions, substantial 
hyporeactivity to LPS (1 pg m l1) was evident at 6  and 20 h time points (EMax 0.47 ±
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0.13 g and 0.75 ± 0.09 g, respectively compared to 1.56 ± 0.16 g in controls; n=5-6, P < 
0.001, two-way ANOVA), but not at 46 h (Emex 1.55 ± 0.17 g) (Fig. 2.7 D). However, 
in tissues incubated in serum, LPS induced significant hyporeactivity at all time points 
including 46 h (maximal response 0.21 ± 0.05 g compared to 1.56 ± 0.14 g in controls; 
«=7, P  < 0.001, two-way ANOVA) (Fig. 2.7 B).
When comparing the effect of serum on pECso values, there was only a difference 
between the control tissues at 2 0  h incubation with the concentration-response curve 
shifting to the right when the tissue was incubated with serum (7.44 ± 0.09 to 6.75 ± 
0.11, P  = 0.008, «=10, ANOVA; Table 2.2).
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Table 2.2 Effect of serum on contractile responses in rat mesenteric artery to PE in 
control or LPS-treated tissues
Comparison of pECso and Emex values for endothelium-intact LPS-treated and control 
tissues incubated in culture medium ± serum for 6  -  46 h. Data are expressed as mean ± 
s.e.m. of > 5-10 observations
Incubation
time
Control pECso EMax (§) LPS pECso EMax (§)
-Serum
Oh 6.87±0.09 0=6) 1.54±0.15
6  h 6.45±0.23 0=8) 1.29±0.06 5.78±0.10 (n=5) 0.75±0.09
2 0  h 7.44±0.09* O=10) 1.31±0.13 6.10±0.16 0 =6) 0.4±0.13
46 h 7.11±0.14 (n=6) 1.7±0.15 6.78±0.21 («=6 ) 1.55±0.17
+ Serum
6  h 6.48±0.09 («=6 ) 1.63±0.07 5.79±0.07 0=8) 0.31±0.04
2 0  h 6.75±0.11*0=10) 1.71±0.1 5.78±0.19 0 =8) 0.19±0.04
46 h 6.93±0.13 (n=9) 1.57±0.06 5.99±0.57 0=7) 0.23±0.07
* /M).008 when directly compared
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Figure 2.7 Effect of incubation time and serum on LPS-induced hyporeactivity in RMA. 
Endothelium intact tissues were incubated in the absence (controls) or presence of LPS for 
0-46h with (A, B) or without (C, D) serum. LPS induces hyporeactivity at all times 
(PO.OOl) except at 46 h in the absence of serum. Data are expressed as mean of 6-10 
observations from 8-12 rats.
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2.5.1.3 Effect of endothelium on contractile responses to phenylephrine
iNOS can be expressed in all 3 arterial cell layers (the endothelium, smooth muscle and 
adventitia). The major site of production is however, controversial with earlier studies 
suggesting the smooth muscle (Knowles et a l , 1990) but more recent evidence points 
towards the adventitia as the primary location of iNOS (Zhang et al., 1999 and Muller 
et al., 2000). It has been shown that the presence of endothelium appears to enhance the 
sensitivity to LPS (Baydoun et a l ,  1993), but also that the magnitude of the 
hyporeactivity seen is unaffected by endothelial removal (Rees et a l ,  1990). Thus I 
investigated the effect of LPS on hyporeactivity in the presence and absence of 
endothelium.
In the absence of LPS, the presence o f endothelium, in either fresh control tissues or 
tissues incubated in culture medium containing serum for 20 h, produced a rightward 
shift in the concentration-response to PE, although the maximum contraction observed 
was similar in both cases (Fig. 2.8A and B). In fresh tissue the pECso was shifted from 
6.87 ± 0.09 in endothelium-intact rings to 8.19 ± 0.27 in endothelium-denuded rings (P 
< 0.001, ANOVA; n=6). In tissues incubated at 20 h, the pECso was shifted from 6.35 ± 
0.29 in endothelium-intact rings to 7.73 ± 0.27 in endothelium-denuded rings (n=6; P < 
0.01, one-way ANOVA). However, following a 20 h incubation in LPS (1 pg ml'1), the 
same level o f hyporeactivity was observed regardless o f whether the endothelium was 
present or not (Fig. 2.8B) and there was no difference in the pECso values (Table 2.3).
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Figure 2.8 Effect of endothelium (endo) on contractile responses to phenylephrine. 
Tissues were either immediately transferred to the organ bath (A) or incubated with serum 
in the absence (controls) or presence of 1 pg ml'1 LPS for 20 h (B). Removing endo after 
incubation increased contractile responses in fresh RMA (PO.OOl, n=6-7) and controls 
(P<0.05, n=6); responses in LPS treated RMA were unaffected. Data are expressed as 
mean of 6-8 observations from 8-10 animals.
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Table 2.3 Effect of the endothelium on contractile responses to PE
Comparison of pECso and Em&x values for LPS-treated and control tissues incubated for 
20 h. Data are expressed as mean ± s.e.m. of 6-9 observations.
Rat mesenteric artery pECso EMax (§) n
Control ± endothelium 6.35 ± 0.30* 1.36 ±0.09 6
Control - endothelium 7.74 ± 0.27* 1.31 ±0.17 6
LPS ± endothelium 6.05 ± 0.22 0.51 ±0.11 6
LPS - endothelium 6.41 ±0.14 0.38 ±0.8 6
* P<0.001 when directly compared
2.5.2 Effect of inhibitors of the NO pathway on LPS responses in rat mesenteric 
artery
2.5.2.1 Effect of NOS inhibition on contractile responses to PE
To investigate the role of different NOS isoforms enzymes, L-NAME (a non-selective 
NOS inhibitor; Schwartz et al., 1997), amino guanidine (a more selective iNOS 
inhibitor; Ruetten and Thiemermann, 1996), and the highly selective iNOS inhibitor 
1400W (Garvey et al., 1997) were used. At 6 h after incubation, the addition of either 
aminoguanidine (400 pM) or L-NAME (300 pM) to the organ bath fully reversed LPS- 
induced hyporeactivity («=7-9) (Fig. 2.9 A). There was no difference in pECso values 
between controls and both these iNOS inhibitors (Table 2.4 A).
85
Characterisation o f  in vitro orsan culture models o f  LPS-induced vascular hyporeactivity
Surprisingly, at 20 h no reversal was seen with L-NAME (Fig. 2.9 B and Table 2.4 B). 
However, partial reversal was achieved with either aminoguanidine or 1400W, the latter 
being significantly more effective above 0.3 pM PE (P<0.01, two-way ANOVA) (Fig.
2.9 B). At 46 h partial reversal of hyporeactivity was seen with 1400W, whereas 
aminoguanidine and L-NAME had no effect on PE contractions (Fig. 2.9 C). There was 
little difference between the pECso values for PE using the 3 inhibitors (Table 2.4 C). 
The differential and time-dependent effects of these NOS inhibitors prompted further 
investigations using GW273629, another specific iNOS inhibitor (Young et a l , 2000; 
Alderton et al., 2005). Similar effects to 1400W were seen at 20 h and 46 h with 10 pM 
of this agent (Fig. 2.10 A & B and Table 2.4 B & C). In addition, when tissues were 
preincubated with both LPS and 1400W i.e. the inhibitor was added to the culture 
medium at the same time as LPS, hyporeactivity was fully reversed at 20 h and 46 h. 
Thus, the effect was superior to that seen when the inhibitor was added to the organ 
bath 25 min prior to contraction with PE (Fig. 2.11 A & B and Table 2.4 B & C).
In control tissues, small but significant (P < 0.05, two-way ANOVA; «=6-10) increases 
in the contractile responses to PE were seen in the presence o f 1400W and 
aminoguanidine at all time points (Fig. 2.12 B). The maximal response was increased 
by 14 %, 26 % and 19 % to 1.75 ± 0.16 g, 1.75 ± 0.22 g and 2.06 g ± 0.12 g at 6, 20 and 
46 h, respectively; although there was no significant effect on pECso values (Table 2.4 
D). However, since aminoguanidine did not potentiate PE contractions in fresh control 
tissues (Fig. 2.12 A) this suggests some induction of iNOS when tissues were incubated 
in culture medium containing serum.
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Figure 2.9 Effect of NOS inhibitors, aminoguanidine (300pM), L-NAME (300pM) & 1400W 
(10pM) on LPS-induced hyporeactivity. RMA was incubated ± LPS for (A) 6, (B) 20 & (C) 
46 h. All completely reversed hyporeactivity at 6h; AMG & 1400W caused partial reversal at 
20h (P<0.05 c.f. LPS) whereas 1400W alone caused partial reversal at 46h (P<0.05 c.f. LPS). 
Data is expressed as mean ± s.e.m. of 7-11 observations from 12-14 rats.
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Figure 2.10 A comparison of the specific iNOS inhibitors, 1400W (lOpM) and 
GW273629 (lOpM). Endothelium-intact rings were incubated for (A) 20 h and 
(B) 46 h in the absence or presence of 1 pg ml'1 LPS ± iNOS inhibitor. Both 
inhibitors had a similar effect and partially reversed LPS-induced hyporeactivity 
at 20 & 46 h (PO.OOl c.f. LPS). Data are expressed as mean ± s.e.m. of 7-11 
observations from 14-16 animals.
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Figure 2.11 Effect of preincubation (adding to culture medium) with 1400W (10 pM) 
for (A) 20 or (B) 46 h compared to adding 1400W to the organ bath 25 min prior to 
concentration-response curve. Preincubation with 1400W fully reversed LPS-induced 
hyporeactivity at 20 & 46 h (P0.001 compared to adding 1400W to the organ bath). 
Data are expressed as mean ± s.e.m. of 7-11 observations from 10-12 animals.
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Figure 2.12 Effect of AMG (300pM) on endothelium intact fresh control tissues 
compared with rings incubated for 20 h. AMG increased contractile responses in RMA 
incubated for 20 h compared to fresh tissue (P<0.05). Data are expressed as mean ± 
s.e.m of 6 observations from 6 animals.
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Table 2.4 Effect of NOS inhibition on contractile responses to PE in control and 
LPS-treated tissues
Comparison o f pEC50 and Em&x values for LPS-treated and control tissues incubated 
in culture medium + serum for 6 -  46 h. Data are expressed as mean ± s.e.m. of > 8 
observations.
A. 6 h incubation
Rat mesenteric artery pECso EMax (§) n
Control 6.44 ± 0.07 * 1.54 ±0.1 1
LPS 5.77 ±0.08 * 0.28 ± 0.03 1
LPS + AMG 6.27 ±0.10 1.36 ±0.15 9
LPS + L-NAME 6.15 ± 0.11 1.54 ± 0.15 8
LPS + 1400W 6.75 ±0.14 1.69 ±0.09 7
* P<0.001 when directly compared
B. 20 h incubation
Rat mesenteric artery pECso EMax (§) n
Control 7.97 ± 0.27 1. 9 ± 0.11 10
LPS 5.78 ± 0.22* 0.28 ± 0.07 7
LPS + AMG 6.20 ± 0.20* 0.81 ±0.11 8
LPS + L-NAME 5.55 ± 0.24* 0.45 ±0.11 8
LPS + 1400W 6.35 ± 0.09* 1.16 ±0.1 10
LPS + GW273629 6.84 ± 0.29# 1.44 ±0.13 7
LPS + ODQ 7.86 ±0.53 1.66 ±0.09 8
*P<0.001 andP<0.05 compared to control
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C. 46 h incubation
Rat mesenteric artery pECso EMax (§) n
Control 7.06 ±0.16* 1.45 ±0.11 10
LPS 5.99 ± 0.57* 0.31 ±0.08 7
LPS + AMG 6.51 ±0.14 0.31 ±0.06 10
LPS + L-NAME 6.45 ±0.15 0.34 ± 0.06 10
LPS + 1400W 6.40 ± 0.33 0.89 ±0.18 7
LPS + GW273629 7.11 ±0.19 0.8 ± 0.09 11
LPS + ODQ 7.55 ± 0.20 1.05 ±0.12 11
*P<0.05 when directly compared
D. Effect upon control tissues
Rat mesenteric artery pECso EMax (g) n
Fresh 6.87 ± 0.09 1.44 ±0.16 6
Fresh + AMG 7.18 ±0.06 1.38 ±0.12 6
Control (6 h) 6.77 ±0.14 1.32 ±0.09 8
Control (6 h) + 1400W 7.22 ±0.21 1.7 ±0.07 6
Control (20 h) 6.91 ±0.10 1.67 ±0.08 10
Control (20 h) + 1400W 7.13 ±0.09 1.85 ±0.1 7
2.5.2.2 Effect of guanylyl cyclase inhibition on vascular hyporeactivity
Once formed, NO diffuses to adjacent target cells where it activates soluble guanylyl 
cyclase by binding to the iron located in the active site o f this enzyme. The resulting 
formation of cGMP, in turn, is considered to mediate many, though not all o f the 
biological effects o f NO (reviewed by Carvajal et a l , 2000). In view of the substantial 
inhibition of vascular hyporeactivity by NOS inhibitors, I wished to test whether cGMP
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was also responsible for the relaxant effects of LPS. I used the highly selective soluble 
guanylyl cyclase inhibitor, lH-(l,2,4)oxadiazole(4,3-a)quinoxalin-l-one, ODQ 
(Schmidt et al., 2003). ODQ (3|iM) produced similar reversibility o f LPS-induced 
hyporeactivity to 1400W. In tissues incubated with LPS for 20 h and 46 h, ODQ, like 
1400W, only produced partial recovery o f PE contractions when added to the organ 
bath (Fig. 2.13 A & B and Table 2.4 B & C).
2.5.3 Comparison of the contractile responses to U46619 and phenylephrine
Thromboxane A2 is a potent vasoconstrictor of many vascular beds (reviewed by 
Samuelsson et al., 1975). It has been suggested that its production may act as a 
compensatory mechanism to LPS induced hypocontractility (Cirino et al., 1996). 
Interestingly, there was no significant hyporeactivity to U46619 following 20 h 
incubation with LPS in endothelium-intact tissue despite LPS inducing marked 
hyporeactivity to PE in tissues taken from the same animal. In endothelium-denuded 
tissue however, some hyporeactivity was observed (Fig. 2.14 B). When compared to 
PE, the maximum response obtained to U46619 in LPS-treated tissues was significantly 
greater in either the presence (1.31 ± 0.13 g vs 0.51 ± 0.11 g; Fig. 2.14 A) or absence 
(1.01 ± 0.07 g vs 0.38 ± 0.08 g; Fig. 2.14 B) of endothelium («=6 - 10; P  < 0.001, one­
way ANOVA). In addition the concentration-response curves to U-46619 were shifted 
to the left compared to PE (Table 2.5).
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Figure 2.13 Effect of the soluble guanylyl cyclase inhibitor, ODQ (3 pM), on LPS- 
induced hyporeactivity; comparison with 1400W '' ? r ~ " Rings were incubated for 20 h 
(A) or 46 h (B) in the absence or presence of 1 mg ml'1 LPS. There was no difference 
between the 2 agents -  both partially reversing hyporeactivity (PO.OOl c.f. LPS). Data 
are expressed as mean ± s.e.m. of 8-10 observations from 8 animals.
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Table 2.5 Comparison of U-46619 vs phenylephrine in control or LPS-treated 
tissue ± endothelium (endo) after 20 h incubation with serum.
Data are expressed as mean ± s.e.m. of > 5 observations
Rat mesenteric 
artery
pECso EMax (§) n
Phenylephrine
Control + endo 6.35±0.30 1.4±0.1 6
Control -  endo 7.74±0.27 1.32±0.18 6
LPS + endo 6.05±0.22* 0.51±0.11 6
LPS -  endo 6.39±0.13# 0.38±0.78 9
U-46619
Control + endo 6.65±0.07 1.88±0.26 5
Control -  endo 7.52±0.13 1.46±0.12 10
LPS + endo 7.46±0.18* 1.3±0.13 7
LPS -  endo 7.04±0.11# 1.01±0.17 8
* and # P<0.002 when directly compared to each other
2.5.4 Effect of the nitric oxide donor, SNAP upon contractile responses to PE and 
U-46619
LPS caused significantly less hyporeactivity to U46619 than PE. In order to determine 
whether the differential effect of LPS on responses to PE and U46619 relate to 
differences in the ability o f NO to inhibit contraction to these agonists, I examined the 
effect of the NO donor, SNAP. SNAP is considered to cause vasorelaxation by 
releasing NO from within the smooth muscle cell (Lopez-Lopez et al., 2001). 
Endothelium-intact tissues were precontracted with either 1 pM PE (mean contraction
1.09 ± 0.05 g; «=6) or 0.1 pM U46619 (mean contraction 1.33 ± 0.08 g; n=8). Figure
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2.15A shows that SNAP relaxed PE and U46619 induced contractions with a similar 
potency, the log pECso values being 6.41 ± 0.13 and 6.32 ± 0.19 for U46619 and PE, 
respectively («=6). The concentration-relaxation curves to SNAP following 
precontraction with 1 pM PE were significantly inhibited by the guanylyl cyclase 
inhibitor, ODQ (P < 0.001). The highly specific iNOS inhibitor 1400W had no effect 
(Fig. 2.15 B).
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Figure 2.14 Effect of LPS (20h) on PE or U46619 induced contractions in RMA in 
the presence (A) or absence (B) of endothelium (endothelium removed after 
incubation in culture medium). LPS did not induce significant hyporeactivity to 
U46619 with 20 h incubation in endothelium-intact RMA, some hyporeactivity was 
induced by LPS in endothelium-denuded RMA (P<0.05). Data are expressed as the 
mean± s.e.m. of 8-10 observations from 12 animals.
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Figure 2.15 (A) Effect of SNAP following precontraction with PE and U-46619. (B) 
Effect of ODQ (3 fiM) and 1400W (10 pM) on concentration-relaxation curves to SNAP 
following contraction with PE in fresh RMA. SNAP relaxed PE and U46619 induced 
contractions with a similar potency. Concentration-relaxation curves to SNAP were 
significantly inhibited by ODQ (P < 0.001); 1400W had no effect. Data are expressed as 
mean ± s.e.m.
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2.5.5 Effect COX-2 inhibition on contractile responses to PE
COX-2 inhibition did not appear to contribute to the development of circulatory failure 
or multiple organ dysfunction in an in vivo model of rat endotoxic shock (Leach et al., 
1998). However, the role of the AA metabolites generated by COX-2 in vascular 
hyporeactivity in vitro is unclear. Previous studies tend to use indomethacin that inhibits 
both COX 1 and 2. I thus investigated manipulation of the cyclo-oxygenase pathway 
using the COX-2 inhibitor, NS-398 (Futaki et al., 1994) a relative selective inhibitor of 
COX-2. However, NS-398 (10 pM) had no effect upon the degree o f vascular 
hyporeactivity to PE following incubation with LPS for 20 h (Fig. 2.16). In fact, it 
actually significantly suppressed responses to PE in control tissues, possibly suggesting 
a non-specific effect on contraction.
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Figure 2.16 Effect of the COX-2 inhibitor, NS-398 on LPS-induced hyporeactivity. RMA 
was incubated for 20 h in the presence/absence of 1 pg ml'1 LPS ± NS-398 (10 pM). NS- 
398 had no effect upon vascular hyporeactivity in LPS treated tissues and indeed 
significantly suppressed responses to PE in control tissues (P<0.05). Data are expressed as 
the mean ± s.e.m of 5-6 observations from 5 animals.
2.5.6 Nitrite production in organ culture model
Having established an organ culture model of LPS induced vascular hyporeactivity that 
is reversible by inhibitors of iNOS, I was interested to determine whether NO was being 
released from the RMA rings. Measuring N02- is the standard way to assay NO 
production. Incubating RMA with LPS (1 pg ml"1) for 20 h doubled the amount of 
nitrite that could be detected in the culture media being 1.13 ± 0.15 and 2.19 ± 0.21 pM 
mg 1 protein in control and LPS-treated tissues respectively (P<0.001; Fig. 2.17). This
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increase in nitrite accumulation induced by LPS could be fully inhibited by the specific 
iNOS inhibitor, 1400W (10 pM) (0.93 ± 0.9, P<0.05; Fig. 2.17). The guanylyl cyclase 
inhibitor, ODQ (3pM) had no significant effect.
2.51
ZD
■G 0.5-+-*
Z,
0.0
Control LPS LPS+ LPS+ODQ 
1400W
Figure 2.17 Effect of 1400W and ODQ on accumulation of nitrite within culture media 
induced by LPS. Rings were treated for 20 h in the absence (control) or presence of 1 pg 
ml'1 LPS ± 1400W (10 pM) or ODQ (3 pM). LPS doubled the amount of nitrite 
produced within the culture media compared to controls (P0.001). This increase was 
inhibited by 1400W (P0.001) but ODQ had no effect. Data are expressed as the mean 
± s.e.m of 6 observations from 5 animals.
2.5.7 iNOS immunoreactivity
I have established that enhanced production of NO corresponded with LPS induced 
vascular hyporeactivity and that specific inhibitors of iNOS could reverse both. I thus
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used an immunohistochemical staining technique to visualise iNOS within the RMA 
following incubation with and without LPS in the presence of serum. 
iNOS protein was seen in all cell layers following incubation with LPS (1 pg ml'1) 
though expression levels varied between the different layers («=3; Fig. 2.18 & 2.19 and 
Table 2.6 and see Fig 3.3 for 4 h data). Staining was time-dependent with maximum 
protein levels seen at 20 h. The heaviest staining was consistently found in the 
adventitia with moderate amounts seen in the endothelium and only small amounts in 
the smooth muscle except at 46 h in LPS (Table 2.6). As expected, iNOS induction was 
also seen in control tissues incubated in culture medium, with significant staining 
evident at 46 h; heaviest staining again being in the adventitial layer with only small 
amounts evident in the smooth muscle layer. iNOS staining in control tissues 
corresponds with the organ bath experiments, in which 1400W significantly increased 
PE contractions in tissues incubated in culture medium in the absence of LPS.
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Figure 2.18 Distribution of iNOS within RMA in control and LPS (lfig m l1) 
treated RMA following 20 h incubation in culture medium + serum. Dense 
brown staining represents iNOS immunoreactivity («=3).
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Figure 2.19 Distribution of iNOS within RMA in control and LPS (lpg m l1) 
treated RMA following 46 h incubation in culture medium. Dense brown staining 
represents iNOS immunoreactivity (n=3).
Endothelium
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Table 2.6 Distribution of iNOS staining in RMA incubated in culture media ± LPS 
lpg ml-1
Symbols: - = no iNOS; -/+ = barely detectable; + = mild; ++ = moderate; +++ = heavy 
iNOS staining. Data compiled from a number of sections from 3 animals.
Endothelium Smooth Muscle Adventitia
Control 4 h - +/- -
LPS 4 h + + -
Control 20 h +/- +/- +/-
LPS 20 h ++ + +++
Control 46 h ++ + +++
LPS 46 h ++ ++ +
2.5.8 Characterisation of an in vitro model of sepsis using human vessels
Interestingly, there was little or no relaxation to the endothelium-dependent 
vasorelaxant, ACh (10 pM) in marginal artery rings precontracted with 2 pM PE at time
0 (immediately after dissection), 20 or 46 h (approx. 5-10%). When rings of marginal 
artery were incubated either alone or with a combination of LPS (1-100 pg ml ■‘) ±  IL- 
1(3 (10 units ml'1) for 20 h no hyporeactivity to PE was observed (n=4, data not shown).
1 thus prolonged the incubation period to 46 h which did produce significant 
hyporeactivity to PE and a depression in the maximal response compared to control 
tissues (P<0.001, «=6-10; Fig. 2.20A). The hyporeactivity was observed with either 
incubation of LPS (100 pg ml'1; n=9) or IL-1 (3 alone (10 units ml'1, «=10) or in 
combination («=8). With the combination of LPS and IL-1 p, the maximal contraction
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was reduced by 68 % from 3.81 ± 0.50g to 1.26 ± 0.16g). Despite a depression in EMax, 
there was no difference between the pECso values (control 5.59 ± 0.08 vs. LPS + IL-lp 
5.58 ± 0.08). However, neither the non-specific NOS inhibitor, L-NAME (300 pM; 
n=4) nor the specific iNOS inhibitor 1400W (10 pM) {n= 2) increased contractions to 
PE at 46 h (Fig. 2.20B).
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Figure 2.20 (A) Effect of LPS ± IL-1 p on contractile responses to PE in human 
marginal artery (HMA). There was hyporeactivity to PE incubated for 46 h with LPS 
(lOOpg ml'1), ILl-p (5 units ml'1) and LPS (lOpg ml'1) + IL-1 (3 (5 units ml'1) P0.001. 
(B) NOS inhibition had no effect on contractile responses to PE in HMA treated with 
LPS+ IL-1 p. Data are expressed as mean ± s.e.m. of 6-9 observations from tissue 
derived from 6 patients (n=4 for L-NAME and n-2 for 1400W).
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2.6 Discussion
2.6.1 Summary of results
I have successfully developed a reproducible in vitro organ culture model of sepsis in 
which LPS induces substantial vascular hyporeactivity to the oti-agonist, PE in rat 
mesenteric artery. LPS significantly depressed contractile response to PE at 
concentrations as low as 0.0 lng ml'1 which is akin to endotoxin levels found in human 
sepsis (Brandtzaeg et al., 1988 & Danner et al., 1991). The responses were dependent 
upon incubation time with LPS. Serum prolonged the effects of LPS causing marked 
depression of the contractile response even at 46 h, whereas without serum, responses 
had fully recovered by this time. In addition, hyporeactivity did not depend upon the 
presence of an intact endothelial layer.
I investigated the contribution of iNOS using inhibitors with varying selectivity towards 
this isoform. While these inhibitors fully reversed the LPS-induced hyporeactivity at 6 
h, the effects of these agents varied thereafter. Pre-incubation (adding the iNOS 
inhibitor to the culture medium at the same time as LPS) provided what appears to be 
complete reversal of vascular hyporeactivity compared to just adding the inhibitor 25 
min prior to the PE concentration-response curve. Consistent with this observation, 
ODQ reversed (-75%) the hyporeactivity at 20 and 46 h, confirming involvement of the 
NO/cGMP pathway in mediating hyporeactivity. I also demonstrated iNOS staining and 
increased production of nitrite in the culture medium of RMA rings treated with LPS. 
The latter was inhibited by the iNOS inhibitor 1400W, confirming that NO had been
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generated by this NOS isoform. An increase in contractile response to PE following 
addition of iNOS inhibitors in control tissues incubated in culture medium containing 
serum is consistent with the observation of iNOS staining in these tissues, which was 
particularly evident at 46 h. Nonetheless, a greater amount of iNOS staining was found 
in the RMA incubated with LPS compared to controls. The adventitial layer appeared to 
produce significantly more iNOS than in the endothelial layer, with only small amounts 
seen in the smooth muscle layer.
In contrast to PE, contractions to the thromboxane mimetic, U46619 were only weakly 
affected by LPS. The differential effects of LPS upon PE and U-46619 did not appear to 
be a NO-mediated phenomenon, as the NO donor SNAP caused an equipotent 
relaxation o f contractions induced by either agonist. Inhibition o f the COX-2 pathway 
had no effect on hyporeactivity. My attempt to transfer the rat model to human vessels 
was successful in that I managed to produce depression of contractile responses to PE in 
tissues incubated with a combination of LPS and the pro-inflammatory cytokine IL-lp 
at the 46 but not the 24 h time point, though neither L-NAME nor 1400W appeared to 
reverse this hyporeactivity.
2.6.2 Nitric oxide and sepsis
Substantial evidence across a variety of different species suggests that NO is the main 
mediator of vascular hyporeactivity in sepsis (reviewed in Thiemermann, 1994, 1997 
and Vallance and Charles, 1998). In septic patients, elevated levels of the stable 
breakdown products of NO (nitrate/nitrite) have been measured (Ochoa et a l, 1991)
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while administration o f the non-selective NOS inhibitor, L-NMMA produced 
significant elevations in blood pressure and a 60-80% reduction in vasopressor 
requirements (Grover et al., 1999). Similar findings have also been reported in rat and 
mouse models (reviewed by Rees et a l, 1998 and Vincent et al., 2000). Enhanced NO 
production may result from activation of eNOS in the early stages of the septic insult 
(<1 h) followed by expression of iNOS commencing after 2-3 h (Thiemermann, 1997). 
Consistent with a major role for iNOS, vascular hyporeactivity in arteries removed from 
animals treated with LPS for 12 h was only observed in wild-type but not iNOS- 
deficient mice (Gunnett et a l, 1998). Moreover, long-term exposure to LPS results in 
changes in the expression of iNOS but not eNOS such that after 24 h in culture with 
LPS there was no increase in eNOS expression in rat aorta (Bishop-Bailey et a l, 1997).
An important new finding in my in vitro model was the variable time and individual 
agent response to NO inhibition. While complete reversal with NO blockade was 
achieved at 6  h, sensitivity to the NOS inhibitors decreased over time when they were 
added directly to the organ bath. L-NAME completely lost its effect at 20 h, though 
1400W and aminoguanidine still remained partially effective, whereas only 1400W 
increased PE contractions at 46 h. As ‘pre-incubation’ with 1400 W for 20 or 46 h 
appeared to fully restore hyporeactivity this could imply that prolonged activation of 
iNOS may have irreversible effects on the contractile machinery, either through NO 
itself or from the down-stream activation o f other pathways by iNOS. Whether 
reversibility was indeed really complete remains undetermined since I did not pre­
incubated the control tissues with 1400W. Based on my results in which I showed that
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iNOS was produced in control tissues, NO " was detected in the culture media of 
controls and that addition o f other NOS inhibitors increased contractile responses to PE 
in control tissues, I would predict 1400W to have effects in control tissues. An 
alternative explanation to the above is that incomplete NO blockade is occurring in the 
organ both or that NO-independent mechanisms do indeed produce hyporeactivity at 20 
and 46 h. Incomplete NO blockade may be due either to inadequate NOS inhibition, 
NOS-independent generation o f NO, or release of NO from nitrosylated thiols (e.g. 
albumin). An inadequate dose of AMG or L-NAME is a possibility, although I did 
observe a full reversal with both these agents at 6  h. In addition, the doses I used are 
well above the reported IC50 values for inhibition o f NOS, being 30 pM and 11 pM, 
respectively for aminoguanidine and L-NAME against iNOS and 0.6 pM for L-NAME 
against eNOS (Yen et al., 1995). However, it has been shown that a combination of 
NOS inhibitor and NO scavenger was required to inhibit NO production in rat 
mesenteric and hepatic arteries (Chauhan et a l, 2000). Furthermore, NO release 
induced by LPS in rat aortic segments after 48 h in culture medium was found to be 
only partially inhibited by 1 mM L-NAME, though fully by a protein synthesis inhibitor 
(Bishop-Bailey et al., 1997). While this latter observation suggests that NO production 
was probably occurring through iNOS, continued production of NO and/or its 
metabolites may lead to the formation o f NO stores within the blood vessel.
Little is known regarding the ability o f iNOS-derived NO to interact with physiological 
substrates such as thiols to yield biologically active S-nitrosothiols during endotoxemia. 
It has been suggested that these relatively stable, vaso-active compounds may act as a
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storage system for NO and thus play an important role NO mediated effects. Indeed, 
endotoxemia has been shown to enhance circulating S-nitrosothiol formation 
considerably (JourdTieuil et al., 2000 and Ottesen et al., 2001). In addition mice with a 
targeted gene deletion o f S-nitrosoglutathione reductase exhibited substantial increases 
in whole-cell S-nitrosylation, tissue damage, and mortality following endotoxic or 
bacterial challenge (Liu et al., 2004). The generation of nitrated/nitrosylated 
compounds by reaction of NO or its metabolites with either components of the tissue 
bathing medium or complexes in blood vessels has been well recognised (Dowell & 
Martin, 1998; Muller et al., 1998; Stubauer et al., 1999 and Amirmansour et al., 1999). 
Cellular degradation and subsequent release of NO may also explain at least in part, the 
ineffectiveness of aminoguanidine and L-NAME at reversing vascular hyporeactivity at 
46 h. It may also be responsible for the greater hyporeactivity seen when serum was 
added to the incubation medium. Such a mechanism has been proposed to explain L- 
NAME-resistant vascular hyporeactivity (Muller et al., 1998).
I was surprised to find an effect, albeit partial, of 1400W at 46 h, but no reversal at all 
from either AMG or L-NAME. This could simply reflect the greater potency 
(nanomolar range) o f this agent or its apparent irreversibility as an inhibitor of iNOS 
(Garvey, et al., 1997). Alternatively, 1400W may have actions unrelated to iNOS 
inhibition that have not been demonstrated thus far. It is not likely to be due to an effect 
of 1400W on COX-2 activity, since I was unable to show any reversal o f hyporeactivity 
with the selective COX-2 inhibitor, NS-398 after 20 h in LPS. The production of 
prostaglandins E2 and F2Q has been demonstrated in vitro in LPS-treated rat aortic
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tissues, and this was successfully blocked by NS-398 (Bishop-Bailey, 1997). Although 
blockade o f the inducible and/or constitutive COX pathways rarely reverses 
hypotension (Bernard et al., 1997 and Leach et al., 1998), it has been shown to partially 
reverse LPS-induced hyporeactivity (McKenna, 1990 and Gunnett et al., 1998).
To compliment the finding that overproduction of NO via iNOS was the major factor in 
the development of vascular hyporeactivity to LPS, I measured nitrite levels in the 
culture medium supernatant and examined the rat mesenteric artery for iNOS 
expression at different time points. Compared to control supernatant, NO2 ' levels 
doubled in the presence o f LPS (1 pg ml'1) after 20 h incubation and this rise was 
completely inhibited by the specific iNOS inhibitor, 1400W (10 pM). In addition, I also 
demonstrated that LPS increased production of iNOS within the vessel itself via 
immunohistochemistry. In the presence of LPS NO2 ' levels peaked at 20 h but 
significant amounts were seen in non-LPS incubated (control) tissues which peaked at 
46 h. Complimentary to these results was the observation that significant iNOS activity 
was seen in the control tissues at 20 and 46 h.
2.6.3 LPS and vascular hyporeactivity
The continued presence o f LPS within the incubation medium is likely to have 
prolonged the duration o f vascular hyporeactivity. In vivo animal models given a bolus 
of LPS have demonstrated shorter-lived effects. In mice given i.v. LPS, maximum 
haemodynamic effects were seen at 12 h, which corresponded with peak iNOS activity 
(Rees et a l, 1998). Surviving animals showed some recovery by 18 h, this
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corresponded with a fall in iNOS activity. In rats receiving intraperitoneal LPS, levels 
of mRNA for iNOS peaked at 4-8 h, decreasing markedly thereafter (Lui et a l , 1997). 
In a similar model, Mitchell and co-workers (1993) showed maximum induction of 
NOS at 6  h which returned to control levels by 24 h. However, arterial and venous 
mesenteric vascular beds removed from these animals at 6  h were not hyporeactive to 
PE, U44619, endothelin-1 or 5-HT. In contrast, using an in vitro organ culture model in 
rat aorta, the expression of iNOS and COX-2 remained elevated over the entire 10-day 
duration in the presence o f LPS (Bishop-Bailey et al, 1997). Although vascular 
hyporeactivity was not assessed, nitrate/nitrite levels peaked on day 2 and 9. There was 
hyporeactivity at 46 h in my model when LPS was added to culture medium containing 
serum. I thus speculate that continued presence o f LPS in the incubation media prolongs 
the period of iNOS induction in blood vessels compared to a bolus dose administered to 
rodents. I have been unable to find organ bath experiments utilising vessels incubated in 
LPS or harvested from endotoxaemic rats that have been extended beyond 24 h.
Previous results from this laboratory demonstrated that a 6  h incubation of aortic rings 
with LPS in the organ bath is sufficient to produce substantial hyporeactivity to PE 
(Hall et al., 1996). However, I was unable to reproduce this effect in mesenteric rings 
unless tissues were first incubated in culture medium. This represents the first in vitro 
model of hyporeactivity using mesenteric vessels. Subsequently LPS-induced 
hyporeactivity in mesenteric arteries has been demonstrated after 5-6 h incubation 
(Mitsumizo et al., 2004 and Hemanz et al., 2004). Studies have demonstrated 
hyporeactivity ex-vivo, albeit inconsistently, where the mesenteric artery is harvested 4-
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6  h from rats treated with LPS (e.g. Schneider et al., 1992 and Mitchell et al., 1993 
demonstrated hyporeactivity but Buyukafsar et al., 2004 did not).
The addition of serum to the incubation medium enhanced and prolonged the effects of 
LPS. This most likely reflects the fact that culture medium contains soluble CD 14 and 
LPS-binding factor that are involved in recognition of LPS by toll receptors causing 
subsequent cellular activation and production of pro-inflammatory cytokines and 
transcription nuclear factor NFk-B activation o f cells within the blood vessel (reviewed 
by Heumann and Roger, 2002). However, membrane bound CD 14 also contributes to 
this process accounting for the profound hyporeactivity observed with LPS in the 
absence of serum.
I found the lowest concentration o f LPS required to produce significant hyporeactivity 
was 0.01 ng ml"1. Most other in vitro studies use LPS concentrations o f 1-10 pg ml' 1 
(Glembot et al., 1995; Scott et al., 1966 and Muller et al., 1998). In septic humans 
endotoxin concentrations measure a mean peak of 0.5 ng ml"1 (Danner et al., 1991), 
although levels can rise up to 100 ng ml' 1 in septic patients with meningitis (Brandtzaeg 
et al., 1988). There has been one report of concentration-dependent depression of 
vascular contractility at much lower concentrations o f LPS (1-100 ng ml'1) in aortic 
rings incubated for 16 h (McKenna, 1990). Perhaps, in retrospect it would have been 
more relevant if experiments had been performed using LPS at a more ‘physiological’ 
concentration. Unfortunately, having managed to succeed with an organ culture model 
of vascular hyporeactivity using a concentration of 1 pg ml' 1 o f LPS, I continued with
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this and only performed the LPS threshold experiments towards the end of my time in 
the laboratory.
2.6.4 The role of the endothelium, vascular smooth muscle and adventitia
I observed that the concentration-response curve to PE in control tissues shifted to the 
left at 2 0  h incubation in culture medium compared to that observed with only 6  h 
incubation. While I have no precise explanation for this, the removal o f the endothelium 
did increase the responsiveness to PE in my experiments, suggesting that loss of 
endothelial function may be occurring over time. Against this, I found that endothelium- 
dependent relaxation to acetylcholine was similar at 6  & 2 0  h, suggesting that 
alterations in the release o f endothelial-derived relaxing factors per se cannot account 
for these changes. Alternatively, increased basal production of contracting factors may 
be occurring over time that, in turn, might enhance sensitivity to PE. In rat mesenteric 
artery, organ culture increases the potency of ET-1 and this is associated with the 
appearance o f contractile ETb receptors after 24 h (Adner et a l ,  1998).
Denuding vessels o f endothelium following incubation with LPS and serum did not 
affect the level o f vascular hyporeactivity observed with LPS. This would suggest that 
the medial and/or adventitial layers are principally responsible for continued 
hyporeactivity once the vessel has been transferred to the organ bath. This is consistent 
with previous studies showing that an intact endothelium is not necessary for endotoxin- 
mediated vascular suppression (McKenna 1990; Julou-Schaeffer et al., 1990 and Hall et 
a l, 1996). However, to have proved this hypothesis, I should have denuded the
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endothelium prior to incubation with LPS and serum. Interestingly, data in rat aorta 
suggest that the adventitia is responsible for the majority of iNOS expression, NO 
production and medial hyporeactivity following exposure to LPS (Kleschyov et a l,  
1998 and 2000; Zhang et al., 1999 and reviewed in Muller et al., 2000). In my studies, I 
found that the major site of iNOS expression in mesenteric artery was also the 
adventitia with lesser amounts in the endothelium and only small amounts in the media. 
Adventitial derived NO can exert immediate down-regulatory effects on smooth muscle 
contraction via activation of cyclic GMP pathway. However, it may also initiate longer 
lasting effects through the formation of NO stores within the medial layer. One possible 
candidate is dinitrosyl non-heme iron complexes (Muller et al., 2000). Recently, in a 
model o f LPS-induced hyporeactivity in rat mesenteric arteries, Hemanz and co­
workers (2004) concluded that hydrogen peroxide generated from superoxide dimutase 
and release of NO from N-acetylcysteine-sensitive stores both contributed to the 
vascular hyporeactivity.
2.6.5 A human model of sepsis
Naturally, I wished to transfer my findings to human blood vessels. However, it proved 
far more difficult to develop a reproducible in vitro model and required a higher 
concentration of LPS or the pro-inflammatory cytokine IL-1 p as well as longer 
incubation times. Previous studies have used ex-vivo vessels from septic patients 
(Stoclet et al., 1999), ‘normal’ coronary arteries (Chester et al., 1998) or saphenous 
veins (Thorin-Trescases et al., 1995) harvested from patients undergoing cardiac 
surgery. A continuous perfusion set-up using lipoteichoic acid over vessels has also
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been employed rather than an organ culture model (Tsuneyoshi et al., 1996). I chose the 
marginal artery to compliment my rat model adapting the organ culture model with the 
addition of the pro-inflammatory cytokine interleukin 1L-|3. Other groups have found 
cytokines necessary for iNOS induction (Thorin-Trescases et al., 1995 and Chester et 
al., 1998). I was able to achieve significant hyporeactivity to PE, although 1400 W was 
not able to reverse it. This result may not be surprising given the rat data, where at the 
longer time points of LPS incubation, reversibility was only achieved by pre-incubation 
with the iNOS inhibitor. My experiences mirror existing data, in that overwhelming 
evidence exists for the role of iNOS in experimental sepsis in animal studies yet 
relatively little exists in humans. The reasons why in vitro expression of iNOS has been 
so difficult in human tissue are unclear. Several studies have shown that administration 
of a non-selective NOS inhibitor to humans with septic shock will raise blood pressure 
(Grover et al., 1999); so perhaps eNOS is more important in humans than iNOS. 
Certainly eNOS not iNOS has been shown to mediate cytokine-induced venodilatation 
in humans (Bhagat et al., 1999). In contrast, both iNOS and eNOS mRNA were found 
to be down regulated in mesenteric arterial smooth muscle cells and peripheral blood 
mononuclear cells obtained from patients with early septic shock compared to control 
patients. In the same study inducible hemoxygenase mRNA was found to be increased, 
suggesting that CO might contribute to vasodilation in sepsis (Reade et al., 2005). 
However, iNOS activity has been found in muscle and fat in patients with septic shock 
from cellulitis (Annane et a l , 2000), in rectus abdominis muscle obtained during 
surgical procedure in 16 septic patients (Lanone et al., 2000) and in omental arteries 
from patients with peritonitis (Stoclet et al., 1999). Interestingly in an in vitro model of
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LPS, endotoxin had no direct vasodilatory effect on the arterioles of human skeletal 
muscle, but, when endotoxin was allowed to pass over an upstream conduit vessel, the 
arteriole showed marked dilation. The authors proposed that release of an endothelial 
factor from the upstream conduit vessels produced the loss of tone in the 
microvasculature (Campbell and Britt, 2004). Clearly this remains a complex area that 
is yet to be fully understood.
2.6.6 The role of thromboxane
As observed previously in pig mesenteric and pulmonary artery (Perez-Vizcaino et al., 
1996), the thromboxane A2 mimetic, U46619 was substantially less affected by LPS 
compared to PE in our study. In an attempt to explain these differences, I thought that 
contractions to U46619 might be significantly less sensitive to the relaxing actions of 
NO. This was not the case, as the NO donor, SNAP was equipotent against PE and 
U46619. Thromboxane A2 has been shown to regulate vascular tone via an inhibitory 
effect upon the expression of iNOS (Yamada et al., 2003) and this could explain the 
results seen here. Consistent with this notion, increased sensitivity to U46619 was 
observed in the presence o f L-NAME in the perfused mesenteric bed taken from rats 
treated with LPS (Mitchell et al., 1993). In addition PE contractions are worsened by 
thromboxane antagonists (Cirino et al., 1996). Increased production and/or sensitivity 
of thromboxane A 2 may account for the vasoconstriction seen in some vascular beds, 
following endotoxin treatment and for the development of pulmonary hypertension in 
early septic shock (Hales et a l , 1981).
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In summary, I have developed a reproducible model using rat mesenteric artery that 
demonstrates in vitro vascular hyporeactivity to LPS. My results highlight the 
importance of both incubation time and serum on the degree of hyporeactivity. Using 
assays for nitrite and iNOS, I have demonstrated that nitric oxide via the induction of 
iNOS is extremely likely to be responsible for this hyporeactivity. Further strong 
evidence to this effect is that the hyporeactivity was reversed by inhibitors of the NO 
pathway. Perhaps hyporeactivity at later time points (46 h) is determined by additional 
pathways to the upregulation o f iNOS. I was very keen to further investigate 
mechanisms in human vessels; unfortunately, although I managed to develop a 
hyporeactive model, I was unable to obtain enough tissue to ascertain the role of NO.
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Chapter 3
Characterisation of an in vivo fluid resuscitated model 
of endotoxin-induced shock
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3.1 Introduction
It should be recognised that animal models are not necessarily representative of the 
clinical condition of septic shock (reviewed in Deitch, 1998). For example, the duration 
of the study may be short, and blood flow, when measured, is often reduced, whereas a 
hyperdynamic response is commonplace in the critically ill patient (Krishnagopalan et 
al., 2002). In addition, most animal models look at blood pressure response alone to an 
agent, and do not assess concurrent regional blood flow. The flow may be compromised 
if the blood pressure rise is at the expense of profound vasoconstriction in certain 
vascular beds. Patients usually receive aggressive fluid resuscitation as first line 
therapy, yet most animal models neglect this.
I sought to characterise a fluid-resuscitated short-term in vivo model of hyperdynamic 
sepsis secondary to endotoxin in order to assess vascular hyporeactivity and 
responsiveness to various agents. Our laboratory has previously described a 
hyperdynamic model of endotoxin-induced sepsis in an anaesthetised, spontaneously 
breathing rat (Rosser et al., 1995 and 1996). I adapted this model, using a different fluid 
resuscitation regimen of gelatin rather than normal saline, a different type of endotoxin, 
and I measured hepatic microvascular oxygen tension rather than bladder oxygen 
tension as a marker of organ perfusion. As inhibition of inducible nitric oxide synthase 
appears to be a successful treatment in animal models, yet not in humans, I investigated 
the effects of the highly specific iNOS inhibitor GW273629 (Young et al., 2000 and 
Alderton et al., 2005). I examined not only the response of mean arterial blood pressure 
to this agent but also the consequences on macrocirculatory (aortic and renal artery
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blood flow measured by ultrasonic flow probes) and hepatic microvascular oxygen 
tension using the technique of palladium porphyrin phosphorescence. This technique is 
based on the phosphorescence decay lifetime of an injected palladium-porphyim 
complex illuminated by a phosphorimeter which is inversely related to the oxygen 
tension of the interrogated vasculature. The relationship between phosphorescence 
lifetime and oxygen pressure is quantitatively described by the stem-volmer equation 
(reviewed by Wilson, 1992). The oxygen measurements are weighted toward detection 
of longer phosphorescence lifetimes; thus the measured values are obtained primarily 
from blood within capillaries and venules. For the Pd-meso-tetra(4-carboxyphenyl) 
porphyrin used in these experiments, pH dependence is neglible between pH 7.2 and 7.8 
and temperature changes are also too small to be considered significant for in vivo 
experiments. As the porphyrin is bound to albumin, the complex remains in the vascular 
compartment, so measurement is restricted to the microvasculature. The presence of any 
significant capillary leak of the porphyrin-albumin complex would be readily 
identifiable as an increase in delay time (this was not observed during the experiments). 
Sinaasappel & Ince (1996) first validated a phosphorimeter calibration of Pd-porphyrin 
phosphorescence for oxygen concentration measurements in vivo. We have used this 
technique successfully in our laboratory (Davies et al., 2003 & 2005).
The microcirculation is a complex and integrated system that supplies and distributes 
oxygen throughout the tissues. Sepsis affects almost every cellular component -  
endothelial cells, smooth muscle cells, leucocytes, erythrocytes and tissue cells. 
Microcirculatory distress not corrected for 24 h was found to be the single independent
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factor most predictive of subsequent patient outcome (Sakr et al., 2004). NO is a central 
component in the autoregulatory control of microvascular patency. The overproduction 
of NO in different organ beds results in pathological shunting of flow (reviewed by 
Ince, 2005). Fluid resuscitation alone has been shown to restore systemic 
haemodynamics but left ‘weak’ microcirculatory areas hypoxaemic (Ince and 
Sinaasappel, 1999 and Golmann et al., 2004). In septic pigs the combination of fluid 
and iNOS inhibition but not fluid alone was successful in recruiting vulnerable 
microcirculatory beds within the intestine (Pittner et al., 2003 and Siegmund et al., 
2005). I was thus interested in comparing the effects of LPS and iNOS inhibition upon 
macro- and micro-circulatory blood flow within my rat model of sepsis.
I also took advantage of this model to examine the presence and distribution of iNOS 
within the rat mesenteric artery at the end of the 4-hour experiment using 
immunohistochemical analysis as before (see chapter 2). Following LPS treatment 
iNOS mRNA had been detected in rat kidney by 60 min after intravenous endotoxin; 
levels had peaked at 2-4 h and declined by 16 h (Sade et al., 1999). In another sepsis 
model, nNOS mRNA increased by 2 h and iNOS mRNA by 3 h in rat brain, with both 
isoforms returning to baseline by 12 h (Harada et al., 1999). Similarly, iNOS mRNA 
was detected at 1 h in the small intestine peaked at 4 h and was barely detected by 24 h 
(Chen et al., 1996). Infusion of Staphylococcus aureus cell wall components caused 
progressive increases in iNOS activity in thoracic aorta, lung and liver and plasma NO2" 
/ NO3" from 2-6 h (Kengartharan et al., 1996). No such time profiles have been
124
Characterisation o f  an in vivo fluid resuscitated m odel o f  LPS-induced shock
determined in humans although there is evidence for elevated both NO2" / NO3' in 
plasma (Evans et al., 1993) and skeletal muscle (Brealey et al., 2002).
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3.2 Methods
3.2.1 Animals and anaesthesia
In vivo procedures were performed under Home Office approval according to the 
Animals (Scientific Procedures) Act (1986). Experiments were performed on 
anaesthetised, spontaneously breathing, male Wistar rats (280-310 g) given free access 
to food and water until surgery. The animals were bought from Charles River and given 
a few days to settle prior to the experiments. The animals were placed in a large glass 
container, and anaesthesia was induced using isoflurane in air via a simple air pump 
driving a Tec 4 vaporiser (Abbott, Maidenhead, UK). A heated operating table was used 
to maintain rectal temperature at 37°C.
3.2.2 Surgery and monitoring
The left carotid artery was cannulated for monitoring of mean arterial pressure (MAP) 
(pressure transducer, and monitor, Powerlab, ADInstruments, Castle Hill, NSW, 
Australia) and intermittent sampling for blood gas analysis (165 pi heparinised capillary 
tube samples, processed by an ABL300 blood gas analyser (Radiometer, Copenhagen, 
Denmark). A cannula was inserted into the right internal jugular vein and connected to 
an infusion pump for fluid resuscitation. A midline laparotomy was performed to allow 
placement of transit time flow probes around the left renal artery (1mm, J reflector, 
1RB) and infrarenal aorta (2mm, J reflector with sliding gate, 2SB, Transonic Systems, 
Ithaca, N.Y., U.S.A.). These probes were connected to a monitor displaying both blood 
flows continuously (monitor T206, Transonic Systems). Pd-meso-tetra-(4- 
Carboxyphenyl)porphyrin (protoporphyrin) (0.9 ml kg'1) dissolved in 5% albumin was
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injected intravenously via the internal jugular catheter. A fibreoptic cable from a 
phosphorimeter (OxySpot, Digitimer, Hertfordshire, U.K.) was held on a manipulating 
arm such that the tip could be maintained at 1 mm above the surface of the left lobe of 
the liver in order to measure hepatic microvascular PO2 . The machine was set to emit 
five flashes over 1 s with delay times set at 40 ps to eliminate flash artefact. These were 
repeated at 30 s intervals to minimize the risk of tissue bleaching, with online 
measurements directly recorede onto computer. Through the avascular dome of the 
bladder a drainage cannula (1.57 mm outside diameter polythene tubing) was sited to 
drain urine. After instrumentation, the animals were left to stabilise for 30-60 min until 
three consistent haemodynamic measurements had been obtained at 5 min intervals.
3.2.3 Experimental protocols
Three experimental groups were used:
(i) Group A (n=6) was given 40 mg kg' 1 LPS {Klebsiella Pneumoniae) in 0.9 % saline 
by infusion over 30 min at a rate of 20 ml kg' 1 h"1. Ideally, I would have liked to have 
used Salmonella Typhosa as for my in vitro model in chapter 2; however, previous work 
within the laboratory had found that Klebsiella Pneumoniae gave the best 
haemodynamic response for this model. For the remainder of the experiment, all 
groups were fluid resuscitated with 25 ml kg' 1 h' 1 of the synthetic gelatin colloid, 
Gelofusin®. This was supplemented with 1 ml 10% glucose solution per 25 ml to keep 
blood sugar levels above 5 mM. I used Gelofusin® as this was the fluid most commonly 
used for resuscitation in sepsis in the intensive care unit at University College London 
Hospitals. Rosser’s previous model had used 0.9 % saline at 20 ml kg' 1 h '1.
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(ii) Group B (n -6 ) received isotonic saline rather than LPS over the first 30 min (sham- 
operated controls).
(iii) Groups C comprised either LPS-treated rats {n -6 ) or sham-operated controls {n-3). 
These rats received the specific iNOS inhibitor, GW273629, a 50 mg kg' 1 bolus 
(approx. 0.7ml volume) followed by a 50 mg kg' 1 h' 1 infusion. This dose was suggested 
by Richard Knowles, a senior pharmacologist at GlaxoSmithKline, whose group had 
used GW273629 previously.
Continuous recordings were made of mean arterial pressure (MAP), aortic blood flow 
(ABF), renal blood flow (RBF), hepatic microvascular oxygenation (HmvOi) and rectal 
temperature. Arterial blood gas analysis (for measurement of arterial pC>2, pC02, pH 
and standard base excess) was performed at 0, 120, 180 and 240 min after injection of 
LPS (or saline in sham-operated animals). After the last recordings were made, the 
animals were killed via a rapid intravenous injection of pentobarbitone sodium, 2 0 0 mg 
k g 1.
3.2.4 Analysis of iNOS via immunohistochemistry
The mesenteric artery was immediately removed and stored in HBSS. 
Immunohistochemical analysis was performed as described in chapter 2.
3.3 Statistical analysis
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As chapter 2. Where appropriate, Student’s t-test was used to compare two groups
3.4 Reagents and solutions
Immunohistochemistry - as chapter 2. Pd-meso-tetra-(4-Carboxyphenyl) Porphyrin 
(Protoporphyrin) was supplied by Digimeter Ltd (Herts, U.K.). LPS (K. Pneumoniae) 
was obtained from Sigma Chemical Company (Poole, Dorset, U.K.). GW273629 was 
kindly donated by Glaxo SmithKline (Stevenage, U.K.). Pentobarbitone sodium was 
obtained from Rhone Merieux Ltd, (Harlow, U.K.).
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3.5 Results
3.5.1 Effect of endotoxin (LPS) upon MAP, aortic and renal blood flow and 
microvascular oxygen tension in an in vivo model of rat sepsis
In sham animals MAP, RBF, hepatic microvascular oxygenation (HmvC^) and arterial 
base deficit did not change significantly throughout the experiment (see Fig. 3.1A-D). 
However, there was a tendency for MAP and RBF to increase, while ABF and Hmv0 2  
initially rose then fell. These changes, particularly in ABF, were probably related to the 
fluid resuscitation.
Following infusion of LPS, there was a rapid fall in all measured variables within 0-30 
min (see Fig. 3.1A-D). Recovery in MAP was observed within 30 min (before fluid 
resuscitation was commenced), although aortic and renal blood flow took 2-3 h to return 
to baseline values. However, Hmv0 2  failed to show any significant recovery after the 
initial abrupt fall. After 120 min the MAP fell significantly in LPS treated rats 
(P<0.001, «=6 , ANOVA), I thus chose this timepoint to administer GW273629.
3.5.2 Effect of treatment with the selective iNOS inhibitor GW273629
Injection of the iNOS inhibitor at 120 min after injection of LPS (or saline control) 
resulted in a marked pressor response in the LPS-treated rats compared to shams (Fig. 
3.2A). MAP was maintained at this elevated level until termination of the experiment at 
240 min (7M).03, n~6, ANOVA). However, in the LPS group no differences were seen 
in ABF, RBF, Hmv0 2  or arterial base deficit between GW273629 treated and non-
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treated animals (Fig. 3.2B-D). In sham animals treated with or without the iNOS 
inhibitor, RBF or arterial base deficit did not change however ABF and Hmv0 2  fell 
significantly with GW273629 treatment (P = 0.042, n~6, ANOVA; Fig. 3.2 B-D).
3.5.3 iNOS immimoreactivity
Immunohistochemistry revealed that iNOS induction was seen in the smooth muscle 
and endothelium of the mesenteric artery but not in the adventitial layer 4 h following 
the bolus dose of LPS (40 mg kg' 1 over 30 min) («= 1; Table 3.1). Only a small amount 
of iNOS was seen in the endothelium and smooth muscle of sham-operated rats (Fig.
3.3 and Table 3.1). This was similar to the distribution observed after 4 h incubation in 
the in vitro model. GW273629 completely inhibited the LPS-induced production of 
iNOS within the mesenteric artery removed from the animal at the end of the 
experiment (Fig. 3.4 and Table 3.1).
Table 3.1 Distribution of iNOS seen in RMA at 4 h following a bolus dose of LPS
(40 mg kg' 1 over 30 min)
Symbols: - = no iNOS; + = mild / ++ = moderate staining for iNOS («=1)
Endothelium Smooth Muscle Adventitia
Sham + + -
LPS ++ ++ -
LPS + GW273629 - - -
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Figure 3.1 Effect of LPS (K. Pneumoniae 40 mg kg'1) on (A) mean arterial blood pressure 
and (B) renal blood flow. MAP fell after 120 min (P0.001, ANOVA) and RBF 
immediately following LPS (P=0.028). LPS was infused over 30 min and then Gelofusin® 
at 25 ml kg'1 hr'1. Data are expressed as mean ± s.e.m. for 6 rats per group.
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Figure 3.1 Effect of LPS (K. Pneumoniae 40 mg kg'1) on (C) aortic blood flow and (D) 
hepatic microvascular oxygenation. LPS reduced both significantly (P<0.001, 
ANOVA). LPS was infused over 30 min and then Gelofusin® at 25 ml kg'1 hr'1. Data are 
expressed as mean ± s.e.m. for 6 rats per group.
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Figure 3.2 Effect of the highly specific iNOS inhibitor GW273629 (50 mg kg'1 
bolus + 50 mg kg"1 h '1 infusion) on (A) mean arterial blood pressure and (B) renal 
blood flow in sham and LPS-treated rats. GW273629 raised MAP in LPS-treated 
rats (P =0.003, ANOVA) but non-significantly in shams. There was no effect 
upon RBF in either group. GW273629 was given at 120 min (see arrow). Data are 
expressed as mean ± s.e.m for 3-6 rats per group.
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Figure 3.2 Effect of the highly specific iNOS inhibitor GW273629 given at 120 
min -  see arrow (50 mg kg'1 bolus + 50 mg kg'1 h'1 infusion) on (C) aortic blood 
flow and (D) microvascular oxygenation in sham and LPS-treated rats. GW273629 
had no effect upon ABF or Hmv02 in LPS-treated rats. In shams GW273629 
reduces both ABF and Hmv02 (P=0.042). Data are expressed as mean ± s.e.m. for 
3-6 rats per group.
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Figure 3.3 Comparison of the distribution of iNOS within RMA following either 
in vitro incubation with LPS for 4 h or 4 h following a bolus dose in vivo (n=3 for 
in vitro and 1 for in vivo). (Endo -  endothelium; SM -  smooth muscle).
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Figure 3.4 Distribution of iNOS within mesenteric artery removed after the in vivo 
experiment at 4 h from sham and LPS-treated animals ± the iNOS inhibitor 
GW273629 {n-1 for each). (Endo - endothelium ; SM - smooth muscle).
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3.5.4 Effect of LPS upon haemoglobin, PaC>2, PaCCh and metabolic acidosis
(i) Haemoglobin: In both sham and LPS treated rats the haemoglobin dropped 
significantly over the course of the experiment (P <0.001, Student’s t-test,
#f=6; Table 3.2).
(ii) PaC>2 : There was no difference between arterial pC>2 at time 0 and 240 min for 
either the sham or LPS-treated animals (Table 3.2).
(iii) PaC02: The arterial pC 02 decreased in both sham and LPS treated rats over the 
study period, but this was only significant for the LPS treated animals (PO.OOl, 
Student’s t-test, «=6; Table 3.2).
(iv) Metabolic acidosis (base excess): The degree of acidaemia, as measured by 
arterial base deficit, increased throughout the experiment in both the LPS- 
treated rats and sham rats. There was no difference between sham and LPS 
values at 0 min or 180 min. However, the acidosis was worse in the LPS-treated 
rats at 120 and 240 min (P<0.05, t-test, Student’s n=6; Table 3.2). This increase 
was not attenuated by treatment with GW2733629.
Table 3.2 Differences between haemoglobin, PaC>2, PaCC>2 and arterial base excess
at time 0 and 240 min (* P  <0.001 and # P<0.05 when time 0 and 240 min compared)
Sham («=6) LPS (n=6)
0 min 240 min 0 min 240 min
Haemoglobin (g dl'1) 
Pa02 (kPa)
PaC02 (kPa)
Base Excess
15.9±0.41
11.26±0.29
5.27±0.09
-4.43±0.94
13±0.28
12.17±0.78
4.77±0.25
-6.73±1.13
16.47±0.77
10.96±0.37
5.41±0.1*
-3.35±0.45#
11.25±0.22 
12.24±0.99 
4.03±0.22* 
-11±1.45#
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3.6 Discussion
I have developed a reproducible short-term in vivo rat model of septic shock with 
monitoring of both macro- and microcirculation by adapting the model used previously 
by our group (Rosser et al., 1995). I have used this model to investigate the effect of 
iNOS inhibition upon mean arterial blood pressure and regional blood flow. A true 
infectious insult such as caecal ligation and puncture would better represent sepsis seen 
in humans rather than a 30 min bolus of LPS. Certainly, iNOS protein and activity is 
detected in such rats at later time points than in LPS models; for instance Sheih and co­
workers found that thoracic aorta and lung iNOS protein increased by 6 h and remained 
elevated for 48 h (Sheih et al., 2000). I also did not administer antibiotics, which is an 
integral part of management of sepsis in humans. However, this model did generate a 
critically ill animal with highly reproducible hypotension, disruption of both macro and 
micro-circulatory blood flow and metabolic acidosis. Thus I believe the model has merit 
and was highly suitable to investigate the effects of iNOS inhibition in vivo.
LPS infusion induced the characteristic early response, presumably related to 
myocardial depression, of a fall in blood pressure that spontaneously recovers. Although 
in my model MAP was restored within 15 minutes, aortic blood flow took much longer 
to recover, requiring major intravascular volume resuscitation with a colloid solution. 
Despite the fluid infusion, renal blood flow never regained baseline values. The hepatic 
microvascular circulation, as assessed by HmvCh, an indicator of microvascular 
perfusion, failed to show significant improvement despite fluid resuscitation. This 
indicates persistence of microcirculatory defects, possibly related to local shunting.
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Local tissue hypoxia, metabolic alterations such as increased Na/K ATPase activity 
(Levy et al., 2005) and, possibly, increased anaerobic respiration are likely to account 
for the increased metabolic acidosis seen in the LPS-treated rats compared to the shams. 
Immunohistochemistry revealed a greater production of iNOS in the LPS-treated rat 
compared to the sham animal in the mesenteric artery removed at the end of the 
experiment. The amount and distribution of iNOS detected was similar to that seen in 
vitro following 4 h incubation with LPS. At this early time point the endothelial and 
smooth muscle layer produce iNOS rather than the adventitial layer which becomes the 
major source of iNOS in vitro which occurs after 20 h (see chapter 2).
Administration at 120 min of the iNOS inhibitor GW273629 succeeded in elevating 
blood pressure in the LPS and sham-treated rats, but was more pronounced in LPS- 
treated rats. Despite the improvement in blood pressure, there was no improvement in 
the macro or microcirculatory blood flow and no attenuation of the metabolic acidosis. 
Immunohistochemistry revealed that GW273629 completely attenuated the production 
of iNOS in RMA, an unexpected finding for an iNOS inhibitor.
As described previously, overproduction of nitric oxide is considered to play a key role 
in the pathogenesis of septic shock. Although an upregulation of constitutive NOS has 
been demonstrated in early sepsis (Salvemini et al., 1990), the major route of NO 
production in sepsis is considered to be via induction of iNOS by specific pro- 
inflammatory stimulants including endotoxin, tumour necrosis factor, interferon-gamma 
and interleukin-1. The mechanisms by which NO causes vasodilatation, hypotension
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and vascular hyporeactivity in sepsis are not fully elucidated but are thought to 
primarily involve activation of soluble guanylyl cyclase and increased production of 
guanosine 3’5’-cyclic monophosphate (cGMP). Overall benefits have been observed 
with inhibitors selective for iNOS or with low doses of non-selective inhibitors, whereas 
high doses of non-selective NOS inhibitors have been detrimental (reviewed in Vallance 
and Charles, 1998 and Vincent et al., 2000). We chose to use GW273629, which is 
considered highly selective for iNOS (Young et al., 2000 and Alderton et al., 2005). 
This produced a marked rise in blood pressure when given 2 h following LPS and the 
response was significantly greater than that seen in sham rats. The lack of any decrease 
in aortic blood flow implies improved ventricular contractility to compensate for the 
increase in afterload. Indeed NO-induced myocardial depression has been previously 
described (Kumar et al., 1999). However, despite this rise in blood pressure, there was 
no improvement in renal blood flow, hepatic microvascular oxygenation nor metabolic 
acidosis. This study clearly offers further evidence for the role of iNOS in the 
hypotension induced by sepsis, though iNOS inhibition does not appear to improve the 
abnormalities seen in regional blood flow.
Although treatment with GW273629 had no effect upon renal blood flow, renal effects 
of NO inhibition extend beyond its effect upon arterial pressure and renal perfusion 
pressure. Selective NO inhibition increases arterial pressure without affecting renal 
function (Schwartz et al., 1997). It has been demonstrated that high levels of iNOS- 
generated NO could lead to renal vasoconstriction and a reduction in glomerular 
filtration rate (GFR) by inhibiting endothelial NO synthase activity (Schwartz et al.,
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2001). In addition, NO scavenging inhibits the increase in medullary perfusion, thus 
maintaining glomerular hydrostatic pressure and the GFR (Millar and Thiemermann,
2002).
The microcirculation consists of the smallest blood vessels — arterioles, capillaries and 
venules (<100 pM diameter) in which oxygen release to tissues takes place. In sepsis, 
the heterogenous expression of iNOS in different areas of the same organ beds results in 
pathological shunting of flow (Revelly et al., 1996 and Morin et al., 1998). 
Furthermore, the smooth muscle cells lining the arterioles lose their adrenergic 
sensitivity and tone (Baker and Willmoth, 1984). Thus tissue oxygenation is severely 
impaired which is a major contributor to the development of multi-organ dysfunction. 
Unlike the studies of Siegemund or Pittner, I could not demonstrate any improvement in 
microcirculatory flow with fluid resuscitation ± iNOS inhibition (Pittner et al., 2003 and 
Siegemund et al., 2005). Perhaps the dose of LPS used is too ‘toxic’ to the rat; had I 
used a smaller dose an improvement may have been observed. Certainly, the 
discrepancy between flow and pressure is well illustrated in my studies.
Immunohistochemistry confirmed the presence of iNOS in both LPS and shams, with a 
greater production clearly seen following LPS. In addition, no iNOS was seen in the 
LPS-treated rat mesenteric artery following administration of GW273629. Interestingly, 
this would suggest that the drug not only inhibits iNOS but also inhibits its production. 
This is in contrast to studies using other iNOS inhibitors where iNOS protein was 
increased (Aulak et a l , 2004 and Frost et al., 2005). This may reflect an effect of
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GW273629 on the stain itself rather than the agent inhibiting iNOS protein production. 
As I only performed the staining on 1 occasion it is difficult to make an accurate 
comment. iNOS seen in the shams probably reflected induction of iNOS following 
instrumentation and this is supported by the small increase in blood pressure seen in 
shams following administration of GW273629.
A lesser finding was that the haemoglobin fell to a greater degree in the LPS-treated rats 
compared to the shams. Clearly there is a dilutional effect related to the large volume of 
fluid infused as resuscitation. The greater difference in the LPS animals may possibly 
be related a vasodilatation-related increase in intravascular volume and a decreased 
renal excretion ability that is not offset by any capillary leak.
My results suggest that overproduction of nitric oxide is heavily implicated in the 
development of hypotension in septic shock. Inhibiting iNOS reversed the hypotension 
very effectively but there was a lack of any corresponding improvement in organ 
perfusion or its microcirculation. Interestingly, in a porcine model of sepsis, NO donors 
in combination with fluid resuscitation improved gut microcirculatory oxygenation and 
corrected gastric PCO2 whereas fluid alone did not (Siegemund et al., 2000). Perhaps 
future therapies will have multiple sites of action. For instance, combining an NO donor 
(to open the microcirculation and perfuse weak circulatory units) with an iNOS 
inhibitor (to reduce pathological shunting and redirect blood flow to recruit weak 
circulatory units) may prove beneficial. Activated protein C prevented LPS-induced 
hypotension in rats by inhibiting excessive production of NO (Isobe et al., 2001). In
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addition, it reduced leukocyte activation and release of reactive oxygen species (Yamaji 
et al., 2005). These actions have also been shown to improve the microcirculation in 
septic animals (Iba et al., 2005).
In summary, I have developed a model of sepsis that is reproducible and allows 
monitoring of macro and microcirculatory changes. I have demonstrated the induction 
of iNOS and its role in the development of LPS-induced hypotension. In later studies I 
investigated K Atp channel inhibition and terlipressin using this model.
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Chapter 4
Is the potassium channel an important mediator of 
endotoxin-induced vascular hyporeactivity or
hypotension?
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4.1 Introduction
Having developed in vitro and in vivo models of rat sepsis (see chapters 2 & 3), I 
proceeded to investigate the role of K+ channels in mediating vascular hyporeactivity 
and hypotension with specific reference to the K atp channel.
The organ culture model of LPS-induced vascular hyporeactivity demonstrated that the 
degree of reversal with NOS inhibitors was time-dependent (chapter 2 & O'Brien et a l , 
2001). Thus, NO derived directly from NOS activity appeared to fully account for 
hyporeactivity in the short term (6 h), but only partially in the long term (>20 h), 
suggesting involvement of additional mechanisms at the later time points. The full 
reversal of LPS-induced hyporeactivity seen with ‘pre-treatment’ of the iNOS inhibitor 
1400W suggests a more complex picture possibly involving the formation of NO stores 
and/or irreversible damage due to prolonged iNOS activation. Using this model, I 
specifically investigated whether agents acting on the K Atp channel could reverse the 
effects of LPS. I examined the effects of inhibitors of the sulphonylurea receptor (SUR)
-  glibenclamide, tolbutamide and PNU-9963, and inhibitors of the pore-forming subunit
-  BaCb and PNU-37883A. There is a variation in arterial responses to glibenclamide in 
proximal or distal sections of rat mesenteric artery in vitro (Tolvanen et al., 1998) so I 
took care to consider this.
To compliment my in vitro work I also investigated the effects of PNU-37883A and 
glibenclamide in vivo. The effects on hypotension, renal and aortic blood flow and 
microvascular oxygen tension were monitored as per chapter 3. Glibenclamide is
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usually diluted in the solvent dimethyl sulfoxide (DMSO) but this has been shown to 
inhibit LPS-induced NO synthesis (Liang and Akaike, 1997). I thus managed to obtain a 
lyophilised preparation of glibenclamide, kindly donated by Hoechst. I used two 
different concentrations, lmg kg _1 and lOmg kg'1 followed by a 5 mg kg'1 per hour 
infusion for the duration of the experiment. I used an infusion and bolus for the higher 
concentration as the pressor effect of glibenclamide is transient in vivo when 
administered as a bolus (Landry & Oliver, 1992; Vanelli et al., 1995; Vanelli et al., 
1997; Gardiner et a l , 1999 and Sorrentino et al., 1999) despite its long half-life in 
plasma (Wu et al., 1995).
BKca channels are also activated by LPS (Taguchi et al., 1996; Chen et al., 1999 and 
Yakubovich et al., 2001) and this laboratory has previously shown that hyporeactivity is 
reversed using the non-selective K+ channel inhibitor tetraethylammonium chloride 
(TEA+) (Hall et al., 1996). I thus compared the effects of TEA+ with the K atp channel 
inhibitors.
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4.2 Methods 
4.2.1 In vitro model of LPS-induced vascular hyporeactivity
4.2.1.1 Tension experiments
The methods for the organ bath experiments are fully described in chapter 2.
I assessed endothelial function by monitoring relaxation to acetylcholine (5 pM) in 
rings precontracted with 1 pM PE. Cumulative concentration-response curves were 
constructed to PE (10'9 to 10'5 M) with increasing doses added at 5 min intervals at 
which time the contraction had reached a plateau. At the end of some experiments in 
which tissues had been incubated with LPS for 20 h, I added the thromboxane-A2 
mimetic, U44619 (9, ll-dideoxy-9oc, 1 la-methanoepoxy prostaglandin F2a; 10'7 M).
4.2.1.2 Experimental protocols
At least six mesenteric rings, taken from a minimum of three animals, were used in each 
experimental group.
(i) Effect of K Atp channel inhibitors
Rings were incubated with and without LPS (1 pg ml'1) for either 6 or 20 h. Various 
inhibitors of the Katp channel were added 25 min prior to the addition of the lowest 
dose of PE. The sulphonylurea receptor inhibitors, glibenclamide (10 pM), tolbutamide 
(1 mM) and PNU-99963 (1 pM; Cui et al., 2003), or the pore-forming subunit inhibitors 
BaCl2 (300 pM) and PNU-37883A (1 pM; Surah-Narwal et al., 1999) were added to
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separate organ baths containing tissues previously treated with LPS. In separate studies 
I used BaCl2 30 pM -  a concentration that selectively inhibits inward rectifier K+ 
channels (K ir; IC50 2 pM; Quayle & Nelson, 1995). As tolbutamide and PNU-99963 
were dissolved in 100% dimethyl sulphoxide (DMSO), a potent free radical scavenger, 
and glibenclamide in 50% DMSO and 50% polyethylene glycol, the solvent mixture 
was added to control tissues (0.1%) to ascertain its effect on contractile function. In a 
separate series of experiments, BaCl2 (300 pM) and PNU-37883A (1 pM) were added 
to fresh control tissues.
(ii) Effect of the K+ channel inhibitor, TEA+
Rings were incubated with and without LPS (1 pg ml'1) for either 6 or 20 h. 25 min 
prior to addition of PE the K+ channel inhibitor, TEA+ (1 or 10 mM) was added to those 
organ baths containing LPS-treated tissues. At a concentration of 1 mM, TEA+ is 
considered to be a relatively specific inhibitor of BKca, channels, while at 10 mM, it 
blocks other K+ channels including the Katp channel, for which it has an IC50 of 7 mM 
(Nelson & Quayle, 1995).
(iii) Effect of a combination of K+ channel inhibitors
Rings were incubated with and without LPS (1 pg ml'1) for 20 h. 25 min prior to 
addition of PE, TEA+ (1 mM) and BaCl2 (300 pM) were added in combination to the 
organ baths containing LPS-treated tissues.
(iv) Temporal effect of LPS on contractile responses to KC1
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Rings were incubated with or without LPS (1 pg ml'1) for either 6 or 20 h and 
contracted with PSS containing 60 mM K+ was added to the organ baths. In this 
solution KC1 replaced NaCl in PSS with the concentration of all other salts remaining 
the same.
(v) Addition of the thromboxane A2 mimetic U44619
At the end of some experiments following a 20 h incubation with LPS, the 
thromboxane-A2 mimetic, U44619 (10‘7 M) was added to those tissues previously 
treated with K Atp inhibitors. Glibenclamide and tolbutamide are known to have 
antagonist effects at thromboxane receptors (Delaey & Van de Voorde, 1995) which 
would be predicted to worsen hyporeactivity. I wished to investigate whether PNU- 
99963 affected thromboxane-induced contractions.
(vi) Concentration-response curves to the NO donor, SNAP in fresh control tissue 
Cumulative concentration-relaxation curves to S-nitroso-N-acetyl-D, L-penicillamine 
(SNAP; 1 0 10 to 10'5 M) were constructed in fresh tissues following precontraction with 
1 pM PE. 25 min prior to addition of PE, the K+ channel inhibitors - TEA+ (1 and 10 
mM), BaCl2 (300 pM) and PNU-37738A (1 pM) were added to separate rings. Once 
contractions to PE had reached a plateau, concentrations of SNAP were added in 
cumulative fashion every 5 min beforehand.
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4.2.1.3 Nitrite production in organ culture model
The method is as described in chapter 2. Tissues were incubated for 20 h in the presence 
or absence of LPS, with or without the addition of either (i) the sulphonylurea K Atp 
receptor inhibitors, glibenclamide (10 pM), tolbutamide (1 mM) and PNU-99963 (1 
pM) or (ii) the pore-forming subunit inhibitors BaCL (300 pM) and PNU-37883A (1 
pM). Nitrite was measured as previously described in chapter 2.
4.2.2 In vivo fluid resuscitated rat model of endotoxin induced shock
The method and model are described in detail in chapter 3.
Five experimental groups were used:
(a) Group A in -6) was given 40 mg kg'1 LPS (Klebsiella Pneumoniae) administered as 
0.9% saline infused over a 30 min period at a rate of 20 ml kg'1 h"1. Throughout the 
experiment, animals were fluid resuscitated with 25 ml kg'1 h"1 of the synthetic gelatin 
colloid, Gelofusin®. This was supplemented with 1 ml 10% glucose solution per 25 ml 
to keep blood sugars > 5 mM.
(b) Group B {n-6) received isotonic saline rather than LPS over the first 30 min (sham- 
operated controls).
(c) Group C comprised either LPS-treated rats in -6) or sham-operated controls in -  3). 
These rats were given glibenclamide as a 1 mg kg'1 bolus (low dose glibenclamide), 
while Group D in -6) received a 10 mg kg'1 bolus of glibenclamide followed by an
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infusion of 5 mg kg^h'1 for the duration of the experiment (high dose glibenclamide). 
Glibenclamide was administered 120 min after the LPS infusion was initiated.
(d) Group E comprised either LPS-treated rats («=6) or sham-operated controls {n -3). 
These rats were given the pore-forming subunit K Atp channel inhibitor, PNU 37883A as 
a 1.5 mg kg"1 bolus followed by a 1 mg kg"1 h"1 infusion for the duration of the 
experiment. No previous data existed for the use of this agent in septic models. Thus the 
optimum dose for PNU 37883A was determined by giving 0.5 -  5 mg kg"1 boluses to a 
sham animal that had received the K Atp channel opener levcromakalim (D'Alonzo et a l , 
1995). A previous in vivo study in rabbit had used 3 mg kg"1 to inhibit levcromakalim 
responses (Meisheri et al., 1993). I found that 1.5 mg kg'1 had the optimum effect i.e. 
full reversal of hypotension induced by levcromakalim. PNU 37883A was administered 
120 min after the LPS infusion was initiated.
4.2.3 Case Report: Effect of glibenclamide in norepinephrine-resistant septic shock 
in a single patient on an intensive care unit
I gave a single dose of 1 mg kg'1 of intravenous glibenclamide over 5 min to a critically 
ill patient in severe septic shock not responding to high doses of the catecholamine 
vasopressor norepinephrine. Furthermore the hypotension remained despite treatment 
with corticosteroids or methylene blue (guanylate cyclase inhibitor). Prior to the study 
approval had been obtained from the University College London Hospitals (UCLH) 
Ethics Committee and agreement sought from the patient’s next-of-kin. The patient was 
intubated and ventilated. Cardiac output and fluid loading were assessed by
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transoesophageal Doppler ultrasound. Mean arterial blood pressure (MAP), 
norepinephrine requirements, central venous pressure, oxygen saturations, heart rate, 
urine output and cardiac output were monitored continuously and arterial blood gases 
were sampled.
4.3 Statistical analysis
As indicated in chapter 2.
4.4 Reagents and solutions
Aventis Pharma (Kent, U.K.) kindly donated the glibenclamide used in the in vivo 
model and in the human patient. Glibenclamide (for in vitro experiments), tetraethyl 
ammonium chloride, barium chloride and tolbutamide were all obtained from Sigma 
Chemical Company (Poole, Dorset, U.K.). PNU 99963 and PNU 37883A were kindly 
donated by Pharmacia-Upjohn (Kalamazoo, U.S.A.). In later studies PNU 37738A was 
obtained from Affrniti-Research, (Exeter, U.K.). Glibenclamide, tolbutamide, PNU- 
99963 and PNU-37883A were dissolved in dimethylsulphoxide and diluted into PSS. 
The highest final concentration of DMSO used in experiments was 0.1%. The other 
reagents are described in chapter 2.
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4.5 Results
4.5.1 Effect of K+ channel inhibition in an in vitro rat model of sepsis
4.5.1.1 Effect of endotoxin on the contractile responses to phenylephrine
Cumulative concentration-response curves to PE in rat mesenteric arterial rings 
incubated in the absence and presence of 1 pg ml'1 LPS are shown in Figure 4.1. In the 
presence of LPS, marked hyporeactivity to PE was observed at 6 h (P < 0.001, n= 14) 
and 20 h (P < 0.001, n - \ l ) .  In addition, LPS caused a rightward shift of the pEC5o 
value at 6 h which was associated with a marked reduction in the maximal contraction 
(EMax) to 10'5 M PE (P  < 0.001; Table 4.1). An accurate pEC50 value could not be 
calculated at 20 h as the contractile responses to PE in the presence of LPS were too 
small. The magnitude of the relaxation induced by acetylcholine in control tissues did 
not alter with time in culture medium, being 80.6 ± 0.2%, n= 13 versus 79.0 ± 9.7, n=8, 
at 6 & 20 h, respectively.
4.5.1.2 Effect of K a t p  channel inhibitors on LPS-induced vascular hyporeactivity
The SUR inhibitors, glibenclamide (10 pM), tolbutamide (1 mM) and PNU-99963 (1 
pM) all failed to reverse LPS-induced vascular hyporeactivity either at 6 or 20 h (Fig.
4.1 and Table 4.1). Indeed, glibenclamide further reduced PE contractions at 6 h (P = 
0.002 compared to LPS alone). Lack of reversal of PE contraction with the SUR 
inhibitors could not be attributable to solvent effects since DMSO (0.1%) failed to 
significantly alter hyporeactivity to PE induced by LPS at 20 h (P = 0.34). The
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maximum contraction in the presence of DMSO was 0.23 ± 0.01 g, n -4 compared to 
0.13 ± 0.05, w=17 with LPS alone.
To investigate the effect of inhibiting the pore-forming subunit of the K Atp channel, we 
used and PNU-37883A (1 pM). At 6 h, BaCl2 fully reversed LPS-induced 
hyporeactivity while PNU-37883A produced a 75% reversal (P = 0.035; n - 8) (Fig. 
4.2A & Table 4.1). In contrast, no reversal was seen with 30 pM BaCl2 (Fig. 4.2A), a 
concentration sufficient to inhibit strong inwardly rectifying K+ (Kir) channels (Nelson 
& Quayle, 1995), suggesting these channels do not contribute to LPS-induced 
hyporeactivity. At 20 h incubation with LPS, less reversal was achieved with either 
BaCl2 or PNU-37883A with both inhibitors only producing a 50 % reversal (Fig. 4.2B). 
To rule out the possibility that pore-inhibitors blocked basal K atp channel activity, 
thereby increasing the sensitivity to PE independently of LPS, concentration-response 
curves to PE were performed in control tissues that had previously been incubated in 
culture medium for 6 h. In the absence and presence of PNU-37883A, dose-response 
curves for PE were essentially super imposable, with pECso values being 7.03 ± 0.07 
and 7.22 ± 0.03, respectively (P = 0.11; n-1). Similarly, BaCl2 did not affect EMax (P = 
0.71) although it caused a small, but significant (P < 0.05) increase in the pEC50 value 
(7.34 ±0.13; n -4) compared to control.
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Figure 4.1 Effect of the SUR KATP inhibitors glibenclamide (10 pM), tolbutamide (1 mM) 
and PNU-99963 (1 jiM) upon LPS-induced hyporeactivity at (A) 6 & (B) 20 h. All failed 
to reverse hyporeactivity, indeed, glibenclamide further reduced PE contractions at 6 h {P 
— 0.002 compared to LPS alone). Data are expressed as the mean ± s.e.m. of 8-10 
observations from 10-12 rats.
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Figure 4.2 Effect of the pore-forming subunit K Atp channel inhibitors, BaCl2 (300 
pM) and PNU-37883A (1 pM) upon LPS-induced hyporeactivity at 6 (A) & (B) 20 h. 
At 6h, BaCl2 fully reversed hyporeactivity and PNU-37883A produced 75% reversal 
(P = 0.035). At 20h both produced partial reversal (P<0.05). BaCl2 (30 pM) had no 
effect. Data are expressed as the mean ± s.e.m. of 8-10 observations from 10-12 rats.
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Table 4.1 Effect of K At p  channel blockers on phenylephrine contractions in tissues 
incubated for 6 h in culture medium ± LPS
Comparison of pECso values and maximal contraction (Emhx) obtained against 
contractions to 10'5 M PE in the absence (control) and presence of LPS ± channel 
inhibitors. Data are expressed as mean ± s.e.m. of n observations.
Rat mesenteric artery pECso EMax (g) n
Control 6.53 ±0.10 1.53 ±0.05 18
LPS 5.71 ±0.18** 0.50 ±0.05** 14
LPS ± Glibenclamide (10 pM) 5.16 ±0.38** 0.17 ± 0.03** # 10
LPS ± Tolbutamide (1 mM) 5.99 ±0.08 0.64 ±0.13** 8
LPS + PNU-99963 (1 pM) 5.80 ±0.13* 0.49 ±0.10** 6
LPS + PNU-37883A (1 pM) 6.01 ±0.12 1.14 ±0.11* # 6
LPS ± BaCl2 (30 pM) 6.03 ± 0.05 0.65 ±0.07** 6
LPS ± BaCl2 (300 pM) 6.41 ±0.07 1.46 ± 0.16# 8
LPS + TEA+ (ImM) 6.13 ±0.21 0.94 ± 0.08* # 8
LPS + TEA+ (lOmM) 6.43 ± 0.22 1.36 ±0.21 6
* = P  <0.05, ** = P< 0.001 when compared to control, #- P <  0.05 
when compared to LPS alone
4.5.1.3 Effect of tetraethylammonium chloride
I investigated the effects of TEA+ - a relatively selective inhibitor of BKca channels at 
ImM and a non-selective inhibitor of K+ channels at 10 mM (Nelson and Quayle, 
1995). At 6 h, TEA+ 1 mM produced a partial reversal of LPS-induced hyporeactivity 
reducing CP=0.029) EMax to 0.94 ± 0.08g («=8) from -1.53 ± 0.05g («=18) (Fig. 4.4A &
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Table 4.1). Increasing the concentration of TEA+ to 10 mM produced almost complete 
reversal of LPS-induced hyporeactivity (Fig. 4.5.2.C) (P<0.001, n -8).
At 20 h, TEA+ at ImM caused a partial reversal of LPS-induced hyporeactivity but only 
when concentration-response curves of the peak contractions were compared (Figs 4.3 
& 4.4B) (P<0.05, max contractions 0.81 ± 0.23g, n -8 c.f. control tissues max 
contractions 1.53 ± 0.05, «=18). In the presence of TEA, contractions were transient, 
unlike the contractions obtained in the presence of either PNU-37738A (Fig 4.3B) or 
BaCl2 which were sustained.
4.5.1.4 Effect of inhibiting K+ channels using a combination of BaCl2 and TEA+
The combination of BaCl2 (300 pM) and TEA+ (ImM) produced no greater peak 
contractions to PE (Fig 4.4B and Table 4.1). However, the pEC5o was significantly (P -  
0.034) shifted to the left (6.9 ±0.18 with BaCl2 + TEA+, n -8 compared to 5.79 ± 0.48 
for BaCl2 alone, n-6).
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Figure 4.3 A comparison of concentration response traces obtained to PE in LPS tissues 
(incubated for 20 h) treated with (A) TEA+ (1 mM) and (B) PNU-37883A (1 pM). The 
contractions seen in the presence of TEA+ are transient compared to those in the PNU-37883A 
tissues.
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Figure 4.4 Effect of TEA+ (1& lOmM) upon LPS-induced hyporeactivity at (A) 6 and (B) 
20 h and a combination of BaCl2 (300pM) and TEA+ (ImM) at 20 h. At 6 h, 1 mM TEA+ 
produced partial (P -  0.029) while TEA+ at 10 mM produced almost complete reversal. At 
20h TEA+ produced some reversal but contractions were non-sustained. The combination of 
BaCl2 / TEA+ produced similar reversal to BaCl2 alone. Data are expressed as the mean ± 
s.e.m. of 6-8 observations from 8-10 rats.
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4.5.1.5 Effect of LPS on contractions to 60 mM KC1
The degree of reversal of LPS-induced hyporeactivity with the K+ channel inhibitors 
suggests that the mechanism of relaxation predominately involves opening of K+ 
channels at 6 h, but additional pathways at 20 h. To test this, we investigated the effect 
of LPS on contractions induced by 60 mM KC1, where relaxation cannot be promoted 
by K+ channel opening due to a lack of transmembrane driving force on K+ ions 
(Gurney & Clapp, 1994). Whereas a 6 h incubation with LPS did not significantly 
reduce contractions to 60 mM KC1 (P=0.102, n=16), the contractile response was 
significantly depressed (-40%) at 20 h (P<0.001, n -  10; Fig. 4.5). The lack of effect of 
LPS on KC1 contractions at 6 h is consistent with a predominately K+ channel 
mechanism at this time point, while additional mechanisms are likely to contribute at 20 
h.
4.5.1.6 Effect of the thromboxane A2 mimetic U-46619 on contractile responses
Sepsis up-regulates the production of thromboxane (Bernard et al., 1997) although LPS 
only weakly affected contractile responses to thromboxane agonists in our organ bath 
model (O’Brien et al., 2001; see chapter 2). Competitive antagonism of thromboxane 
receptors by the SUR inhibitors glibenclamide and tolbutamide (Cocks et al., 1990) 
may underlie their inability to reverse hyporeactivity. No data exist for the potent 
pinacidil-derived inhibitor, PNU-99963. We observed a significant contraction 
following addition of the thromboxane-A2 mimetic, U-46619 (10'7 M) when applied to 
PE-hyporeactive tissues previously incubated with LPS for 20 h (Fig. 4.6A & B). While 
tissues pre-treated with either glibenclamide (10 pM) or tolbutamide (1 mM) failed to
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contract to U-46619, a large contraction was observed in tissues pretreated with PNU- 
99963 (1 pM). In rings not exposed to LPS, U-46619 only caused a small contraction 
(from 1.48 ± 0.06g to 1.78 ± 0.17g; n-5), presumably because the contractile response 
to PE at 10'5 M was close to the maximum tension the tissue could generate.
A 1-5-i
Control
O 0.5
Control LPS
Figure 4.5 LPS (lpg m l1) induces hyporeactivity to contractions with 60 mM KCL 
following (B) 20 h incubation (P < 0.001) but not (A) 6 h. Data are expressed as the 
mean ± s.e.m of 10-16 observations from 6-8 animals
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Figure 4.6 Addition of the thromboxane agonist U-44619 (10‘7 M) at the end of 
concentration response curves to PE (A). LPS treated tissues incubated with tolbutamide 
(Tolb, ImM) & glibenclamide (Glib, 10 pM) failed to contract compared to LPS treated 
tissues with PNU99963 (1 pM). *—P  < 0.001 compared to LPS alone and P<0.05 
compared to control). Data are expressed as mean ± s.e.m of 6 observations from 8 rats.
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4.5.1.7 Effect of K At p  channel inhibitors on LPS-induced nitrite accumulation
I demonstrated in chapter 2 the contribution of the iNOS / NO pathway to LPS induced 
hyporeactivity in an organ culture model. Having achieved reversal of vascular 
hyporeactivity using K+ inhibitors, I needed to confirm that these agents had no effect 
upon NO production itself. I thus investigated whether the Katp inhibitors inhibited 
nitrite production in the culture medium supernatant. Nitrite (NO2 ), a metabolite of NO, 
is a marker of NO production (Thiemermann, 1997). Compared to control supernatant 
of rat mesenteric rings, NO2' levels doubled in the presence of LPS (1 pg ml'1) after a 
20 h co-incubation (P < 0.001; Fig. 4.7). This rise was completely inhibited by the 
specific iNOS inhibitor, 1400W (10 pM) and by 70% with tolbutamide (1 mM) (Fig 
4.7). Neither glibenclamide (10 pM), PNU-37883A (1 pM) nor BaCL (300 pM) 
significantly affected LPS-induced nitrite production at the concentrations used in the 
tension studies (Fig. 4.7), although there was a trend to lower nitrite production in the 
presence of BaCL.
4.5.1.8 Effect of K a t p  inhibitors on relaxation to the nitric oxide donor, SNAP
I performed these experiments to investigate whether relaxation of vascular tone by NO 
donor is inhibited by K channel blockade. NO has been shown to activate BKca 
channels (Hohn et a l ,  1996). Vanheel & Van de Voorde (1997) showed that NO did not 
activate K Atp channels, however, Davie and co-workers (1997) and Murphy & Brayden, 
1995) demonstrated that NO activates K Atp channels in aorta and mesenteric artery. The 
effect of the pore-forming subunit inhibitors PNU-37883A (1 pM) and BaCL (300 pM) 
were investigated in mesenteric rings mounted within an hour of being taken out of the
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animal. N either agent had a significant effect on the concentration-dependent relaxation 
o f  PE contractions (1 pM ) induced by the NO donor, SNAP (Fig. 4.8). In contrast, the 
guanylyl cyclase inhibitor, ODQ (3 pM ) fully inhibited relaxation to SNAP. In addition, 
TEA+ (1 and 10 mM) significantly inhibited concentration-relaxation curves to SNAP 
(P < 0.001, Fig. 4.8) shifting the pEC5o to the right (see Table 4.2).
£
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Figure 4.7 Rat mesenteric artery incubated with LPS (lpg ml'1) for 20 h induces nitrite 
accumulation within culture media compared to control tissues {P < 0.001). This was inhibited 
by tolbutamide (Tolb ImM, P < 0.05) but not by the other KATP channel inhibitors (PNU- 
37738A 1 pM, Glibenclamide -  Glib 10 pM and BaCl2 300 pM). Data are expressed as the 
mean ± s.e.m of 6 observations from 5 animals.
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Figure 4.8 Effect of KATP inhibitors on concentration-relaxation curves to SNAP 
compared to the guanylyl cyclase inhibitor, ODQ (3pM). TEA+ at 1 or 10 mM 
significantly inhibited relaxation to SNAP (P < 0.001 when compared to control). PNU- 
37738A (lpM), and BaCl2 (300pM) had no effect. Data are expressed as mean ± s.e.m. of 
6 observations from 6-8 animals.
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Table 4.2 Effect of K+ channel inhibitors on relaxation responses to SNAP in fresh 
rat mesenteric arteries precontracted with phenylephrine (10-6 M).
Data are expressed as mean ± s.e.m. of > 6  observations.
Rat mesenteric 
artery
pECso n
Control 6.76 ±0.18 1 0
BaCl2 (300 pM) 6.15 ±0.23 6
PNU-37883A (1 pM) 6.42 ±0.14 6
TEA+ (1 mM) 5.73 ±0.10* 6
TEA+ (lOmM) 5.41 ±0.33* 7
* P <  0 . 0 0 1  compared to control
4.5.2 Effect of K Atp channel inhibition in an in vivo rat model of endotoxaemic 
sepsis
4.5.2.1 Effect of LPS upon MAP, aortic and renal blood flow and micro vascular 
oxygen tension
The baseline parameters and the effect of LPS are described fully in chapter 3. Briefly, 
in sham animals MAP, RBF, hepatic microvascular oxygenation (HmvC>2) and arterial 
base deficit did not change significantly throughout the experiment (Fig. 3.1). However, 
there was a tendency for in MAP and RBF to increase; a rise followed by a fall in ABF 
and HmvC>2 was also observed. These changes, particularly in ABF, were probably 
related to the fluid resuscitation. Following infusion of LPS, there was a rapid fall in all 
measured variables within 0-30 min (see Fig. 3.1). Recovery in MAP was observed
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within 30 min (before fluid resuscitation was commenced), although aortic and renal 
blood flow took 2-3 h to return to baseline values. However, HmvC>2 failed to show any 
significant recovery after the initial abrupt fall. After 120 min the MAP fell significantly 
in LPS treated rats (P < 0.001, n - 6 , ANOVA) and as such this was the time at which I 
chose to administer the K Atp inhibitors.
4.5.2.2 Effect of K At p  channel inhibitors in LPS treated and sham-operated 
animals
I chose to use both a low (1 mg k g 1) and high (10 mg kg' 1 bolus and 5mg kg' 1 h' 1 
infusion) dose of glibenclamide. Previous studies in rats have used lmg kg' 1 bolus (Wu 
et al., 1995) and I found in the sham rats that a 1 mg kg' 1 bolus of glibenclamide 
reversed hypotension induced by the K Atp channel opener levcromakalim (3 pg k g 1) by 
70%. I chose to use a high dose of glibenclamide in addition as 10 mg kg' 1 
glibenclamide was required to produce complete reversal of levcromakalim-induced 
hypotension.
Low dose glibenclamide administered at 120 min had no discernible effect upon the 
measured parameters in either LPS-treated or sham rats (data not shown). In contrast, 
high dose glibenclamide resulted in a significant rise in MAP in both sham and LPS- 
treated rats (P = 0.007 and P  < 0.001, n - 6 , ANOVA for shams and LPS respectively; 
Fig. 4.9 & 10). The intial 8  rise in MAP seen (from 120 to 135 min) is similar in the 
LPS and sham treated tissues (-20 mmHg compared to -18 mmHg) but the effect is 
more sustained in shams -  until the end of the experiment (240 min) compared to 200
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min with LPS rats. In LPS rats the RBF, ABF and arterial base deficit were unaffected 
by high dose glibenclamide treatment but there was a tendency to a reduction in Hmv0 2  
compared to untreated rats. In sham rats high dose glibenclamide worsened ABF and 
Hmv0 2  compared to controls; the RBF and arterial base deficit appeared unaffected.
PNU-37883A (1.5mg kg' 1 and lmg kg' 1 IT1 infusion) also resulted in a significant rise 
in MAP in both sham and LPS-treated rats (P = 0.004 and P < 0.001, n - 6 , ANOVA for 
shams and LPS respectively; Fig. 4.9 & 10). Here the rise in MAP is greater in shams 
(~30 mmHg) compared to LPS-treated rats (~15 mmHg). Again the effect is more 
sustained in shams where it lasts until 240 min compared to 200 min with LPS. In LPS- 
treated rats the RBF and Hmv0 2  were unaffected by PNU-37883A, however there was 
a significant fall in the ABF and increase in acidaemia compared to LPS alone (arterial 
base excess: LPS -9.64 ± 0.41 and LPS + PNU-37738A -14.15 ± 1.11, P  = 0.031, n=6 , 
ANOVA). In shams PNU-37883A had no effect on the RBF and Hmv0 2 ; however there 
was a significant fall in the ABF, similar to that observed in LPS treated animals and 
there was an increase in acidaemia.
4.5.3 Effect of an intravenous bolus dose of glibenclamide in a septic shock patient
An intravenous bolus dose of 10 mg of glibenclamide over 5 min had no effect on MAP 
or norepinephrine dose in 1 patient with streptococcal septicaemia and liver failure. No 
effect was seen on cardiac output, arterial base excess or blood glucose.
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Figure 4.9 Effect of the K Atp inhibitors glibenclamide (10 mg kg'1 bolus + 5 mg kg'1 
infusion) and PNU-37883A (1.5 mg kg'1 bolus + 1 mg kg'1 infusion) given at 120 min 
(see arrow) on (A) mean arterial blood pressure and (B) renal blood flow in shams. High 
dose glib and PNU-37883A raised MAP (P<0.05, ANOVA). PNU-37883A did not raise 
renal blood flow significantly. Low dose glib had no effect (not shown). Data are 
expressed as mean ± s.e.m. from 3-6 rats.
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Figure 4.9 Effect of the KAtp inhibitors glibenclamide (10 mg kg'1 bolus + 5 mg kg'1 
infusion) and PNU-37883A (1.5 mg kg'1 bolus + 1 mg kg'1 infusion) given at 120 min 
(see arrow) on (C) aortic blood flow and (D) micro vascular oxygenation in sham rats. 
PNU-37883A and high dose glib reduced ABF significantly (P<0.05, ANOVA).Glib 
also reduced Hmv02 significantly (B<0.05). Low dose glib had no effect (not shown). 
Data are expressed as mean ± s.e.m. from 3-6 rats.
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Figure 4.10 Effect of the KATp inhibitors glibenclamide (10 mg kg'1 bolus + 5 mg kg'1 
infusion) and PNU-37883A (1.5 mg kg'1 + lmg kg'1 infusion) given at 120 min (see 
arrow) on (A) mean arterial blood pressure and (B) renal blood flow in LPS-treated 
rats. High dose glibenclamide and PNU-37883A raised MAP (P < 0.001, ANOVA) 
without affecting RBF. Low dose glibenclamide had no effect (data not shown). LPS 
was infused over the first 30 min. Data are expressed as mean ± s.e.m. from 6 rats.
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Figure 4.10 Effect of the KATP inhibitors glibenclamide (10 mg kg'1 bolus + 5 mg kg'1 
infusion) and PNU-37883A (1.5 mg kg'1 bolus + 1 mg kg'1 infusion) given at 120 min 
(see arrow) on (C) aortic blood flow and (D) microvascular oxygenation in LPS-treated 
rats. PNU-37883A reduced ABF at later time points (P<0.05, ANOVA). Neither agent 
restored Hmv02. LPS was infused over the first 30 min. Data are expressed as mean ± 
s.e.m. from 6 rats.
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4.6 Discussion
4.6.1 Effect of inhibition of K+ channels in an in vitro model of sepsis
I have shown that the K Atp channel is an important mediator of LPS-induced vascular 
hyporeactivity in vitro. Importantly, I found that only inhibitors of the pore-forming 
subunit, not the SUR subunit, were effective in reversing this hyporeactivity. Indeed, 
glibenclamide further depressed contractile responses to phenylephrine in the presence 
of LPS as has been shown previously in endothelium-intact vessels (Preiser et al., 
2003). Lack of effectiveness of either glibenclamide or tolbutamide on LPS-induced 
vascular hyporeactivity, could not have resulted from inhibition of thromboxane 
receptors, since PNU-99963, the most potent SUR2 inhibitor available (Cui et al., 
2003), failed to inhibit contractions to the thromboxane A2 mimetic. In addition, 
restoration of vascular reactivity observed with the K atp channel pore-blockers cannot 
be explained by inhibition of NO production, since these agents did not reduce nitrite 
accumulation induced by LPS. The suppressed contractile response to 60 mM KC1 seen 
after 20 h exposure to LPS, but not at 6  h, implies that mechanisms independent of K+ 
channel activation also contribute to hyporeactivity at this later timepoint.
The interpretation of my in vitro experimental data relies heavily upon the specificity of 
the Katp inhibitors used at the stated concentrations i.e. that BaCl2 (300 pM) and PNU- 
37883A ( 1  pM) are specific inhibitors of the pore-forming subunit of the K Atp  channel. 
In vascular smooth muscle, BaCl2 inhibits the K a tp  channel with an IC50 of 100 pM and 
Kir channels with an IC50 of ~ 2-5 pM (Nelson & Quayle, 1995 and Bradley et al.,
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1999). As I observed no effect at 30 pM BaCk, a concentration that effectively inhibits 
vascular relaxation associated with Kir channels (Quayle et al., 1997 and Edwards et 
al., 1998), this would rule out a contribution from these channels. Furthermore, mRNA 
for Kir 1.1 and Kir3.1 has been identified in rat arteries (Michelakis et al., 2001), 
subunits which encode weak (ROMK1) and G-protein gated (GIRK) inwardly 
rectifying K+ channels. Both channels types would be expected to be blocked by Ba2+ in 
the high micromolar range (>100 pM) and thus it is conceivable that GIRK or ROMK1 
channels may be activated by LPS treatment. However, the PNU-37883A data leads 
me to conclude that hyporeactivity does indeed result from activation of K At p  channels. 
PNU-37883A is considered to be a highly selective inhibitor of the K a t p  channel 
(Humphrey, 1999). It antagonises the vasorelaxant effects of pinacidil, levcromakalim 
and minoxidil sulphate in rabbit mesenteric artery (IC5o ~1 pM), while not significantly 
affecting the vasorelaxant responses to forskolin, nitroglycerin or the Ca2+ channel 
blocker, D-600 (Meisheri et al., 1993). Likewise in patch-clamp studies, PNU-37883A 
blocks pinacidil- or levcromakalim-activated K A t p  currents (IC5o = 3 . 5  pM) in isolated 
rat arterial smooth muscle cells, while only marginally inhibiting (> 1 0  %) voltage- 
activated (Kv) or Kir currents at 10 pM (Wellman et al., 1999). I have thus provided 
good pharmacological evidence for the involvement of K A t p  channels in mediating 
LPS-induced vascular hyporeactivity. Additional evidence comes from the observation 
that relaxations to K At p  channel openers such as levcromakalim are potentiated in both 
in vitro and ex -vivo models of LPS-induced hyporeactivity (Sorrentino et al., 1999; 
Chen et al., 2000 and Wilson & Clapp, 2002). The iNOS pathway probably mediates 
this since both 1400W and, to a lesser extent ODQ, reversed potentiation (Wilson &
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Clapp, 2002). I can exclude an effect upon the generation of nitric oxide, as PNU- 
37883A did not reduce nitrite production in the culture media following LPS treatment. 
Likewise, I have previously shown that inhibition of the inducible cyclo-oxygenase 
pathway did not reverse vascular hyporeactivity in our organ culture model (O'Brien et 
a l , 2001), excluding a contribution from the prostaglandin pathway in mediating KAtp 
channel activation.
I have previously shown that both iNOS and guanylate cyclase inhibitors fully reverse 
hyporeactivity in mesenteric arteries treated with LPS for 6  h in vitro (O'Brien et al., 
2001, chapter 2). Thus the NO / cyclic GMP pathway is likely to be responsible for 
K atp channel activation at this time-point. Indeed, other studies have demonstrated 
activation of K Atp channels in response to NO in mesenteric artery (Garland & 
McPherson, 1992; Murphy & Brayden, 1995). In my work, neither BaCl2 nor PNU- 
37883A inhibited relaxations to the NO donor, SNAP in fresh control tissues. Similarly, 
relaxation to NO in endothelium-denuded aortic tissue was only weakly affected by 
either Ba2+ or 4-aminopyridine, suggesting activation of K+ channels does not appear to 
be the primary mechanism of relaxation for authentic NO (Wilson & Clapp, 2002). 
Thus, additional factors associated with incubation of LPS may aid NO activation of 
K Atp channels in this model. Consistent with this notion, relaxation to SNAP (or 
forskolin) in rat aorta was only inhibited by PNU-37883A in the presence of LPS 
(Wilson & Clapp, 2002). However, the degree of reversibility achieved by the KATp 
channel inhibitors declined at 20 h. This mirrors my previous finding of decreased 
responsiveness to iNOS inhibitors over time (O'Brien et al., 2001, chapter 2).
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Bioenergetic failure and/or disruption of the actin cytoskeleton have been demonstrated 
in sepsis and perhaps either of these contributes to vascular hyporeactivity (Williams et 
al., 1999 and Brealey et al., 2003). Such a mechanism may also account for the reduced 
contractile response to 60 mM KC1 at 20 h.
Different mechanisms of Katp channel activation may underlie the hypotension and 
vascular hyporeactivity induced by LPS, perhaps due in part to circulating hormones 
and mediators not present in vitro. For example, calcitonin gene-related peptide, a 
known activator of vascular Katp channels (Quayle et al., 1997), is increased in septic 
shock (Arden et al., 1994). Alternatively, Katp channels may open secondary to a fall in 
tissue ATP, oxygen tension or pH, conditions associated with severe forms of shock 
(Clapp & Tinker, 1998). However, the extent to which these metabolic defects occur in 
sepsis remain controversial (Singer & Brealey, 1999) and has not been investigated in 
vitro. Nonetheless, over-production of NO via iNOS is an integral part of both 
hypotension and hyporeactivity in sepsis (Vincent et al., 2001).
The fact that glibenclamide had no effect ex vivo may be related to the use of aorta in 
previous studies (Wu et a l ,  1995; Taguchi et a l ,  1996 and Sorrentino et al., 1999), 
which is a conduit vessel that makes little contribution to blood pressure. Results from 
this laboratory reported that glibenclamide was also ineffective at preventing iNOS- 
mediated relaxation induced by L-arginine in rat aorta (Wilson & Clapp, 2002). 
However, in the present study, I found that glibenclamide also failed to reverse 
hyporeactivity in the mesenteric artery. Another consideration may be the counter­
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balancing effect of glibenclamide on the contractile effects of thromboxane (Cocks et 
al., 1990). Thus, inhibiting thromboxane-induced vasoconstriction could negate any 
reversal of vascular hyporeactivity that might have occurred through blocking the K atp 
channel. It is worth noting that cytokine-induced hyporesponsiveness of aorta to 
phenylephrine was significantly augmented in TXA2 receptor knockout mice (TP'7'), 
suggesting a protective role for TXA2 against the development of vascular 
hyporesponsiveness (Yamada et al., 2003). Although I demonstrated that glibenclamide 
and tolbutamide antagonised thromboxane-induced contractions in mesenteric artery, 
PNU-99963 did not. I thus conclude that lack of reversal of SUR inhibitors on LPS- 
hyporeactivity is unrelated to thromboxane inhibition.
The striking difference between the effectiveness of glibenclamide and PNU-37883A in 
vitro could relate to their different sites of action (SUR versus pore). It has previously 
been reported that actin filament disruption with cytochalasin D abolishes high-affinity 
glibenclamide binding to the SUR subunit in rat aortic rings whereas KCO binding is 
unaffected (Loffler-Walz & Quast, 1998). Similar effects on glibenclamide binding can 
be achieved with metabolic inhibition or hypoxia (Loffler & Quast, 1997). Furthermore, 
NO can cause cytoskeletal disassembly either through actin nitration (Banan et al., 
2001) or through inhibition of the RhoA kinase pathway by cyclic GMP (Sauzeau et al.,
2000). Thus, LPS may cause NO- or ATP-dependent disruption of the cytoskeleton, 
rendering SUR agents ineffective, while leaving pore-blockers relatively unaffected. 
Indeed, we have previously shown that glibenclamide is significantly less effective than
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PNU-37883A at inhibiting levcromakalim responses in the presence of LPS (Wilson & 
Clapp, 2002).
The greater degree of reversal obtained with BaCL compared to PNU-37883A at 6  h 
suggests K atp channel independent mechanisms. This is consistent with the small 
increase in potency to PE in control tissues pre-incubated with Ba2+ but not PNU- 
37883 A. Using the non-selective K + channel inhibitor, TEA+ a similar reversal of LPS- 
induced hyporeactivity to that observed with PNU-37883A or BaCl2 was seen at 10 
mM. At this concentration TEA+ is likely to inhibit K atp channels as well as other K + 
channels. Some reversal of LPS-induced hyporeactivity was also seen at concentrations 
as low as ImM TEA, suggesting a contribution from BKca channels. The role of 
additional K + channels is also consistent with a small, but significant leftward shift of 
the PE dose-response curve elicited by TEA over and above that observed with BaCE 
alone. Indeed, a role for the BKca channel in mediating some of the effects of LPS has 
previously been described in aortic smooth muscle (Hall et a l , 1996; Taguchi et a l , 
1996; Chen et al., 1999, and Yakubovich et a l , 2001). Furthermore, activation of BKca 
channels in rat mesenteric artery has been shown to be involved in the development of 
vascular hyporeactivity following haemorrhagic shock (Zhou et a l , 2005). To be certain 
that BKca channels were involved in LPS-induced hyporeactivity, I should have 
repeated experiments using iberiotoxin, a highly specific and potent inhibitor of this 
channel (Nelson and Quayle, 1995). At 20h however, there was a clear difference in the 
nature of the reversal of LPS-induced hyporeactivity. Contractions to PE were transient 
in the presence of ImM TEA+ whereas those obtained in the presence of PNU-37883A
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or BaCl2 were sustained. Depolarisation by whatever means may boost contractions to 
PE and the transient contractions observed with TEA+ may represent just a smaller 
depolarisation with this agent. This may have the consequence of allowing significant 
calcium release from HVsenstive stores (see Quast et al., 1994), which would give rise 
to a transient contraction, while not providing a greater enough depolarisation to 
promote Ca2+ entry through voltage-gated Ca2+ channels.
4.6.2 Effect of inhibition of the Katp channel in an in vivo model of sepsis
In the in vivo model administration at 120 min of the K Atp channel inhibitors PNU- 
37883 A and glibenclamide at high dose (10 mg kg'1 bolus and 5 mg kg'1 h '1) infusion 
elevated blood pressure significantly in the LPS-treated rats and shams. However, low 
dose glibenclamide (lm g kg'1 bolus) had no effect in shams or LPS treated rats. Despite 
the improvement in blood pressure, neither agent improved the macro nor 
microcirculation. Indeed there were adverse effects in LPS-treated rats with high dose 
glibenclamide worsening the HmvC>2 while PNU-37883A reduced ABF and worsened 
the metabolic acidosis.
This is the first in vivo study to demonstrate that the pore-forming subunit inhibitor, 
PNU-37883A raises blood pressure in septic rats. Glibenclamide has previously been 
shown to reverse LPS-induced hypotension in several in vivo models (e.g. Landry and 
Oliver, 1992 and Vanelli et al., 1995). However the difference between high and low 
dose glibenclamide despite both inhibiting levcromakalim relaxations has never been 
described. Unlike previous work, however, in my model, the effects of both K Atp
180
Is the K* channel an important mediator o f LPS-induced vascular hvporeactivitv or hypotension
inhibitors on blood pressure were greater in the shams than LPS-treated rats (this is in 
contrast to the iNOS inhibitor GW273629A that has a significantly greater effect upon 
LPS-treated rats, see chapter 2). It is tempting to suggest that the differing effects seen 
with low and high dose glibenclamide might be due to the higher dose acting on the 
pore-forming subunit of the K Atp channel as the effect seen is very similar to that of 
PNU-37883A. Although the IC50 for inhibition of the SUR by glibenclamide is ~10-200 
nM (Fujita & Kurachi, 2000), at a 1000-fold higher concentration, glibenclamide 
appears to interact with the pore directly (Gribble et al., 1998; Bryan & Aguilar-Bryan, 
1999). The calculated peak plasma concentration of glibenclamide for a dose of 1 mg 
kg"1 equates to approximately 60 pg ml'1 (or 120 pM) (Wu et al., 1995). At this 
concentration (low dose) glibenclamide would be expected to inhibit the pore directly. 
Thus my assumption that both high dose glibenclamide is acting on the pore-forming 
subunit of the K atp channel, as PNU-37883A, may not be accurate. Interestingly many 
investigators have used much higher doses in in vivo rat models of sepsis. The in vivo 
studies that have demonstrated an increase in blood pressure in endotoxic animals with 
glibenclamide have used doses that range from lmg kg'1 to 20 mg kg'1 intravenously 
and 40 mg kg'1 intraperitoneally (Landry and Oliver, 1992; Vanelli et al., 1995; Wu et 
al., 1995; Vanelli et al., 1997; Gardiner et al., 1999 and Sorrentino et al., 1999). In 
addition, almost all in vivo studies use doses of 5 mg kg'1 or above to inhibit the 
potassium channel opener levcromakalim (Pratz et al., 1991, Saito & Sakai, 1998 and 
Zhang et al., 1999). Smits et al., (1997) found that using concentrations of 
glibenclamide as low as 0.3 mg kg'1 significantly attenuated levcromakalim responses 
but that 10 mg kg'1 was required for full inhibition. Indeed in the sham rats I found that
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glibenclamide 1 mg kg'1 reversed the potassium channel opener levcromakalim induced 
hypotension by 70% and 10 mg kg'1 by 100%. i.e. higher concentrations of 
glibenclamide were required to raise blood pressure in sham or LPS-treated rats than 
inhibit levcromakalim-induced hypotension. The specific vascular K atp inhibitor PNU- 
37883 A (Humphrey, 1999) has never been used before in sepsis models. 3 mg kg'1 will 
prevent and reverse the fall in blood pressure induced by the potassium channel opener 
pinacidil in an anaesthetised rat (Smith et al., 1994). I found in shams that PNU- 
37883 A (1.5 mg kg'1) fully reversed the hypotensive effects of levcromakalim.
Previous studies have not shown a pressor effect of glibenclamide upon shams (e.g 
Landry and Oliver, 1992; Vanelli et al., 1995 and Wu et al., 1995). Indeed one study 
described a reduction in blood pressure in shams that was considered to be related to an 
increase in cardiac afterload secondary to vasoconstriction (Presier et al., 2003). As 
mentioned above, in stark contrast to these studies, the effects seen in shams in my 
model is superior to that seen in LPS-treated rats. Clearly K atp channels are activated in 
the absence of LPS in this model. Interestingly, SUR2 knockout mice are hypertensive 
and therefore one might predict an effect of K atp channel inhibitors upon blood 
pressure in the shams (Chutkow et a l , 2002). Although in vitro, glibenclamide and 
PNU-37883A had no effect upon contractile responses to PE in control tissues. 
Glibenclamide has been shown to inhibit the production of iNOS (Wu et al., 1995) but I 
found it to have no effect upon nitrite production in vitro, although tolbutamide did 
reduce nitrite production. The laparotomy and instrumentation of the rat would be 
extremely likely to induce iNOS and certainly the iNOS inhibitor GW273629A had a
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haemodynamic effect in shams (though non-significant) and iNOS was identified by 
immunohistochemistry in sham animals (see chapter 2). In addition the anaesthetic 
agent used, isoflurane is a K atp channel opener (Ida et al., 1998 and Sumikawa et al., 
1998). Thus it is not surprising that the K atp channel is activated in shams, however, as 
levcromakalim still caused hypotension in shams, the channel was clearly not fully 
activated. Perhaps the superior effect seen in shams is because sepsis reduces the ability 
of the pore-forming subunit of the K Atp channel to bind to PNU-37883A and 
glibenclamide; possibly due to metabolic acidosis. Why this has not been demonstrated 
in previous septic in vivo models I cannot readily explain.
A possible confounding factor when using glibenclamide is that it is difficult to dissolve 
and so the solvent dimethyl sulfoxide (DMSO) is often used (e.g Wu et al., 1995 and 
Sorrentino et al., 1999). DMSO has been shown to inhibit NO synthesis (Liang and 
Akaike, 1997) and I confirmed its pressor effect in a separate experiment -  with 0.7 ml 
of a 100% solution of DMSO raising MAP from 76 to 116 mmHg in an LPS treated rat 
(not shown). 0.7 ml was the volume used for the bolus of all drugs in vivo. In these 
experiments, we use a lyophilised preparation of glibenclamide that was originally 
made for use in humans (and kindly donated by Aventis Pharma). The preparation 
contained mannitol and sodium hydroxide but not DMSO and has previously been used 
by Presier et al., (2003) in dogs. Given that low dose glibenclamide had no significant 
effect on MAP in shams or LPS treated animals, would argue against non specific 
effects on this parameter. There should be no solvent problem for PNU-37883A, which 
was dissolved in water.
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There was no response to glibenclamide in the one patient with septic shock. Obviously 
I would like to have recruited more patients, to see if this was a consistent finding. I 
gave this patient 1 mg kg"1 and perhaps had I used a higher dose as in my in vivo model 
there may have been a response. It has been shown that dexamethasone reduces 
vascular hyporeactivity induced by LPS in vivo, at least in part, by modulating K At p  
channel activity (D’Emmanuel di Villa et al., 2003). It was suggested that steroids 
might work by reducing K a t p  channel expression. Such an effect may underpin the 
observation that the administration of hydrocortisone to septic shock patients improves 
the response to PE i.v. infusion (Bellissant & Annane, 2000). Indeed hydrocortisone has 
been shown to improve survival in septic shock patients (Annane et al., 2002). Steroids 
are known to have a multitude of effects that may account for these effects including 
inhibition of iNOS and COX-2 expression, complement activation and PAF release 
(Imai et a l ,  1982; Han et a l ,  1997; Thiemermann, 1997; Leach et a l ,  1998). Thus it 
remains to be determined if the beneficial effect of steroids is partially due to inhibition 
of the Katp channel expression.
In summary, I have shown that the Katp channel is an important mediator of LPS- 
induced vascular hyporeactivity in an in vitro model. Moreover, I have demonstrated for 
the first time that inhibitors binding to the K a t p  channel pore rather than the SUR are 
effective at reversing vascular hyporeactivity. Whether this relates to a structural change 
or functional uncoupling between K a t p  channel subunits remains to be determined. 
These findings were complimented by my in vivo study in which glibenclamide and
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PNU-37883A both raised blood pressure, however, the effect seen in shams was 
superior to that seen in LPS-treated rats. As seen with the iNOS inhibitor GW273629A 
in vivo (chapter 4), an improvement in MAP did not correspond to an improvement in 
microvascular or renal and aortic blood flow.
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Chapter 5
Is vasopressin an important mediator of sepsis-induced 
vascular hyporeactivity or hypotension?
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5.1 Introduction
Thus far, I have been able to thoroughly characterise an in vitro and an in vivo model of 
septic shock. I have demonstrated evidence for activation of both the NO pathway and 
vascular potassium channels (especially K a t p ) -  In addition, I have shown that inhibition 
of either pathway reverses hypotension and vascular hyporeactivity induced by 
endotoxin. As a clinician, I wished to see whether my animal studies could be 
translated to the clinical environment. I had given intravenous glibenclamide to one 
patient with septic shock to no effect (see chapter 4). Moreover, the iNOS inhibitors that 
I had used in my experimental models were not considered safe to use in humans.
Several studies in patients have reported that infusions of vasopressin (VP) can increase 
blood pressure and lead to reduction in vasopressor requirements (e.g. Landry et al., 
1997 and see introduction). However, mechanisms underlying increased pressor 
sensitivity to VP and its relative deficiency in septic shock remain unknown.
I chose to study VP and its long acting analogue terlipressin (TP) in my two rat models 
of sepsis. I initially compared the vasoconstrictor properties of VP with phenylephrine 
(PE) in the in vitro rat mesenteric artery model of LPS-induced vascular hyporeactivity. 
I then examined the effect of TP upon LPS-induced hypotension in the in vivo rat model 
of sepsis, measuring its effects upon aortic and renal blood flow and arterial acid-base 
status. I chose TP in preference to VP as only the former was available for use in 
patients. I then conducted a short clinical study examining the effect of TP upon
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hypotension, norepinephrine (NE) requirements and outcome in humans (O’Brien et al 
2002).
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5.2 Methods 
5.2.1 Effect of LPS on responses to vasopressin in vitro
The methods for the organ bath experiments are fully described in chapter 2. Rings 
were incubated with and without LPS (1 pg ml"1) for 20 h. Endothelial function was 
assessed by monitoring relaxation to acetylcholine (5 pM) in rings precontracted with 1 
pM PE. Cumulative concentration-response curves were constructed to PE (10'9 to 105
1 9  7M) and to VP (10' to 10' M) with increasing doses added at 5 min intervals at which 
time the contraction had reached a plateau. Although I used TP for the in vivo model 
and the human study, it is a long acting drug with a half-life of 4 hours. I thus used the 
short acting agent, VP for constructing the concentration-response curves. The NOS 
inhibitor, aminoguanidine (300 pM) was added to some LPS-treated tissues 25 min 
prior to the VP concentration-response curve being commenced.
5.2.2 Effect of treatment with terlipressin and norepinephrine in vivo rat sepsis
The method and model are described in detail in chapter 3. Four experimental groups 
were used:
(a) Group A («=6) was given 40 mg kg'1 LPS (Klebsiella Pneumoniae) in 0.9 % saline 
by infusion over 30 min at a rate of 20 ml kg'1 h '1. For the remainder of the experiment, 
all groups were fluid resuscitated with 25 ml kg'1 h '1 of the synthetic gelatin colloid, 
Gelofusin®. This was supplemented with 1 ml 10% glucose solution per 25 ml to keep 
blood sugars > 5 mM.
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(b) Group B {n-6) received isotonic saline rather than LPS over the first 30 min (sham- 
operated controls).
(c) Group C comprised either LPS-treated rats {n-6) or sham-operated controls {n -3). 
These rats received the a-1-agonist NE as a 1 mg kg'1 bolus at 120 min (approx. 0.7ml 
volume) followed by a 0.5 mg kg'1 h '1 infusion (administered with gelofusin® in a 
similar volume to controls). This was to simulate the management of septic shock in 
which fluid resuscitation and catecholamines, such as NE, are the mainstays of 
treatment.
(d) Group D comprised either LPS-treated rats {n-6) or sham-operated controls {n -3). 
These rats received the long-acting vasopressin analogue, TP, as a 0.02 mg kg'1 bolus at 
120 min.
5.2.3 Effect of terlipressin in norepinephrine-resistant septic shock in humans
This was an open-label pilot study performed in critically ill patients in severe septic 
shock requiring high doses of the catecholamine vasopressor NE, and in whom 
hypotension had not previously responded to corticosteroids or methylene blue (a 
guanylyl cyclase & iNOS inhibitor; Geng et al., 1998).
TP was given to eight patients with vasodilatory shock and proven or suspected 
bacteraemia on the intensive care unit (ICU) at University College London Hospitals
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(UCLH). Prior to the study approval had been obtained from the UCLH Ethics 
Committee and agreement sought from the patient’s next-of-kin. Patients were 
unselected but were enrolled between January 1999 and June 2001 when at least one of 
three doctors involved in the study was present. All were intubated and ventilated, with 
high cardiac outputs and severe hypotension despite appropriate fluid loading to 
maximal stroke volume and high doses of NE. Cardiac output and fluid loading were 
assessed by transoesophageal Doppler ultrasound. In all patients, hypotension had 
previously failed to respond to both dexamethasone (16mg intravenously (iv)) and 
methylene blue (2mg kg'1 (iv) over 15 min) -  the standard “rescue therapy” for 
catecholamine-resistant septic shock on the intensive care unit at UCLH. All patients 
were given an intravenous bolus dose of TP (0.5-2 mg) over 5 min which could be 
repeated at 30-min intervals to a maximum of 2 mg. As the 2mg bolus (a standard dose 
routinely given to liver failure patients with variceal bleeding or hepatorenal syndrome 
with a small haemodynamic effect ~ 10 mmHg - Therapondos et a l , 2004) produced 
such a rise in blood pressure in the first patient (to a mean of 80 mmHg), such that she 
needed glyceryl trinitrate to lower this pressure (!), reduced doses were given to 
subsequent patients. A further dose of TP was administered six hours later to two 
patients. Mean arterial blood pressure (MAP), norepinephrine requirements, central 
venous pressure, oxygen saturations, heart rate, urine output and cardiac output were 
monitored continuously. Arterial blood gases were sampled regularly. The target MAP 
was between 60-70 mmHg. The NE infusion was reduced if this was exceeded.
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5.3 Statistical analysis
As for chapters 2
5.4 Reagents and solutions
As for chapters 2 & 3. TP was purchased from Ferring Pharmaceuticals Ltd (Berkshire, 
U.K.) and had its own diluent. NE was purchased from Abbott (Maidenhead, U.K.) and 
was dissolved in 0.9% saline.
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5.5 Results
5.5.1 Effect of LPS on contractile responses to vasopressin in vitro
In fresh control endothelial-intact tissues there was a triphasic response to increasing 
concentrations of VP (Fig. 5.1 A). The maximum contraction was 0.65 ±0.18 g at 10'7 
M while at 10~5 M there was no contractile response. When the endothelium was 
denuded there was a biphasic response with an increased maximal contraction of 1.88 g 
(n- 1 at this concentration of VP only). The effects of LPS upon contractions to PE in 
RMA have been described in chapter 2. Following incubation with LPS for 20 h there 
was virtually no contractile response to all concentrations of vasopressin, even in 
control tissues incubated in culture media without LPS (Fig. 5.IB). This hyporeactivity 
was not reversed by the iNOS inhibitor aminoguanidine.
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Figure 5.1 Comparison of contractile responses to vasopressin - VP (1012 tolO5 M) 
and phenylephrine - PE (10’9 to KT6 M) in (A) fresh tissue and (B) tissue incubated 
± LPS for 20 h. Data are expressed as the mean ± s.e.m of 6-8 observations from 6 
animals.
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5.5.2 A comparison of norepinephrine and terlipressin in an in vivo model of sepsis
In sham animals MAP, RBF, hepatic microvascular oxygenation (HmvCh) and arterial 
base deficit did not change significantly throughout the experiment (see Fig. 3.1 A-D). 
There was a tendency, albeit non-significant, for MAP and RBF to increase. A rise 
followed by a fall in ABF and Hmv02 was also observed. These changes, particularly in 
ABF, were likely related to the fluid resuscitation. Following infusion of LPS, there was 
a rapid fall in all measured variables within 0-30 min (see Fig. 3.1 A-D). Recovery in 
MAP was observed within 30 min (before fluid resuscitation was commenced), 
although aortic and renal blood flow took 2-3 h to return to baseline values. Flowever, 
FhnvC>2 failed to show any significant recovery after the initial abrupt fall. After 120 
min the MAP fell significantly in LPS treated rats {P < 0.001, /7=6, ANOVA). I thus 
chose this time point to administer either NE or TP.
NE (0.5mg kg'1 bolus and lmg kg'1 h '1 infusion) caused a large sustained rise in the 
blood pressure in sham rats that was significantly greater than that achieved in LPS- 
treated rats (P -  0.007; Fig. 5.2 A). In LPS-treated rats, there were small, non­
significant falls in RBF, ABF and HmvCh while the arterial base deficit was unaffected 
(Fig. 5.2 B-D). In sham animals, RBF and arterial base deficit were unaffected, however 
there was a significant fall in ABF and HmvC^ (P < 0.05; Fig. 5.2 B-D).
Conversely, a 0.02 mg kg'1 (equivalent to 1.5mg for a 75 mg man) bolus of TP caused a 
significantly greater rise in the MAP in LPS-treated rats than shams (P < 0.001; Fig. 5.2 
A). The effect of this bolus appeared to last for approximately 75 min. In LPS-treated
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rats, there were non-significant falls in the RBF, ABF and Hmv02 following 
terlipressin, however the acidaemia significantly worsened (P < 0.001, see Table 5.1). In 
sham animals, the RBF, Hmv02 and arterial base deficit were unaffected by TP, 
however there was a significant fall in ABF (P < 0.05; Fig 5.2B-D).
Thus the pressor effect of NE was attenuated significantly by LPS, whereas this was 
emphatically not the case with TP (Fig. 5.2 A). However, in spite of its superior pressor 
effect, TP was unable to improve renal or aortic blood flow or Hmv02 (Fig 5.2 B-D). 
Neither did TP attenuate the metabolic acidosis seen in septic animals (Table 5.1); 
indeed at 180 min it worsened the acidosis.
Table 5.1 Effect of terlipressin and norepinephrine (given at 120 min) upon the 
arterial base deficit.
Data are expressed as mean ± s.e.m. of 3-6 observations from 3-6 animals.
Time (min)
0 120 180 240
Sham -4.4 ± 0.9 -7.5 ±0.9 -7.7 ± 0.9 -6.73 ± 1.13
LPS -3.4 ±0.5 -11.1 ±0.6 -9.64 ± 0.4* -11 ± 1.45
Sham + TP -4.2 ± 1.95 -6.2 ± 1.94 -8.9 ±0.57 -8.5 ±0.95
Sham + NE -3.8 ± 0.45 -5.9 ±0.71 -5.57 ±0.35 -6.57 ±0.2
LPS + TP -5.2 ± 0.6 -13.5 ±0.9 -17.1 ± 1.2* -15.8 ± 1.9
LPS ± NE -3.17 ±0.45 -11.9 ± 0.6 -10.4 ±0.4 -10.3 ±0.3
*P<0.001 when directly compared with each other
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Figure 5.2 Comparison of a bolus of TP (0.02 mg kg'1) with a bolus + infusion of NE 
(0.5 mg kg'1 & 1 mg kg'1 h'1) given at 120 min (see arrow) upon (A) MAP & (B) RBF in 
LPS and sham treated rats. Data are expressed as mean ± s.e.m. of 3-6 observations from 
3-6 animals. NE induced a rise in MAP (P = 0.007, ANOVA) in shams compared to 
LPS. Conversely, TP induced a rise in MAP in LPS-treated rats compared to shams (P < 
0.001. ANOVA).
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Figure 5.2 Comparison of a bolus of TP (0.02 mg kg'1) with a bolus + infusion of NE (0.5 
mg kg'1 & 1 mg kg'1 h"1) given at 120 min (see arrow) upon (C) aortic blood flow (ABF) 
and (D) microvascular oxygenation (Hmv02) in LPS and sham treated rats. Data are 
expressed as mean ± s.e.m. of 3-6 observations from 3-6 animals. ABF fell significantly in 
shams with both NE and TP (P <0.05, ANOVA). Hm v02 also fell in shams treated with 
NE (P < 0.05 after 135 min).
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5.5.3 Effect of terlipressin in norepinephrine-resistant septic shock in humans
The 8 patients to whom TP was given were all extremely ill, with APACHE II scores 
ranging from 25-37 (Knaus et al., 1985) and persisting low mean arterial pressures, 
despite high dose NE and previous administration of corticosteroids and methylene blue 
(see Tables 5.2 A and B). In all patients, the bolus of TP (ranging from 1-2 mg) 
produced, within minutes, a progressive rise in MAP (Fig. 5.3). The peak effect was, 
however, not seen until 20-30 min after administration. This enabled major reductions 
or cessation of the high-dose NE in 7 of the 8 patients (Fig 5.4). The elevation in MAP 
was sustained for at least 6 hours. Four patients required no subsequent increase in NE 
and survived the septic episode to be discharged from the ICU; three were subsequently 
discharged alive from hospital. No major chronotrophic effects and no deleterious 
consequences were observed, e.g. digital, splanchnic or myocardial ischaemia. The fall 
in cardiac output was commensurate with the elevation of blood pressure (Fig. 5.3) and 
did not appear to compromise organ perfusion. Six patients were anuric and being 
haemofiltered. Urine output in the other two patients rose following administration of 
TP. In the patient who received a repeat bolus dose, the pressor effect was similar, 
though of shorter duration.
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Table 5.2A Patient demographics, severity of illness and shock
Patient Cause of septic shock Age (yr) Apache
II
Baseline NE 
(US kg'm in1)
1 Dog bite 56 25 0.41
2 Unknown 68 25 0.34
3 Streptococcal pneumonia 50 25 0.85
4 Staphylococcal septicaemia 52 37 0.53
5 Streptococcal septicaemia & 
liver failure
40 30 0.30
6 Faecal peritonitis 68 31 0.73
7 Salmonella gastroenteritis 82 25 0.73
8 Meningococcal septicaemia 62 28 0.82
Table 5.2B Patient demographics, severity of illness and outcome
Cause of 
septic shock
TP (mg) NE
(pg kg^min"1)
Further NE Outcome
Dog bite 2 0.41 No, needed GTN to 
lower MAP
Discharged to 
ward after 1 
month
Unknown 1 0.34 Unchanged dose, 
good pressor 
response
Died 10 days 
later
Streptococcal
pneumonia
1 0.85 NE weaned over 24 h Discharged to 
ward after 2 
months
Staphylococcal
septicaemia
2 0.53 Effect for 5 h & then 
steady increase in NE
Died within 
24 h
Streptococcal 
septicaemia & 
liver failure
2 0.30 Effect for 5 h & then 
steady increase to 0.7 
pg kg'1 min'1 over 
15 h
Died within 
24 h
Faecal
peritonitis
1 0.73 Weaned off over 24 h Discharged to 
ward 14 days 
later
Salmonella
gastroenteritis
1 0.73 Weaned off over 2 
days
Discharged to 
ward 17 days 
later
Meningococcal
septicaemia
1.5 0.82 Continued at low 
dose for 4 days & 
then gradual 
deterioration
Died after 6 
days
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P<0.0001 for MAP,/><0.07 for CO (ANOVA)
Figure 5.3 Terlipressin significantly raises mean arterial blood pressure in 
septic patients with a non-significant reduction in cardiac output (CO). Data 
are expressed as the mean ± s.e.m of 8 observations from 8 patients.
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Figure 5.4 The effect of terlipressin on norepinephrine dose in 8 patients with 
septic shock. The survivors (white squares) had a dramatic, sustained (24 h) 
reduction in norepinephrine dose whereas the non-survivors (red circles) had 
only a short term reduction in dose. Data are expressed as the mean ± s.e.m of 
8 observations from 8 patients.
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5.6 Discussion
In these experiments I used the in vitro and in vivo models of endotoxin induced rat 
sepsis previously described in chapters 2 & 3 to investigate the effects of VP and its 
analogue TP during sepsis. In addition, I also investigated the effect of TP upon human 
patients with septic shock.
In the in vitro model VP was as hyporeactive as PE in LPS-incubated rat mesenteric 
artery. In addition, there was no contractile response in control tissues incubated for 20 
h in culture media with serum, as opposed to the concentration response curves seen 
with PE. In fresh control tissues, however, there was a significant contractile response 
to VP. In fresh tissues denuded of endothelium, greater contractions were elicited by VP 
compared to endothelium intact tissues. Thus, in this in vitro LPS model, the 
vasculature appears highly hyporeactive to VP. LPS-induced hyporeactivity could also 
not be reversed with the NOS inhibitor aminoguanidine (chapter 2). Aminoguanidine 
was not added to control tissues incubated for 20 h.
On the other hand, TP did elicit a greater response than NE in the in vivo LPS model, 
whereas the pressor effect was greater for NE in the sham rats. As seen with both 
inhibition of iNOS and vascular K At p  channels, there was no improvement in the macro 
and microcirculation despite the improvement in blood pressure in septic rats. Indeed, 
some adverse effects were noted with both drugs; TP administration resulted in a 
reduction in ABF and an increase in metabolic acidaemia whereas NE caused a fall in 
ABF and Hmv02.
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In patients the use of a bolus of TP was a success in that a critically low blood pressure, 
unresponsive to standard therapies, was elevated in all eight patients studied, and a large 
reduction (or cessation) in NE dosage was achieved in all but one. Four of these 
patients, who would be at high risk of dying, recovered from their shock and multi­
organ failure to leave the ICU alive. The supersensitivity witnessed in septic rats was 
observed in humans. Though cardiac output initially fell, no obvious deleterious 
consequences were observed. We are unable to measure regional organ perfusion 
clinically, although there was no worsening of the metabolic acidosis (arterial base 
deficit).
Septic shock is associated in patients with a biphasic response in VP levels. In early 
shock appropriately high levels of VP are produced but, in established and prolonged 
shock, the levels are similar to those seen in healthy subjects (Landry et al., 1997). The 
reason for this reduction in circulating concentration of VP is unclear. Depletion of 
neurohypophyseal stores has been demonstrated (Morales et al., 1999) while NO has 
been shown to inhibit its release (Reid, 1994). Additionally, several studies have shown 
that a low-dose infusion of VP will restore blood pressure in septic patients (Landry et 
a l , 1997A; Malay et al., 1999; Holmes et al., 2001; Tsuneyoshi et al., 2001; Patel et al., 
2002 and Dunser et al., 2003). I showed, for the first time that the long-acting VP 
analogue, TP raised blood pressure and reduced NE requirements in septic patients 
(O’Brien et al., 2002). A number of other studies demonstrating an increase in blood 
pressure and reduction in NE requirements with TP have been published subsequently 
(e.g. Leone et al., 2004 and Morelli et al., 2004), including paediatrics and neonates
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(Matok et al., 2004). Interestingly, the rebound hypotension requiring recommencement 
of catecholamines seen in studies when the VP infusion was stopped was not witnessed 
in half of my patients receiving TP. All of whom were able to be subsequently 
discharged from intensive care. Similar findings have been reported by Leone et al., 
(2004) and Morelli et al. (2004). This rebound hypotensive effects reported on 
discontinuation of VP was even seen after infusion for 96 h (Tsuneyoshi et al., 2001). 
Although TP has a plasma half-life of 6 h, an explanation for the sustained effect on 
blood pressure is still outstanding. I did not measure plasma levels to see whether its 
clearance is affected during sepsis. Potentially, it may be more effective at upregulating 
VI receptors, thus increasing sensitivity to endogenous VP, or even have downstream 
intracellular effects. This question is currently undergoing further investigation in the 
host lab.
The reasons underlying the hypersensitivity of the septic vasculature to VP are 
unknown. Putative mechanisms (described in chapter 1) include autonomic 
insufficiency in sepsis unmasking the pressor effect of VP (Landry et al., 1997), 
synergy with adrenergic agents (Noguera et al., 1997), inhibition of K a t p  channels 
(Wakatsuki et al., 1992) and modulation of NO inhibition (Umino et al., 1999). I saw 
no evidence of baroreceptor-mediated bradycardia after the bolus of TP although this 
phenomenon has been considered as supporting evidence for autonomic insufficiency 
causing a relative deficiency of VP (Landry et al., 1997). All my patients were being 
treated with NE thus any comment on synergy cannot be made. All patients had been 
given methylene blue, an inhibitor of both iNOS and guanylyl cyclase, which had not
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increased blood pressure indicating that TP’s effects were not secondary to modulation 
of NO. Likewise, corticosteroids, which are known to inhibit iNOS (Korhonen et al., 
2002) had had no effect on blood pressure when given pre-TP. Against a synergism 
between corticosteroids (and/or methlyene blue) and terlipressin was the fact that a 
similar and prolonged vasopressor effect of TP was seen without these drugs by both 
Leone et al., (2004) and Morelli et al., (2004),
Concern has been expressed over whether TP or VP may over-constrict some vascular 
beds causing serious adverse effects. Certainly, all studies using these agents have 
reported a corresponding reduction in cardiac output in line with the rise in blood 
pressure. Since I completed my series, there have been instances on the UCLH ICU 
where TP has been given (inappropriately) to some septic patients with low cardiac 
outputs. This resulted in considerable worsening of their metabolic acidosis and the 
clinical manifestations of digital ischaemia (with black fingers and toes) and generalised 
patchy skin blanching. The latter features have also been seen sporadically in patients 
with high cardiac outputs, but also in patients receiving high-dose norepinephrine (see 
Fig 5.5). Thus, current practice on the ICU is to only use the drug in patients with a high 
cardiac output circulation who have been well fluid resuscitated. Much smaller doses 
(0.25-0.5 mg) are used, but can be repeated at 30 min intervals to a maximum of 2 mg, 
watching carefully for any signs of digital, cutaneous, coronary or splanchnic 
ischaemia. If these should appear, no more TP is given and a prostacyclin infusion is 
commenced promptly, usually to good effect. This complication has also been shown
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with VP. Ischaemic skin lesions were reported in 30 % of patients receiving VP 
infusions (Dunser et al., 2003B).
Figure 5.5 Digital ischaemia seen in patients treated with terlipressin (left) and
norepinephrine (right).
Pre-existing peripheral vascular disease was found to be a risk factor. In addition, skin 
necrosis has been reported in one patient after extravasation of VP used to treat septic 
shock (Kahn et al., 2002). Interestingly, TP (lmg) has been shown to increase gastric 
mucosal perfusion (Morelli et al., 2003) whereas VP (0.04 units min'1) caused a 
significant increase in gastric and arterial CO2 partial pressure, indicating gastric 
hypoperfusion (van Haren et al., 2003). Both VP and TP have been shown to increase 
urine output and improve renal function (e.g. Patel et al., 2002 and Morelli et al., 2003). 
The reasons for this are likely to be a combination of improving blood pressure and thus 
organ perfusion, an improvement in renal perfusion pressure due to renal efferent 
arteriolar constriction (see below), and improved renal blood flow by intrarenal 
vasopressin receptor stimulation. Pulmonary hypertension using either agent has not
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been reported; indeed, low dose VP has been used to treat septic shock combined with 
chronic pulmonary hypertension (Wang et al., 2003). Sublingual microcirculatory flow 
in a patient with catecholamine-resistant septic shock, as measured by orthogonal 
polarization spectral imaging, was significantly impaired by TP, although this patient 
appeared to be in a low cardiac output state (Boerma et al., 2005). Finally, TP (0.5mg) 
was shown to increase the concentration of L-lactate in the rectal lumen of a patient 
with septic shock for 8 h (Pemer et al., 2004). It may have impaired metabolic 
dysfunction in the rectal mucosa either directly, via vasoconstriction of mucosal vessels, 
or through decreased cardiac output.
Clearly, some of the concerns about regional vasoconstriction and organ perfusion are 
not necessarily bom out by the literature so far. However, in view of the serious nature 
of these potential adverse effects, I would advocate caution when using either VP or TP. 
At present, I would restrict its use to rescue therapy in patients not responding to 
conventional treatment with catecholamines and corticosteroids.
In view of the doubts outlined above regarding excessive constriction of vascular beds 
using TP, I studied its effects in the in vivo rat endotoxin model. Increased sensitivity to 
VP in microvascular beds has been previously demonstrated in rats given endotoxin 
(Baker et al., 1990). In the rat model I used a 0.02 mg kg'1 bolus of TP, which is an 
equivalent weight-adjusted dose to that given to the septic patients. There was a 
significantly increased pressor effect in LPS-treated rats compared to sham animals, 
unlike the pressor effect of NE that was significantly reduced in LPS-treated rats. The
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effects of a bolus of TP appeared to last for approximately 75 min (compared to a half- 
life in humans of approximately 4 h). This may reflect species differences in 
metabolism by arginases. Clearly, the rise in blood pressure is important in terms of 
management of septic shock, however, TP in the septic rats caused a reduction in aortic 
and renal blood flows and a worsening of the metabolic acidosis. In LPS rats treated 
with NE (the standard catecholamine used for septic shock) there were small non­
significant falls in RBF, ABF and Hmv02 while the arterial base deficit was unaffected. 
This is in contrast to an in vivo rabbit model that showed increasing concentrations of 
VP reduced renal and aortic blood flow in shams but increased renal blood flow 
velocity and maintained aortic blood flows in endotoxin-treated rabbits (Albert et al.,
2004). In a canine model of endotoxic shock, both NE and VP had comparable systemic 
and splanchnic effects though vasopressin improved renal blood flow and splanchnic 
oxygen delivery (Guzman et al., 2003). In a sheep model of sepsis, VP alone or in 
combination with NE maintained blood pressure, mesenteric blood flow and cardiac 
output, limited increases in lactate and the gut mucosal-arterial pCC>2 gap, and 
prolonged survival time (Sun et al., 2003). In LPS-treated rats, constriction in renal and 
mesenteric blood flows following VP have been observed (Bennett et al., 2004) 
whereas, in another model, VP had no effect upon renal blood flow but there was an 
improvement in renal function in endotoxic rats. Indeed, VP actually blunted the 
increase in lactate (Levy et al., 2004). However, these studies used either no fluid or 
just 5 ml kg'1 h '1 of crystalloid, unlike my model where 25 ml kg"1 h '1 of the synthetic 
gelatin colloid, Gelofusin® was infused throughout the experiment. Fluid resuscitation, 
usually with colloid, is an integral part of the treatment of septic shock in humans. The
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renal effects of VP / TP are complicated and not simply related to renal blood flow. 
There is an antidiuretic effect through stimulation of V2 receptors but an increase of 
diuresis / natriuresis through VI receptors via efferent arteriolar vasoconstriction and 
oxytocin receptor-mediated stimulation (Rudichenko et al., 1995). I did not study urine 
output or creatinine clearance and thus am unable to comment on renal function in my 
model. In addition, there was no improvement of microvascular oxygenation in the 
septic rat despite the significant improvement in blood pressure; this indicates 
persistence of microcirculatory defects, possibly related to local shunting. Neither 
inhibition of iNOS nor K atp improved microvascular oxygenation despite a significant 
improvement in blood pressure (see chapters 2 & 3). Arginine vasopressin has been 
shown to impair tissue oxygenation and the microcirculation in hamsters (Friesenecker 
et al., 2004) and to decrease intestinal oxygen supply and mucosal tissue PO2 by 
reducing microvascular blood flow in a dose-dependent manner in pigs (Knotzer et al.,
2005). However, neither of these experiments was performed in fluid resuscitated or 
septic animals. Reasons for the differences reported between the different models may 
thus be related to duration of study, dose of endotoxin/sepsis, dosage of VP, and the 
degree of fluid resuscitation. There is a paucity of experimental models using TP.
My animal model thus confirms the super-sensitive pressor effect of TP in sepsis. In 
terms of regional vasoconstriction it appears no more dangerous than NE, although at 
one time point (180 min) the metabolic acidosis was significantly higher in LPS-treated 
rats given TP compared to untreated endotoxic animals. Microcirculatory oxygenation 
did not improve despite the restoration of blood pressure. In future studies I would
210
Is vasopressin an important mediator o f sepsis-induced vascular hyporeactivitv or hypotension
examine the effects of lower doses and also assess the combination of TP and NE which 
would complement my human study.
Contrary to my findings in both patients and the in vivo model, in the in vitro LPS 
model the contractile response to VP was decreased, and even less than that seen for 
PE. This hyporeactivity to VP was not reversed by inhibition of NOS. As addition of 
VP was able to produce contractions in fresh control tissue, possible explanations for 
the disparity in results include activation of nitric oxide synthase; the in vitro absence of 
a necessary plasma factor; the lack of an intact autonomic nervous system; and an 
alteration in VP receptor expression or activity, or in downstream pathways leading to 
calcium release.
In chapter 2 ,1 described the production of iNOS in controls incubated for 20 h and the 
production of nitrite within culture media supernatant in which these tissues had been 
incubated. Thus, sufficient NO may be produced via iNOS in control tissues at 20 h to 
induce hyporeactivity to VP. In future studies, I would use the iNOS inhibitor 1400W 
rather than aminoguanidine as it had a greater effect at 20 h. As inhibition of either 
iNOS or the K a t p  channel (via the pore-forming subunit) reversed LPS-induced 
hyporeactivity in this same model (see chapters 2 & 4), a direct effect of VP on either of 
these pathways is unlikely (Wakatsuki et al., 1992 and Umino et al., 1999).
In contrast to my results, VP has been shown in other septic models to have an effect in 
vitro. In human gastroepiploic arteries, VP potentiated responses to NE in both normal
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and endotoxin-treated tissues via action on Vi receptors, (Hamu et al., 1999). Similarly, 
studies in rats showed that VP strongly potentiated the vasoconstrictor effects of NE, 
electrical field stimulation and potassium chloride depolarization, effects mediated via 
an increase in intracellular calcium through voltage-dependent calcium channels 
(Norguera et al., 1997). A further possible explanation for the lack of an effect in vitro 
is that VP may have differing vasoconstrictor properties according to the vascular bed 
examined. However, against this hypothesis was the fact that VP produced significant 
contractions in fresh control tissue in my studies. The differences in contractile 
responses observed in endothelium-intact or denuded fresh mesenteric artery tissue may 
be explained by the presence of V2 and/or oxytocin receptors on vascular endothelium. 
V2 receptor activation has been demonstrated to cause vasodilatation (Bichet et al., 
1988, see introduction).
In conclusion, TP produced a profound rise in blood pressure in septic patients, 
allowing reduction and/or cessation of NE. This drug offers a potentially important and 
inexpensive therapeutic alternative in hypotensive septic patients not responding to 
high-dose catecholamine therapy that appears easy and generally safe to administer. Its 
mechanisms of action have not been entirely clarified and concern remains that it may 
cause severe vasoconstriction in certain vascular beds. In my in vivo animal model its 
supersensitive pressor effects on blood pressure in septic rats compared to NE was 
confirmed. However, no improvement was seen in macro or micro-circulatory organ 
perfusion and there was some worsening in metabolic acidosis. The vasoconstrictive 
effects of VP in the mesenteric, pulmonary, renal and coronary beds are dose-
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dependent; had I used a lower dose of TP there may have been a similar pressor effect 
associated with improved flows. I would thus advocate that it be used in human patients 
with great care and only when conventional treatment with fluid, catecholamines and 
steroids has failed. I would also use low incremental doses of 0.25-0.5 mg. Ideally, 
large multi-centre outcome studies should be performed with TP, as is currently 
ongoing with VP (Cooper et al., 1993). In view of its frequent ability to reverse 
hypotension with a single dose, a comparison of TP against VP would also be of 
interest.
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6.1 Introduction
The dramatic collapse of the cardiovascular system that occurs during vasodilatory 
septic shock is both fascinating and frightening. When I began my research, the 
management of septic shock had changed little over several decades, with the mainstays 
being fluid resuscitation, antibiotic therapy and the use of catecholamine vasopressors 
(reviewed in Deitch, 1998). These are still critical components of patient care however 
recent years have seen significant advances in management such as the use of 
hydrocortisone and recombinant activated protein C (Bernard et al., 2001 and Annane et 
al., 2002). Yet septic shock still carries a high attendant mortality, both in the short term 
- 56% in one recent study (Annane et a l , 2003) - and in the longer term -  for example, 
Annane et al., reported 20% of survivors dying within a year of hospital discharge 
(Annane et al., 2002).
The stated aims of my thesis were to investigate mechanisms underlying vascular 
hyporeactivity and hypotension (i.e. cardiovascular collapse) in sepsis. To achieve this I 
embarked upon the development of both in vitro and in vivo rat models. Although the 
rat’s response to sepsis does not precisely mimic that seen in humans, I hoped that 
lessons learned from these animal experiments could be extended to the critically ill 
patient, and performed studies accordingly. I was specifically interested in the 
contribution of three putative mechanisms: the nitric oxide (NO) pathway, the ATP- 
gated potassium (K Atp) channel, and vasopressin. I naturally wished to add to the 
existing knowledge on this complex subject but my great hope was that my studies 
would lead to meaningful advances in the clinical management of septic shock.
215
Summary and Discussion
6.2 Summary of Results
These are described in greater detail in the discussions accompanying the individual 
chapters but are summarised here.
6.2.1 Development of Models
I was able to successfully develop a reproducible in vitro organ culture model of rat 
sepsis in which endotoxin (LPS) induced vascular hyporeactivity in the mesenteric 
artery to the oti-agonist, phenylephrine (PE). This hyporeactivity occurred over a range 
of concentrations of LPS (0.01 ng ml'1 to 100 pg ml"1) and was dependent upon time 
(up to 46 h) and the presence of serum. I found that an intact endothelial layer was not 
necessary to maintain hyporeactivity after incubation with LPS.
I created a similar model using the human marginal artery (a branch of the mesenteric 
circulation). I used a combination of LPS (at high concentration) and the pro- 
inflammatory cytokine interleukin 1-P that induced significant hyporeactivity to PE. 
Alas, the iNOS inhibitor 1400W was unable to reverse this hyporeactivity.
I was also able to develop a reproducible short-term in vivo rat model of septic shock 
with monitoring of both macro- and microcirculation by adapting the model used 
previously by our group (Rosser et al., 1995). In this model, an LPS infusion induced an 
early myocardial depression with falls in blood pressure and organ perfusion. Although 
blood pressure was spontaneously restored within 15 min, macrovascular organ flow
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took much longer to recover, and then only partially. This required major intravascular 
volume resuscitation with a colloid solution. As is characteristic of such models, the 
blood pressure eventually fell after several hours. In addition, the hepatic microvascular 
circulation, as assessed by the protoporphyrin technique, an indicator of the balance 
between local oxygen supply and demand, fell sharply after LPS injection and also 
failed to show significant improvement despite fluid resuscitation. This suggests an 
ongoing pathological mechanism involving microcirculatory flow.
6.2.2 Effects of nitric oxide inhibition
In the rat in vitro model, inhibition of either iNOS or soluble guanylyl cyclase reversed 
LPS-induced hyporeactivity, confirming the importance of the NO-cGMP pathway. 
This was more notable at earlier time points (6 h) with the effects subsequently 
diminishing over the next 46 h. I was able to demonstrate increased NO production by 
finding elevated nitrite levels within the culture media in which the artery had been 
incubated. I further demonstrated iNOS production within the artery using 
immunohistochemical analysis. This, too, was time-dependent with maximal iNOS seen 
at 46 h but also significant amounts were seen at 20 h. Although mostly localised to the 
adventitial layer, iNOS was also seen in the endothelial and smooth muscle layer.
iNOS inhibition reversed LPS-induced hypotension in vivo. Administration of the 
specific iNOS inhibitor GW273629 succeeded in elevating blood pressure in both the 
LPS- and sham-treated rats, but was more pronounced in LPS-treated rats. 
Immunohistochemistry revealed a greater production of iNOS in the LPS-treated rat
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compared to the sham in rat mesenteric artery (RMA) removed at the end of the 
experiment and GW273629 inhibited this production of iNOS. This may reflect an 
unknown mechanism of action of this drug or it may be due to the drug interfering with 
the stain. As I only performed this experiment in 1 rat, I cannot make further comment 
upon this. In the human marginal artery model, the iNOS inhibitor 1400W had no effect 
upon contractile responses to PE. Although, on face value, this would suggest that 
iNOS-derived NO would have no part to play in human sepsis, the finding in studies of 
patients with septic shock that L-NMMA increased blood pressure, albeit at the expense 
of a higher mortality, does highlight the importance of nitric oxide in the vascular 
hyporeactivity affecting the human being.
6.2.3 Effects of KAtp inhibition
I was able to demonstrate that the K a t p  channel is involved in mediating LPS-induced 
vascular hyporeactivity in vitro. Importantly, I showed that inhibitors of the pore- 
forming subunit of the K a t p  channel, but not the sulphonylurea (SUR) subunit, were 
able to reverse LPS-induced vascular hyporeactivity. This difference was unrelated to 
the SUR inhibitors’ ability to inhibit thromboxane contractions. After 6 h incubation 
with LPS, the activation of BKca channels was also involved in LPS-induced vascular 
hyporeactivity, but to a lesser extent. After 20 h although there was still reversal of 
hyporeactivity, though now incubation mechanisms independent of K+ channel 
activation appeared to be important. Administration of the K a t p  channel inhibitors 
PNU-37883A and glibenclamide at high dose (10 mg bolus and 5 mg kg'1 h '1 infusion) 
in vivo succeeded in elevating blood pressure in both shams and to a lesser extent LPS-
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treated rats (both agents probably acting on the pore). The rise in blood pressure in the 
LPS-treated rats did not correspond to an improvement in macro or micro-circulatory 
blood flow.
6.2.4 Effects of the vasoconstrictors U-46619, vasopressin terlipressin and 
norepinephrine
In contrast to PE, I found that contractions achieved in response to the thromboxane 
mimetic, U-46619 were only weakly affected by LPS in vitro. The differential effect of 
LPS upon PE and U-46619 did not appear to be a NO-mediated phenomenon, as the NO 
donor SNAP caused an equipotent relaxation to contractions with either agonist in fresh 
rat mesenteric vessels. Contractions to vasopressin (VP) in vitro were more sensitive in 
LPS-treated vessels compared to that seen with PE. In vivo administration of a bolus of 
the long-acting VP analogue, terlipressin (TP), or an infusion of the a i adrenergic 
agonist, norepinephrine (NE), succeeded in elevating blood pressure in the LPS-treated 
rats. However, the pressor effect induced by NE was greater in sham rats, while the 
converse was found with TP which elicited a hyper-sensitive response in LPS-treated 
rats.
In patients with septic shock refractory to fluid resuscitation, conventional vasopressor 
and steroid treatment, I also performed a novel study assessing the impact of bolus 
treatment of TP. In all patients, the TP bolus produced an immediate and sustained 
elevation in mean systemic arterial pressure, enabling major reductions or cessation of
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the high-dose NE infusions. Though cardiac output fell from initial high levels, no 
effects were seen on heart rate and no obvious deleterious consequences were noted.
In summary, I have shown that LPS given to rats results in increased production of 
nitric oxide from iNOS (especially within the adventitial cell layer), and that selective 
inhibition of the nitric oxide pathway reverses the resulting hyporeactivity and 
hypotension. I have shown that in vitro vascular hyporeactivity can also be reversed by 
inhibition of the K Atp channel via its pore-forming subunit but not via its SUR, 
suggesting an endotoxin-induced dissociation. I believe that this effect also occurred in 
vivo. However, endotoxin reduced the ability of glibenclamide and PNU-37883A to 
inhibit the K atp channel. In addition, I was able to demonstrate that TP could also 
reverse LPS-induced hypotension. Although manipulation of these three pathways were 
all successful in elevating blood pressure, no improvement was seen in either blood 
flow within the large vessels (renal and aortic blood flows), or the microvascular 
circulation (as assessed by Hmv02), or in metabolic acidaemia. Indeed, the latter was 
worsened by TP.
Of the three mechanisms investigated in the laboratory, only TP was used 
therapeutically as a rescue therapy in patients with severe septic shock not responding 
to conventional treatment. That four of the eight treated patients subsequently survived 
is a highly encouraging finding that has been since reproduced by other investigators 
(Leone et al., 2004 and Morelli et a l , 2004); in addition it has also been used in 
paediatrics and neonates (Matok et al., 2004). Interestingly, there was no ‘rebound’
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hypotension observed in the patients that survived (as opposed to those treated with a 
VP infusion which is then discontinued e.g. Tsuneyoshi et a l, 2001). This difference 
clearly warrants further investigation; it may be related to specificity of the two drugs 
for the different VP receptors or, possibly, other mechanisms.
6.3 Critique of models used
The majority of my work was performed using animal models. Extrapolation of animal 
data to human patients is fraught with controversy and, clearly, not all of my findings 
may be relevant to the patient. However, it is important to study mechanisms and to 
evaluate putative treatments for both benefit and harm in animals prior to human 
testing. Leaving aside baboon models which cannot be undertaken in the U.K., the pig’s 
circulation is considered the closest to humans but these animals are extremely 
expensive to buy and store, not to mention unwieldy. I thus chose the rat, aiming to take 
my investigations from this animal to a human experimental model, and thence to 
patients.
Most in vitro studies investigating sepsis in rats have used the aorta. This, however, is a 
conduit vessel while vascular resistance within the arteriolar circulation is 
predominantly responsible for determining blood pressure. I used mesenteric artery 
which, although considerably smaller than aorta, is also a conduit vessel. A potential 
future direction would be to study the mesenteric arteriolar circulation using 
myography.
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How relevant is an in vitro model in the investigation of sepsis? The pathophysiology of 
sepsis is far more complicated than simply the effects of circulating endotoxin upon 
blood vessels. An in vitro model does not examine important mechanisms such as 
autonomic pathways and hormonal influences e.g. glucocorticoid deficiency and the 
renin- angiotensin system (reviewed by Annane, 2005). In addition, a crucial aspect of 
treatment is fluid resuscitation that cannot be mimicked in vitro.
Using my in vivo model I was able to fluid resuscitate the rat with synthetic gelatin 
colloid, Gelofusin® -  the colloid most used in human patients at UCL Hospitals 
(UCLH). In addition, I was able to compare the effects of iNOS inhibition, K a t p  
channel inhibition and terlipressin directly with norepinephrine -the catecholamine 
most commonly used to treat high output human septic shock at UCLH. I was also able 
to monitor the effects of LPS and the different pharmacological modulators upon mean 
arterial blood pressure, macro and microcirculatory blood flow in a highly reproducible 
fashion. However, it was not without weakness. The use of a bolus of LPS is less 
relevant than a caecal puncture model; perhaps this provides too ‘toxic’ an insult. Of 
note, despite the aggressive fluid resuscitation, the model was not truly hyperdynamic 
and the microcirculatory flow never recovered despite fluid and pressor treatment. As 
the incidence of Gram-positive infections has now overtaken that of Gram-negative 
infections (Greenberg et al., 2005), it may have been interesting to compare responses 
generated by a Gram positive toxin such as lipoteichoic acid. The model I used was 
short term (4 h) and the rat was sacrificed at the end of the experiment thus no 
information is providing on any survival benefit that may have accrued. In addition, I
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did not use antibiotics. Though clearly an important part of the treatment of sepsis, it is 
not particularly relevant in a 4-hour model. Furthermore, the rat was anaesthetised with 
isoflurane, which does have some K a t p  channel opening properties (Ida et al., 1998 and 
Sumikawa et al., 1998), and the instrumentation performed did induce some production 
of iNOS within the sham animals (as demonstrated by immunohistochemistry of the 
mesenteric artery). Overall, however, I do believe this to be a reasonable model to study 
mechanisms of vascular hyporeactivity and it is clearly more relevant to the clinical 
situation than an in vitro model.
Interpretation of my data also relies heavily upon the specificity of the inhibitors used. 
This is potentially a weakness; however there is currently good evidence that both 
1400W and GW273629A are highly specific iNOS inhibitors (Garvey et al., 1997; 
Young et al., 2000 and Alderton et al., 2005), and that PNU-37883A and PNU-99963 
are highly specific inhibitors of the K At p  pore-forming subunit and the SUR, 
respectively (Khan et al., 1997 and Humphrey 1999). Future studies may nevertheless 
show these compounds to have additional effects on other pathways.
6.4 Discussion
As mentioned in my introduction, clinical trials of treatments for sepsis are difficult due 
to the heterogeneity of patients, highly variable comorbidities, and the high rates of 
culture negative sepsis. Thus, large scale multi-centre studies are often required to 
demonstrate benefit. I clearly did not have the resources to undertake such a project. 
However, I was able to conduct a brief non-randomised, uncontrolled study of
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terlipressin in patients that yielded some important results that have been since adopted 
by the host ICU and many others with success. An adequately powered, randomised 
trial is clearly needed to confirm the anecdotal benefit seen, and to identify subsets in 
whom in could be harmful, such as those with low cardiac output states.
I was able to develop an in vitro model of LPS + cytokine-induced vascular 
hyporeactivity using human marginal artery, however I was unable to reverse this with 
iNOS inhibition. There is a relative paucity of human in vitro models reported in the 
literature. These tend to use cardiac vessels that have little role in vascular resistance in 
sepsis, unlike the mesenteric circulation which thus seemed a natural choice. I was 
unable to progress much beyond establishing hyporeactivity due to lack of tissue but 
this certainly warrants further study.
Norepinephrine is the most commonly used vasopressor to maintain blood pressure in 
high cardiac output septic shock. However, it increases production of the pro- 
inflammatory cytokine tumour necrosis factor via the ot2-adrenergic receptor (Splengler 
et al., 1990). Perhaps epinephrine (a beta-adrenergic agonist) may prove a better choice, 
at least from a pro-inflammatory point of view, as it inhibits TNFa, enhances 
production of interleukin 8 and suppresses production of NO (Severn et al., 1992; van 
der Poll et al., 1996 & 1997 and Zinyama et al., 2001). Interestingly, both NE and the 
beta-adrenergic agonist dobutamine have been shown to accelerate bacterial growth and 
biofilm formation (Lyte et al., 2003) while catecholamines have profound, dose-related 
metabolic effects (reviewed in Annane et al., 2005). Thus, even though NE is presently
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recommended as a first line pressor agent, it may be causing surreptitious harm that 
may not be appreciated by the treating clinician. Small randomised trials in patients 
have yielded conflicting results as to which pressor agent is superior/less harmful 
(Hollenberg et al., 2004 and Mullner et a l, 2004). There are currently a number of 
large, multicentre trials in septic patients. One is comparing epinephrine, dobutamine & 
NE (CATS), another dopamine and NE, and a third is comparing VP and NE (the 
VAST study).
Where does vasopressin, or its analogue terlipressin, fit in? There are good theoretical 
reasons for it to be an ideal vasoconstrictor. It potentiates the effects of NE (Norguera et 
al., 1997 and Hamu, 1999), it is a K a t p  channel inhibitor (Wakatsuki et al., 1992) and it 
can blunt the effects of NO (Umino et al., 1999). The reasons for its increased potency 
as a vasoconstrictor in septic shock states have yet to be elucidated. Landry suggests 
restoration of altered baroreflex sensitivity (Landry et al., 1997A), while others have 
suggested replacement of depleted plasma levels (Morales et al., 1999). A further 
possibility, currently under investigation in the host lab, is that VP sensitivity may be 
enhanced by altered receptor binding and/or changes in downstream signalling or 
intracellular calcium release. In clinical trials of septic shock, vasopressin has been 
predominantly used by continuous infusion at concentrations ranging from 0.01-0.04 
IU/min (Malay et al., 1999; Tsuneyoshi et al., 2001; Patel et al., 2002 and Dunser et al., 
2003A). In these and other studies haemodynamics were improved and catecholamine 
requirements decreased. However, rebound hypotension has been observed when the 
drug is discontinued and this can last for several days, necessitating recommencement
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of vasopressin or re-institution of a norepinephrine (Tsuneyoshi et al., 2001). There also 
remains concern over myocardial, cutaneous or mesenteric vasoconstriction which are 
recognised side-effects of VP and its analogues in the treatment of oesophageal varices. 
Dunser reported ischaemic skin lesions in 30% of patients receiving VP infusions 
(Dunser et a l , 2003B). Holmes reported a high overall mortality rate (85%) in a 
retrospective study of septic patients given vasopressin, and these predominantly 
occurred in patients given higher doses (>0.04 U/min), often due to cardiovascular 
complications (Holmes et al., 2001). Results are eagerly awaited from the VAST trial, 
mentioned above, currently underway in Canada (and Australasia) before 
recommendations for use are made.
I used the long acting analogue TP as rescue therapy for refractory hypotension in septic 
patients not responding to high dose NE, steroids and the NO pathway inhibitor, 
methylene blue. I did not encounter rebound hypotension or evidence of myocardial, 
cutaneous or mesenteric vasoconstriction though this has been seen subsequently in 
patients whose baseline cardiac output was lower in both the host intensive care unit 
and others. In my experience, it had profound effects upon blood pressure and NE 
requirements, as described in more detail in chapter 5. However, given the concerns 
over vasoconstriction in vascular beds, I would not advocate its use as a first-line 
treatment at present and would exercise more caution over dosing, perhaps starting with 
smaller bolus doses, e.g. 0.25-0.5 mg. I nevertheless believe that I have shown it has an 
important role in the treatment of refractory hypotension as mortality in such patients is
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extremely high. Albeit in a small series, I could demonstrate a disproportionately high 
survival rate.
Although terlipressin, nitric oxide synthase inhibition or K At p  channel blockade can 
improve blood pressure in septic shock models, is this necessarily beneficial? In my in 
vivo model all three approaches successfully elevated mean arterial pressure in LPS- 
treated rats; by comparison, the pressor effect of norepinephrine was blunted. Yet none 
of these agents improved either macro or microcirculatory blood flow, nor attenuated 
the development of metabolic acidosis in the rat. It is perhaps a sad indictment that 
despite years of researching and treating septic shock that we still do not know what 
optimal blood pressures we should target in an individual patient (Bourgoin et al., 
2005). Clearly, there will be inter-patient variation depending on their baseline blood 
pressure, yet the tendency over the last decade has been to aim for lower values (e.g. 
mean arterial blood pressure of 60 rather than 80 mmHg). Perhaps this is in belated 
recognition of the potential harmful effects of these agents. The multicentre study 
comparing the non-specific NOS inhibitor L-NMMA against norepinephrine in septic 
patients that was prematurely abandoned because of increased harm showed that the L- 
NMMA group achieved consistently higher blood pressures (Lopez et al., 2004). 
Whether this is causally related to the worse outcomes requires further study.
In my in vivo model, the specific iNOS inhibitor GW273629A did not cause any 
adverse effects in terms of reduction of macrocirculatory flow or worsening of 
metabolic acidosis. Indeed, across both in vitro and in vivo models, the specific iNOS
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inhibitors had the best and most consistent effects against LPS-induced hyporeactivity 
and hypotension. Again, there are other reasons beyond its pressor effect why inhibiting 
the overproduction of NO might be beneficial in sepsis e.g. NO has an important role in 
mitochondrial dysfunction (reviewed by Singer & Brealey, 1999). Yet, as mentioned 
above, non-selective inhibition of nitric oxide synthase was associated with an increased 
mortality from septic shock in a large scale randomised clinical trial (Lopez et al., 
2004). Thus NO derived from constitutive NO synthases may offer a degree of 
protection and thus removing this may prove detrimental. Indeed, constitutive NO 
synthase is essential for homeostasis, cellular immunity, endothelial function 
(Thiemermann, 1997). I believe that my work supports the notion that an inhibitor of 
inducible NO synthase deserves further consideration. Whether a pharmaceutical 
company is willing to invest in the development of a selective iNOS inhibitor for use in 
humans following the failure of the Glaxo Wellcome-led phase III study of a non­
specific NOS inhibitor (Lopez et al., 2004) remains to be seen. Certainly, parallels may 
be drawn with the re-emergence of steroid therapy for sepsis. Doses of 200 mg/day of 
hydrocortisone have been shown to reduce the duration of shock, systemic 
inflammation and mortality (Annane et al., 2002). This dose is considerably lower than 
the 30 mg kg'1 methylprednisolone used in earlier sepsis studies in which survival was 
not improved and outcome may even be worsened, possibly through increasing the 
frequency of secondary infections (Cronin et al., 1995).
K a t p  channels may be activated in septic shock by a number of mechanisms. For 
example, decreases in cellular ATP concentration and/or increases in cellular
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concentrations of hydrogen ion and lactate (Keung 1991 and Davies 1990); 
neurohormonal activators -  atrial natruietic peptide, calcitonin-gene related peptide and 
adenosine (Quayle 1997, Amalich et al., 1996, and Martin, 2000); and via NO through 
a cyclic guanosine monophosphate (cGMP) -  dependent mechanism (Murphy & 
Brayden, 1995). K a t p  inhibitors may also have benefits aside from raising blood 
pressure, for instance the large conductance calcium activated K+ channel is essential 
for innate immunity (Ahwullia et al., 2004). I have shown that inhibiting the K At p  
channel via its pore-forming subunit reverses LPS-induced hyporeactivity in vitro. In 
vivo the differential effect on the pore-forming subunit of the K At p  channel seen in vitro 
was probably observed in that the effect upon blood pressure was only seen with PNU- 
37738A and high dose glibenclamide. However, the effects of glibenclamide and PNU- 
37738A on blood pressure were greater in shams than LPS-treated rats. It would appear 
that endotoxin in vivo reduces the ability of glibenclamide and PNU-37738A to inhibit 
the K At p  channel. Among the KATp channel inhibitors available for use in man are 
glibenclamide, tolbutamide and gliclazide. Glibenclamide could potentially be trialled 
in humans; however an intravenous preparation is not available in the U.K. while 
gastric function is reduced in septic shock, thus making the absorption of oral 
medication unreliable. I did administer 1 mg kg'1 of intravenous glibenclamide over 5 
min (obtained from Hoechst, Germany) to one septic patient (in whom ethics committee 
permission had been obtained) but this had no haemodynamic effect. Had I used a 
higher dose (as with my in vivo model), there may have an increase in the patient’s 
blood pressure. As my supply of intravenous glibenclamide was limited and then
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curtailed by the manufacturers no longer making this preparation, I was unable to test 
this hypothesis further.
I did observe adverse effects of these agents in the in vivo model. Terlipressin, 
norepinephrine and PNU-37883A all caused a reduction in aortic blood flow while 
terlipressin and PNU-37883A worsened metabolic acidaemia. The observed adverse 
effects with terlipressin further strengthen the need for caution with this agent. It may 
be that the rat is more sensitive (I used an equivalent weight-adjusted dose to that used 
in the patients) and that a lower dose would have been as effective with fewer adverse 
effects. However, I do not believe that these findings necessarily imply despondency for 
terlipressin and K a t p  inhibition. As mentioned above, the bolus of LPS may have been 
too toxic both for the microcirculation and to create a truly hyperdynamic model. It may 
be that fewer adverse effects are seen in a longer term model, e.g. using caecal ligation 
and puncture. In addition, a combination of treatments may be required (as described in 
chapter 3). A future approach may see terlipressin and/or a K At p  inhibitor used in 
combination with a NO donor.
The mechanisms underlying hyporeactivity and hypotension may be more physiological 
than pathological. Perhaps such a blanket approach that inhibits selected factors 
contributing to the inflammatory cascade is unwise. Certainly, mediator directed 
therapy has thus far failed to improve survival in sepsis (Marshall, 2003). We are 
interfering with mechanisms that we do not fully understand. For example, the precise 
reasons why hydrocortisone and activated protein C have been successful treatments are
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far from clear as both have multiple effects. A future direction might be a more specific 
strategy using lower, more ‘physiological’ concentrations of vasopressin, or inhibition 
of pathways downstream of nitric oxide or the K a t p  channel.
Treating hypotension in sepsis is considered crucial in improving organ perfusion. 
However, despite an increase in MAP in my in vivo model, there was no corresponding 
improvement in blood flow and some adverse effects were noted. Aggressively treating 
hypotension in septic shock might not actually represent optimum treatment. Other 
goals are also considered in patients within the intensive care unit but an ‘adequate’ 
blood pressure is a predominant target for vasopressor and fluid resuscitation 
requirements. The same criticism can be applied to in vivo animal studies that also 
largely examine the effects of agents upon blood pressure. While obviously important, 
perhaps a superior approach in the future will be to use probes that can assess flow and 
the adequacy of perfusion within various vascular beds so that we might titrate 
vasoconstriction, fluids and other vasoactive drugs accordingly.
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6.5 Conclusion
In conclusion, I have provided evidence that nitric oxide, vascular K a t p  channels and 
vasopressin all play a role in the vascular hyporeactivity and hypotension of sepsis in rat 
models, and that terlipressin can be used to successfully treat refractory hypotension in 
humans. However, I remain unsure as the future role that manipulation of these 
mechanisms will play in the treatment of septic shock. Do these mechanisms represent 
a purely pathological process or a degree of physiological adaptation developed over 
millennia that we would be well advised to study further, rather than to ignore, or to 
impatiently and blindly manipulate, albeit for altruistic motives? I would certainly 
advocate the former. I believe that potential use of agents manipulating these 
mechanisms should be restricted at present to rescue therapy in humans not responding 
to conventional treatments until we better understand their beneficial and detrimental 
effects. This is perfectly illustrated by the Lopez et al., (2004) multicentre study using a 
non-specific NOS inhibitor in patients with septic shock. Only a minority of patients in 
the treatment group actually had high cardiac output vasodilatory septic shock, precisely 
the group that the vast amount of previously published work in animals and humans 
would predict to benefit. Secondly, post-hoc analysis revealed survival benefit from low 
doses but increasing harm from higher doses. Surely, this ill considered approach 
should not be repeated.
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